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BACKGROUND   
Stimulants such as amphetamine, methamphetamine, cocaine and ecstasy are the most 
widely used illicit drugs after cannabis, and may influence the onset and course of 
psychosis. However, evidence about stimulant misuse in people with psychotic disorders 
is limited, because stimulant use is usually preceded by cannabis use, and both are 
associated with other personal and social risk factors. Therefore even large clinical studies 
of people with psychosis have often not examined the impacts of stimulants separately 
from those of cannabis. Epidemiological approaches, using population surveys and 
administrative health datasets, provide an additional method for studying the associations 
and impacts of stimulant drug misuse in people with psychosis.  
AIMS 
This research addresses three questions. First, what is the prevalence of stimulant use 
disorders in people with psychosis? Second, what are the correlates of stimulant use 
disorders in people with psychosis, and how do they compare with people with psychosis 
who do not use stimulants? Third do stimulant use disorders influence the course of illness 
for people with psychosis?  
METHODS 
The research examines three overlapping groups. Part 1 examines the rate and correlates 
of stimulant disorders in the Australian population, using data from the 2007 Australian 
National Survey of Mental Health and Wellbeing. Part 2 focuses on early psychosis, 
examining people admitted with psychosis to hospitals in New South Wales (NSW, 
population 7.2 million) over a 13 year period.  It comprises three studies, examining (i) 
whether admission to hospital with psychoses is influenced by variations in stimulant 
availability in the NSW community, (ii) the prevalence and correlates of stimulant use 
disorders in people with a first admission for psychosis and (iii) the relationship between 
stimulant misuse and hospital readmission over two years. Part 3 examines enduring 
psychosis, using data from NSW hospital and community mental health services. It 
investigates the impact of stimulant use disorders on (i) diagnostic stability and 
progression to a diagnosis of schizophrenia and (ii) service use and social outcomes in 
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people with schizophrenia. All studies measured and controlled for comorbid cannabis use 
disorders and potential personal and social confounders.   
RESULTS 
In the Australian population, the lifetime prevalence of stimulant disorders was 3.3%, and 
12-month prevalence was 0.6%, equating to more than 97,000 Australians.  Stimulant use 
disorders were most common in people with other risk factors for developing psychosis, 
including younger age, male gender, a family history of psychosis, earlier and more 
frequent use of cannabis, anxiety and depressive symptoms, and subclinical psychotic 
symptoms.   
Quarterly variations in amphetamine availability accounted for 50% of variation in the rate 
of admission for stimulant induced psychosis. People with first admission psychoses had 
stimulant use disorders at a rate more than ten times that of the age-matched Australian 
population. Stimulant use disorders were associated with diagnoses of brief and drug 
induced psychoses.  Cannabis and stimulant disorders at first admission did not predict 
readmission, whereas prior admissions with stimulant disorders did. The associations of 
stimulant use disorders differed from those of cannabis use disorders.  
In the five years following admission for psychosis, comorbid stimulant use disorders were 
associated with diagnostic instability, reduced likelihood of diagnostic progression to 
schizophrenia and increased likelihood of revision of an initial diagnosis of schizophrenia 
to other conditions. By contrast, comorbid cannabis use disorders increased the likelihood 
of progression to schizophrenia.   
Fourteen percent (14%) of people admitted to hospital with diagnoses of schizophrenia 
had comorbid stimulant use disorders, and these were associated with physical health 
comorbidities, social dislocation and frequent use of mental health and emergency 
services.  More than 80% of those with stimulant use disorders also had cannabis 
disorders: the risks of cannabis and stimulants appeared additive in this group. 
CONCLUSIONS  
In the Australian population and in Australians with psychosis, the rate of stimulant 
disorders is consistent with that reported from the US but higher than for many other 
developed countries. Around one in seven Australians with psychosis also has a stimulant 
use disorder, a rate at least ten times that of the general population. Because stimulants 
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may precipitate or worsen acute psychotic symptoms, this suggests that they contribute to 
the overall burden of psychosis in Australia.   
The associations of stimulant use disorders are distinct from those of cannabis use 
disorders. For people with early psychosis, stimulant disorders are associated with initial 
diagnoses of brief and drug-induced psychosis, lower rates of ongoing contact with 
specialist mental health services and lower rates of transition to a final diagnosis of 
schizophrenia. These findings are consistent with developmental and dimensional models 
of psychosis: stimulants are potent precipitants of acute psychotic symptoms and may 
therefore trigger psychotic symptoms in people with less personal vulnerability to the 
development of schizophrenia. An implication for clinical services is that stimulant-
associated psychoses mark an important window of opportunity. Young people with 
stimulant-associated psychoses may have positive outcomes if they are supported in 
managing their substance use early in their illness. However, ongoing substance use is 
associated with high rates of relapse and readmission. For those people with 
schizophrenia, ongoing stimulant use disorders are associated with significant harms and 
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A substantial minority of young Australians use stimulants such as methamphetamine. 
Some of those who are the heaviest users experience psychotic symptoms of sufficient 
severity or duration that they require mental health care. For these young people, few 
things could be more frightening. The vignette that follows describes a common situation in 
the Australian health system. Its details are a de-identified composite drawn from many 
individuals. 
At 11pm on a Monday night, in the Emergency Department of a busy outer 
metropolitan hospital, two mental health clinicians are speaking with a distressed 
young man. Tim recently turned 20. He studies computing at a nearby technical 
college and lives with his mother and 17 year old sister. That evening Tim’s mother 
returned from work to find him frightened and angry. He told her that he had 
discovered a surveillance system, with wireless cameras hidden in smoke detectors 
in their ceiling. She tried to calm him, but Tim grabbed a large kitchen knife, saying 
that he needed to protect them all. She called local police.   
It was difficult for Tim to give the clinicians a clear history. He paced around the ED 
interview room. His words and thoughts tumbled over each other; he was afraid for 
his family, they were being watched, he had seen videos on the internet which he 
was sure were of his mother and sister, some neighbours had recently moved in 
and installed a satellite dish, he wanted to go home and confront them.  
Tim’s mother gave the clinicians more details. She described a shy young man with 
a small circle of close friends. His main interests were computers and online 
gaming, and he had become increasingly interested in electronic music. Tim had 
been in the middle of his class academically, and never quite sure what direction he 
wanted to take in life. His first year at technical college had seemed promising; he 
had enjoyed his studies and passed all but one of his courses. His mother was 
pleased when he started attending some live music events and parties with some 
new friends.  Over the summer break he had seemed a little bored and down. His 
mother hoped that things would improve when his second year of studies resumed, 
however in the few months since then she had become increasingly worried. She 
had twice found him smoking cannabis at home. He often stayed out all night with 
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friends on weekends, and seemed tired and irritable for the first half of the week. He 
had started missing some days at college and often seemed worried or forgetful.  
Tim’s parents had separated when he was seven. His father lived in a nearby 
regional town; he saw him rarely but enjoyed their contact. Tim’s mother described 
his father as a heavy drinker who had periods of depression and mood swings for 
which he never accepted care. Tim’s paternal grandmother had been hospitalised 
with a post-partum psychosis.  
Tim’s sister tearfully tells her mother that Tim has been using methamphetamine 
and ecstasy on most weekends. He had made her promise not to tell anyone. 
It is likely that Tim is experiencing a first episode of psychosis and that stimulant drugs 
have played a part in its onset. Many other personal, developmental, family and social 
factors are also likely to have interacted to bring Tim to this point at this time. In the 
months and years that follow, Tim’s story may unfold in many different ways.  
This research examines the relationship between stimulants and psychosis from the 
perspective of specialist mental health services. It focuses on severe drug use, examining 
the role of stimulant abuse and dependence rather than recreational use. It also focuses 
on psychotic syndromes, enduring constellations of symptoms and signs of psychosis 
lasting days, weeks or longer, rather than on brief or transient psychotic symptoms. It is in 
this area, where significant drug use and psychotic syndromes overlap, that many young 
people like Tim experience great harm and disruption. However it also where knowledge is 
most limited and where clinicians and services often struggle to discern what role the drug 
use has played and to deliver effective care.  
The goal of this research is to inform mental health care, service planning and policy. We 
should aim to prevent situations like Tim’s. When they do occur, we should provide the 
most effective care possible, so that Tim has the best possible chance of going on to live 
the life that he wants to live, unburdened by psychosis.  
This research is in three parts. The first examines stimulant disorders in the general 
population, the second examines stimulant disorders in persons with early psychosis and 




Part 1 looks “upstream” of a presentation such as Tim’s to examine stimulant abuse and 
dependence in the Australian population. It asks: how common is stimulant misuse in 
Australia? Who misuses stimulants? How do the risk factors for stimulant use differ from 
those for cannabis and other drugs? Are stimulant disorders more common in people with 
other risk factors for psychosis? Answering these questions helps to understand how 
different levels of exposure to stimulants interact with other risk factors. It provides 
essential context, allowing us to understand whether correlates of stimulant disorders in 
people with psychosis are specific to psychosis or instead reflect correlates of use in the 
broader population.  
Part 2 examines situations like Tim’s, people with first episode psychosis. How common is 
this problem? Who is affected? Are these presentations more common at times of greater 
drug availability? Does initial or ongoing use of stimulants influence the early course of 
Tim’s illness and the likelihood that he will require future admissions? Answers to these 
questions may help to inform clinical care, service planning and public policy.   
Part 3 looks “downstream” from this first psychosis episode. There are many possible 
paths for a young person like Tim. This may be a traumatic but one-off event, the first of 
several episodes, or the beginning of an enduring psychotic illness such as schizophrenia. 
Current models of psychosis emphasise the evolving nature of psychotic disorders, the 
opportunities for intervention and the positive outcomes for many when intervention is 
successful. The research presented here asks whether people with stimulant disorders 
and psychosis are more or less likely to develop ongoing psychoses such as 
schizophrenia. Does ceasing stimulant use change these outcomes? What are the 
outcomes for people with schizophrenia who continue to use stimulants? Answering these 
questions helps to identify whether stimulants play a role as a potentially malleable risk 
factor in the development of psychosis, and whether they contribute to the overall burden 
of psychosis.   
This research uses an epidemiological approach. Part 1 examines data from the Australian 
National Survey of Mental Health and Wellbeing, a survey of common mental health and 
substance use problems in the Australian population. Parts 2 and 3 use data from health 
services for the population of New South Wales (NSW) between 1990 and 2013. The 
relationship between stimulant disorders and psychosis is likely to be influenced by many 
personal, social and illness-related factors. In particular, stimulants cannot be considered 
in isolation from other drugs. Cannabis is the most widely abused illicit drug in young 
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Australians, and most people who use stimulants also use cannabis. Epidemiological 
approaches have the potential to complement clinical studies in trying to disentangle the 
complex relationships between use of these illicit drugs and the development of 
psychoses.  
This introduction briefly summarises some background regarding current views on the 
aetiology and course of psychosis, the role of substance abuse in psychosis and the 
reasons for specific concern about the impact of stimulants in people with psychosis. 
Chapter 2 to 9 comprise a series of linked peer-reviewed published papers. Chapter 2 
systematically reviews the rate and correlates of stimulant use disorders in people with 
psychosis. Chapters 3 to 9 examine stimulant use and disorder in three groups: the 
Australian population (Chapters 3, 4), people with early psychosis (Chapters 5 to 7) and 
people with ongoing psychosis (Chapters 8, 9). Chapter 10 summarises findings across 
these three groups and considers their possible implications.   
Stimulant drugs 
Stimulant drugs are a family of substances which produce physiological states of 
increased arousal and subjective states of increased mood, energy and attention (National 
Drug Research Institute, 2007). They include amphetamine, methamphetamine, 
methylene-dioxy-methamphetamine (MDMA or “ecstasy”) and cocaine. All act on 
dopamine pathways, and shared mechanisms are likely to underlie some of their shared 
effects  (Barr et al., 2006) . However, there are also important differences between these 
substances which may be relevant to understanding any associations with or impacts on 
psychosis.   
Amphetamine and methamphetamine are synthetic compounds produced in various forms  
including a powdered or tablet form (often known as “speed”), concentrated paste or liquid 
form (“base”) and a higher purity, crystalline form (“ice”) (Degenhardt et al., 2008c). 
Amphetamines are small molecules with a close structural affinity to brain amines and in 
particular to dopamine. They increase the availability and activity of dopamine and other 
neurotransmitters through several mechanisms, including: increased release from synaptic 
vesicles; blockage of membrane re-uptake; reduced membrane dopamine transport; 
inhibited activity of metabolizing enzymes such as monoamine oxidase, and; increased 
dopamine synthesis (Barr et al., 2006).  As well as acute chemical effects, there is 
evidence that repeated amphetamine exposure may produce ongoing chemical and 
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structural changes (neurotoxicity) lasting for months or longer (Barr et al., 2006; Hanson et 
al., 2004).  
Methylene-dioxy-methamphetamine (MDMA) or “ecstasy” shares many of the properties of 
methamphetamine, and is often grouped with amphetamine and methamphetamines in a 
broader category of  “Amphetamine-type stimulants”  (United Nations Office on Drugs and 
Crime, 2011a). In addition to stimulant effects, ecstasy may also produce hallucinogenic 
actions (Barr et al., 2006; National Drug Research Institute, 2007), which may be related to 
actions in serotonin pathways (Schenk, 2011; Seger, 2010). Ecstasy has often been 
associated with patterns of less frequent use (Agar and Reisinger, 2004), and there is 
debate as to whether it produces a true dependence syndrome (Degenhardt et al., 2010a).  
Cocaine is a plant-derived compound. It is a larger and more structurally complex 
molecule than amphetamine-type stimulant drugs, and has a shorter half-life: 1-3 hours 
compared with 8-13 hours for methamphetamine (Barr et al., 2006). It acts to increase the 
levels of dopamine within the synapses by blocking mono-amine reuptake, but has less 
effect on intracellular dopamine levels than amphetamine-type stimulants, which may 
indicate a lower potential to cause neurotoxic effects (Seger, 2010).  Cocaine’s powerful 
subjective effects and short half-life may contribute to psychological dependence, and it 
may be associated with a higher risk of dependence when compared to amphetamine-type 
stimulants (Degenhardt and Hall, 2012a; Agar and Reisinger, 2004). 
Stimulant drugs: global prevalence and impacts 
Globally, stimulants are the most widely abused illicit drugs after cannabis (United Nations 
Office on Drugs and Crime, 2011a). In recent decades amphetamine-type stimulants 
(ATS)  have overtaken cocaine as the most widely used stimulant drugs, and ATS 
seizures and ATS use now exceed those of opiates (United Nations Office on Drugs and 
Crime, 2011a; United Nations Office on Drugs and Crime, 2011b; Degenhardt and Hall, 
2012a). Over the last two decades stimulant use has increased in North America 
(Degenhardt et al., 2008a), Europe (Davies and Ditton, 1990) and South East Asia 
(McKetin et al., 2008). 
In 2012 it was estimated that between 13 million and 56 million people globally had used 
ATS drugs in the preceding 12 months (Degenhardt and Hall, 2012a), representing 
between 0.3% and 1.3% of adults. This rate is slightly lower than that estimated for 
7 
 
cannabis (0.3% – 1.3%) but higher than that for cocaine (0.3% – 0.5%) or opiates (0.3% – 
0.5%) (Degenhardt and Hall, 2012a). 
Serious consequences of substance use are typically associated with severe or dependent 
use. The Global Burden of Disease study estimated that in 2010, more than 24 million 
people globally were dependent on stimulants, with most (17 million) being dependent on 
amphetamines (Degenhardt et al., 2014). This equated to an estimated point prevalence of 
amphetamine dependence of 0.25% (0.22% – 0.28%) and of cocaine dependence of 
0.10% (0.09% – 0.11%). Globally, the 12-month prevalence of amphetamine dependence 
has been estimated to be 0.1% – 0.7%, slightly lower than that of cannabis (0.1% – 1.5%) 
and consistent with that of opiates (0.1% – 0.8%) (Degenhardt and Hall, 2012a).    
There are significant regional differences in the type of stimulant used in the general 
population. Cocaine use is estimated to be more common in North America (Degenhardt 
et al., 2008b), while amphetamine use is more common in Oceania (United Nations Office 
on Drugs and Crime, 2011a; Degenhardt et al., 2008c; Degenhardt and Hall, 2012a). 
Amphetamine is more widely used than methamphetamine in Europe and Scandinavia 
(Griffiths et al., 2008), but there are some significant differences between individual 
countries (United Nations Office on Drugs and Crime, 2011a). South East Asia has been 
described as the “global hub” of methamphetamine production and use (McKetin et al., 
2008), accounting for more than 60% of global methamphetamine seizures and more than 
half of the world’s methamphetamine users.  In South East Asia, Australia and New 
Zealand, methamphetamine has been the most widely used stimulant, however there has 
also been a recent increase in the usage of MDMA (Australian Institute of Health and 
Welfare, 2008; Degenhardt et al., 2009b).   
These regional differences in stimulant use are also reflected in estimates for stimulant 
dependence. The Global Burden of Disease study reported higher rates of any stimulant 
dependence in North America, South East Asia and Australasia; cocaine was the main 
substance of dependence in North America, while amphetamine or methamphetamine 
dominated in Australasia and South East Asia (Degenhardt et al., 2014). Estimated 
patterns of burden due to stimulants mirrored those prevalence differences: overall 
amphetamines were estimated to account for 38 disability adjusted life years (DALYs) per 
100,000 population, compared with 16 per 100,000 for cocaine. More than half of 
amphetamine-related DALYs were in Asia and Oceania, and nearly half of cocaine-related 
DALYs  were in the Americas (Degenhardt et al., 2014).  
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Amphetamines have become an emerging problem in the USA: the RAND Corporation 
has estimated that in the USA in 2005 amphetamines accounted for nearly 900 deaths, the 
loss of more than 44,000 quality adjusted life years and an annual economic burden of 
approximately $US 23 billion. Health care comprised only a minority of amphetamine-
related costs: the greatest costs were due to impacts on quality of life, premature death, 
policing and justice (Nicosia et al., 2009; Steinberg, 2009). 
Stimulant use and dependence in Australia   
In Australia, the National Drug Strategy Household Drug Survey (NDSHDS) has reported 
on rates of illicit drug use every three years since 1985, with data currently available to 
2010 (Makkai and McAllister, 1998; Adhikari and Sumerill, 2000; Australian Institute of 
Health and Welfare, 2002; Australian Institute of Health and Welfare, 2005; Australian 
Institute of Health and Welfare, 2008; Australian Institute of Health and Welfare, 2011).  
Between 1998 and 2010 methamphetamine has been the most commonly used stimulant 
in Australia, with prevalence of lifetime use varying between 6% and 8%. The prevalence 
of recent (12-month) use of stimulant drugs has varied between 2% and 3% of the 
population. However self-reported use of both cocaine and ecstasy has increased steadily 
since 1995 and ecstasy use has overtaken methamphetamine use in the two most recent 
surveys, conducted in 2007 and 2010 (Australian Institute of Health and Welfare, 2011).  
These surveys provide valuable information about stimulant use at a population level, but 
also have limitations. Population surveys of drug use may underestimate prevalence as 
they sample conventional households, under-represent drug use “hotspots” and high risk 
subgroups, and may be sensitive to the effect of stigma on self-report (McKetin et al., 
2005). Data on individual drugs reflects the substances that individuals believe they have 
purchased and consumed, however drug seizure data often shows little relationship 
between the apparent and actual content of stimulant drugs. Many tablets sold as ecstasy 
contain little or no MDMA but include other stimulants such as methamphetamine, or a 
range of non-psycho-active substances (United Nations Office on Drugs and Crime, 
2011a).  
Several aspects of these estimates are relevant to the current research and to 
understanding any potential impact of stimulant use on psychosis in Australia. First, while 
the overall prevalence of stimulant use is low, this represents an estimate for the whole 
population aged over 14. In Australia as in other Western countries, stimulant use is most 
prevalent in males (Adlaf et al., 2005; Degenhardt et al., 2007b; Substance Use and 
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Mental Health Services Administration, 2010), especially in their late teens or twenties 
(Durell et al., 2008; Substance Use and Mental Health Services Administration, 2010; 
Wilkins et al., 2006), and this the population group who are also at highest risk for 
psychosis. In 2010, the rate of recent substance use in Australian males aged 20-29 
ranged from 6.8% for methamphetamine to 11.4% for MDMA (Australian Institute of Health 
and Welfare, 2011). Stimulant use is also associated with other risk factors for psychiatric 
illness including social marginalisation, lower education, a family history of mental health 
or drug problems, prior anxiety and depressive symptoms and the use of other drugs 
(Russell et al., 2008; Degenhardt et al., 2007b; Degenhardt et al., 2007c; Degenhardt et 
al., 2008c; Degenhardt et al., 2009b). This concentration of use implies that stimulants 
may have potentially greater effects than their 2-3% population prevalence may suggest, 
precisely because their rate of use is highest in people who are most vulnerable to 
psychosis. Chapter 2 will review the rate of stimulant abuse and dependence in people 
with psychosis, and examine whether this rate is higher in Australia than in other 
comparable countries.  
Second, the changing patterns of stimulant use, changing fashions in the particular type of 
stimulant drug used and inherent inaccuracy in individual’s self-report of the type of drug 
used mean that it is important to examine all stimulant drugs (amphetamine, cocaine, 
ecstasy) rather than limit investigation to only one of these drugs.  
Third, serious drug-related harms are most likely to occur in conjunction with more 
frequent or dependent use, higher potency forms and riskier routes of administration such 
as intravenous injection (Degenhardt et al., 2008c). Therefore when examining stimulant-
related harms such as psychosis, estimates of dependent use or abuse are more relevant 
than estimates of use. In Australia the prevalence of dependent stimulant use has been 
estimated by indirect (benchmark/multiplier) methods (McKetin et al., 2005). Among 
persons aged 15-49 years these methods produce an estimated 12-month prevalence of 
monthly amphetamine use of 1.0%, and dependent amphetamine use of 0.7%. Chapter 3 
of this thesis aims to supplement these estimates with direct estimates of stimulant abuse 
and dependence drawn from a national household survey.  
Dependent stimulant use is associated with serious health harms such as cardiovascular 
and cerebrovascular disease, infection with hepatitis, HIV or other blood borne viruses, 
and psychiatric symptoms (Darke et al., 2008). Amongst the most serious of the 
psychiatric symptoms is psychosis.  
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The impact of psychosis 
Before considering the specific relationship between stimulant use and psychosis, this 
section briefly reviews evidence regarding the impact and nature of psychosis. Psychotic 
disorders are “a diverse group of illnesses that have their origins in abnormal brain 
function and are characterised by fundamental distortions of thinking, perception and 
emotional response” (Morgan et al., 2011).   
Psychoses have been called the “most mysterious and costly of illnesses” (van Os and 
Kapur, 2009). They may cause distress and disability due to a diverse range of positive 
psychotic symptoms, negative symptoms, cognitive impairments and disturbances of 
affect, behaviour and social functioning. They have a substantial adverse impact on 
affected individuals, their families, health systems and society because they are often 
disabling conditions which commence early in life: more than three quarters of incident 
cases occur before the age of 30 (Kessler et al., 2007; Morgan et al., 2011). Treatments 
are only partly effective. It has been estimated that current treatments, even if optimally 
delivered, can only avert 22% of the burden of schizophrenia (Andrews et al., 2004).  
The World Health Report estimated that schizophrenia and bipolar disorder together 
account for at least 5% of total disability for people aged 15-44 (World Health Organisation 
2001).  The Global Burden of Disease study has estimated that schizophrenia and bipolar 
disorder together account for around 14% of the total mental health-related disability 
(Whiteford et al., 2013).  Psychosis accounts for more than 1% of total Australian health 
expenditure and is estimated to cost Australian society Aus$ 4.9 billion annually (Neil et 
al., 2014).  
There is increasing evidence that effective interventions in early psychosis may influence 
the course of illness (McGorry, 2010; Gafoor et al., 2010; Addington and Addington, 2009; 
Birchwood et al., 2000). A significant proportion of people with established psychoses such 
as schizophrenia may also have positive symptomatic and functional outcomes (Leamy et 
al., 2011 ; Warner, 2009). It is therefore critical to understand the factors that may 
influence the onset and course of psychosis, especially those that might lead to 
opportunities for prevention or intervention and thus lead to better outcomes. Psychoactive 
substances such as cannabis and stimulants are one such potentially remediable factor.  
Current models of psychosis 
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Psychoses are seen as neurodevelopmental disorders in which genes and early 
environment interact to produce abnormalities in brain structure and function, manifesting 
at critical stages of brain development such as adolescence (Weinberger, 1987; DeLisi, 
1997; Keshavan, 1999). Psychoses have a significant genetic component: up to 80% of 
variation in the illness may be heritable (Keshavan et al., 2011), however genetic 
influences appear to involve small effects from large numbers of candidate genes (Mitchell 
and Porteous, 2011; Insel, 2010) and concordance in monozygotic twins is no more than 
50% (Insel, 2010).  
Genetic susceptibility to psychoses appears to be shared with a broad range of other 
neurological and psychiatric conditions (Jacka and Berk, 2014). These interact with 
environmental exposures occurring either in intrauterine development (such as hypoxia or 
maternal influenza), during adolescent brain development, or both; “the model that 
emerges is of an early insult, a latent period then emergence of psychosis in late 
adolescence or early development” (p189) (Insel, 2010). Abnormalities in dopamine 
pathways appear to play a role, particularly in positive psychotic symptoms (Insel, 2010). 
Dopamine has been described as “the wind of the psychotic fire” (Laruelle and Abi-
Dargham, 1999), and all effective antipsychotics block dopamine D2 receptors (Keshavan 
et al., 2011).   
Three emerging themes in understanding psychosis are relevant to studying the 
interaction between psychotic conditions and substances. First, the traditional Kraepelinian 
dichotomy of schizophrenia and manic-depressive psychosis has come under sustained 
attack (Tandon et al., 2009; Cuthbert and Insel, 2010). Psychoses are increasingly seen 
as heterogenous and overlapping syndromes rather than specific diseases. It has been 
argued that “schizophrenia is perhaps best seen as a category, such as cancer, epilepsy, 
or dementia” (p 260) (Silverstein et al., 2014). Indeed there have been calls for the term 
“schizophrenia” to be replaced (Henderson and Malhi, 2014).  
Dimensional models of psychoses have been proposed instead of the categorical model 
(van Os and Kapur, 2009).  DSM-5 includes a proposed set of psychosis descriptors with 
eight dimensions; hallucinations, delusions, disorganised speech, abnormal motor 
behaviour, negative symptoms, cognitive impairment, depression and mania (Heckers et 
al., 2013; Barch et al., 2013).  This heterogeneity implies that when studying substance 
use in psychosis it is important to take a broad, multi-diagnostic approach rather than to 
limit study to a specific disorder such as schizophrenia.  
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Second, there is heterogeneity not only cross-sectionally in symptoms, but longitudinally in 
the ways in which psychotic disorders develop over time. Insel (Insel, 2010) has said 
“perhaps the most fundamental change from re-conceptualizing schizophrenia as a 
neurodevelopmental disorder is the notion of trajectory of illness” (p 190). There is 
increasing recognition that sub-syndromal psychotic symptoms are common in healthy 
populations, and that psychotic disorders may emerge initially as brief, transient or poorly 
differentiated clinical syndromes before evolving into more clearly defined illnesses. A 
spectrum model (van Os and Kapur, 2009) has been proposed whereby up to 10-20% of 
the population may have a broad vulnerability to psychosis, and 2-3% have a lifetime 
prevalence of a “complex multi-dimensional psychotic syndrome” which includes episodes 
of brief psychotic syndromes. A further subset (0.5 – 1% of the population) have a severe 
vulnerability expressed as schizophrenia.  
Clinical staging models for psychosis have been developed, for example Yung and 
McGorry (Yung and McGorry, 2007; McGorry, 2010) have proposed a five-stage model 
ranging from at-risk and prodromal states to severe and enduring psychosis. This view of 
psychosis is relevant to studying substance comorbidity. It suggests the need to study 
individuals at different stages of psychosis and to assess whether the associations of 
substance use are specific to that stage or reflect a broader pattern also found in other 
stages. It is also important to assess whether substance use increases the likelihood of 
progression through different stages of psychosis.  
Third, there is increasing evidence that genetic and neurodevelopmental factors interact 
with the social environment to influence the development of psychosis.  Urban location, 
migration and marginalised or minority status are consistently and independently 
associated with psychosis (van Os et al., 2010; McGrath, 2007; McGrath et al., 2004; 
Bourque et al., 2011). Possible explanations for these associations include the impact of  
trauma, social marginalisation and “social defeat” (van Os et al., 2010; Krabbendam et al., 
2014), perhaps mediated through stress-related mechanisms (Jacka and Berk, 2014).  
These findings also have implications for the study of comorbid substance use in 
psychosis, since many of these risk factors for psychosis are also risk factors for 
substance use and other psychiatric syndromes (Jacka and Berk, 2014). Therefore studies 
of substance use in psychosis should ideally measure common risk factors which may 
potentially confound the relationship between substances and psychosis, such as urban 
location, migrant status and disadvantage.   
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Substance comorbidity in psychosis 
Substance misuse is common throughout all stages of psychosis. It occurs in up to half of 
people with first episode psychosis (Wisdom et al., 2011; Green et al., 2005; Addington 
and Addington, 2007; Wade et al., 2005; Grech et al., 2005; Archie et al., 2007) and 
schizophrenia (Regier et al., 1990; Kavanagh et al., 2004; Moore et al., 2012b).  People 
with psychosis use cannabis at least ten times more frequently than the general population 
of the same age (Green et al., 2005; Koskinen et al., 2010; Degenhardt and Hall, 2012b). 
Debate continues about the nature of the association between various types of substance 
use and psychosis and the reasons for elevated rates of substance use in people with 
psychosis. The critical issue for the current research is that, regardless of the mechanisms 
involved, substance use is associated with clinically significant changes in the symptoms, 
course and outcome of psychosis.   
Substance use is associated with earlier onset of psychosis (Foti et al., 2010; Large et al., 
2011; Compton et al., 2009), and greater severity of positive psychotic symptoms both in 
early psychosis (Wade et al., 2007; González-Pinto et al., 2011; Sorbara et al., 2003; 
Grech et al., 2005) and in chronic psychotic disorders (Foti et al., 2010; van Os et al., 
2002). People with psychosis who also use substances are less likely to continue their 
medication (van Rossum et al., 2009; Faridi et al., 2012; Wade et al., 2007) and less likely 
to remain engaged with follow-up care (Miller et al., 2009; Stowkowy et al., 2012). They 
are more likely to experience relapse or readmission (Hides et al., 2006; Sorbara et al., 
2003; Wade et al., 2006a; Strakowski et al., 2007; Linszen et al., 1994) and involuntary 
hospitalisation (Opsal et al., 2011). They are more likely to have a continuous course of 
illness (Bertelsen et al., 2009) with lower rates of remission and recovery (Lambert et al., 
2005; Petersen et al., 2008) and reduced function in social and other domains (Chouljian 
et al., 1995; Wade et al., 2007; González-Pinto et al., 2011; Menezes et al., 2009; Faber et 
al., 2012).  
Conversely, following a first psychotic episode in young people, cessation of drug use is 
associated with better outcomes, increased remission and reduced rates of relapse (Wade 
et al., 2007; Gonzalez-Pinto et al., 2008; Strakowski et al., 2007; Baeza et al., 2009; 
Lambert et al., 2005).  
The strength of the association between substance use and the symptoms, course and 
outcome of psychosis demonstrate the importance of further research in this area. The 
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level of suffering, disability and cost caused by psychosis is substantial. Understanding 
factors which may worsen psychosis or influence its course may lead to more effective 
prevention and care. At the point of first contact with mental health services, many of the 
risk factors for negative outcome in psychosis (such as genetic vulnerability, gender, early 
developmental exposures, childhood social functioning, age of psychosis onset and 
duration of untreated illness) are fixed and hence not amenable to intervention. Substance 
use is one of the few risk factors for the development of a more chronic psychosis which 
can be modified after a first psychosis presentation, along with adherence to care and the 
effectiveness of interventions and social support provided.  
Cannabis and psychosis 
Some of the studies cited above have examined the relationships between psychosis and 
the misuse of any substance. Many have specifically examined the role of cannabis use or 
abuse. Cannabis is the most widely used illicit drug, with international comparisons 
suggesting lifetime rates of cannabis use between 5% and 40% (Degenhardt et al., 
2008b). Cannabis use is illegal in Australia but around 9% of Australians report using 
cannabis in the last twelve months, and around 33% report lifetime cannabis use 
(Australian Institute of Health and Welfare, 2008). 
There is ongoing debate about the nature of the link between cannabis and psychosis. 
Cannabis has a number of active constituents, including delta-9 tetrahydrocannabinol 
(THC) and cannabidiols (Paparelli et al., 2011). THC seems primarily responsible for the 
impact on positive psychotic symptoms (Di Forti et al., 2009), perhaps through actions on 
dopamine pathways (Kuepper et al., 2010). The sensitivity to these effects may be subject 
to genetic variation (Genetic Risk Outcome in Psychosis Investigators, 2011; Henquet et 
al., 2008). Therefore cannabis may precipitate psychosis in vulnerable individuals 
(Degenhardt and Hall, 2006; Hall and Degenhardt, 2011) by interacting with other risk 
factors as a “component cause” (D'Souza et al., 2009). It may also cause a modest 
increase in the risk of developing schizophrenia in people without genetic vulnerability 
(Hall and Degenhardt, 2011). It has been estimated that around 8% of the population risk 
for psychosis can be attributed to cannabis (Thirthalli and Benegal, 2006), and that regular 
cannabis use is associated with a two- to three-fold increase in the relative risk of 
developing schizophrenia (Tandon et al., 2008; Hall and Degenhardt, 2011). 
Different substances have different pharmacological actions, so it is likely that they may 
have different effects on the symptoms and course of psychosis. Stimulants have the 
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potential to worsen psychotic symptoms: their effects on people with psychosis may be 
different from or additive to those of cannabis. However the evidence regarding their 
impact in people with psychotic disorders is more limited than for cannabis. 
The overlap between cannabis and stimulant use disorders 
A critical issue for the current research is the substantial overlap between stimulant use 
and cannabis use. Between 80% and 100% of people with psychosis who use stimulants 
also report concurrent cannabis use (Wade et al., 2005; Tosato et al., 2013; Arndt et al., 
1992; Baeza et al., 2009; Barrigon et al., 2010; Bersani et al., 2002; Brown, 1998; Dekker 
et al., 2012; Archie et al., 2007).  
Cannabis use not only accompanies stimulant use, it typically precedes it, in a so-called 
“gateway” pattern (Degenhardt et al., 2009a). In the US National Comorbidity Study 
Replication, more than 96% of drug users used cannabis before using other illicit drugs 
(Degenhardt et al., 2009a). The second Australian national survey of psychosis found that 
more than 98% of people with psychosis who used stimulants had previously used 
cannabis (Power et al., 2014). In cohort studies cannabis use is one of the strongest 
predictors of later stimulant use (Degenhardt et al., 2007c). Therefore it is not possible to 
examine the effects of stimulant use disorders in people with psychosis without also 
considering and controlling for possible associations and impacts of cannabis.  
Because of this overlap, studies examining “pure” stimulant use (i.e. without comorbid 
cannabis use) are rare. They have mainly been limited to two types of study. First, some 
studies have examined clinical samples of people seeking treatment for specific problems 
of amphetamine dependence. This includes a group of studies from the UCLA  
Methamphetamine Treatment Project (MTP ), a randomised trial of clinical interventions for 
methamphetamine dependence conducted over 8 sites in California and other US states 
(Glasner-Edwards et al., 2010a; Glasner-Edwards et al., 2008b; Rawson et al., 2004; 
Glasner-Edwards et al., 2010b; Glasner-Edwards et al., 2009; Gonzales et al., 2011; 
Glasner-Edwards et al., 2008a; Zweben et al., 2004). The MTP recruited more than 1000 
people meeting DSM-IV criteria for methamphetamine dependence (Zweben et al., 2004), 
and is the largest trial of clinical intervention for this condition. It has provided very 
valuable information on treatment, which is discussed further in Chapter 10. However the 
requirements of a treatment trial limit the extent to which the MTP can be used to 
understand the prevalence or impact of stimulant use disorders in people with serious 
mental health disorders such as psychoses. Follow up studies of the MTP cohort showed 
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that nearly half of those followed up had significant psychopathology, including significant 
rates of depression, anxiety, and antisocial personality disorder (Glasner-Edwards et al., 
2010b; Glasner-Edwards et al., 2008a; Glasner-Edwards et al., 2009; Glasner-Edwards et 
al., 2010a). Significant rates of psychotic experiences were also described: at three-year 
follow up 4.9% had a current psychotic disorder (Glasner-Edwards et al., 2010b) and 13% 
met criteria for a past psychotic disorder (Glasner-Edwards et al., 2008b). However, the 
MTP excluded participants initially meeting DSM-IV criteria for dependence on any other 
substance (such as alcohol or cannabis) or having other psychiatric conditions requiring 
immediate care or precluding a focus on treatment of methamphetamine dependence. 
People with language or intellectual difficulties, or with significant social instability were 
also excluded (Zweben et al., 2004), in order to ensure that people were able to participate 
fully and safely in treatment. As a result, those followed up at three years were 
predominately white, female, aged over 30, college-educated and employed (Glasner-
Edwards et al., 2010b) . This makes it difficult to generalise to the clinical situations 
typically encountered in acute mental health services. 
Second, there is a substantial literature from Japan, Thailand and Taiwan examining 
psychotic syndromes in methamphetamine users. South East Asian countries have high 
rates of methamphetamine use (McKetin et al., 2008) and researchers from these 
countries have contributed many of the studies examining the familial, genetic and 
pharmacological characteristics of methamphetamine-related psychoses (Bousman et al., 
2009).  Most of these studies use a diagnostic construct of “Methamphetamine Psychosis”, 
which is seen as including both acute and transient psychotic states (Kittirattanapaiboon et 
al., 2010) and psychosis which persists or recurs despite abstinence from stimulants (Sato 
et al., 1992; Suzuki et al., 2006; Yamamoto et al., 2007; Yui et al., 2000a).  
Most Western psychiatrists would diagnose enduring psychotic states which continued 
after cessation of drug use as schizophrenia or related psychoses. However these authors 
distinguish chronic methamphetamine psychosis from schizophrenia on the basis of (i) a 
strict application of the exclusion criterion for substance abuse within the DSM criteria for 
schizophrenia and (ii) findings that persons with chronic or recurrent stimulant psychosis 
have fewer negative symptoms than persons with chronic schizophrenia (Tomiyama, 
1990; Yeh et al., 2001; Yui et al., 2000b). Within contemporary views of schizophrenia, the 
absence of negative symptoms is not an exclusion criterion for diagnosis. Studies 
comparing chronic “methamphetamine psychosis” with schizophrenia find that the two 
conditions cannot be distinguished on the basis of their positive symptoms (Iwanami et al., 
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1994b; Tomiyama, 1990), the factor structure of their symptoms (Srisurapanont et al., 
2003), neurophysiological measures (Iwanami et al., 1994a) or response to treatment 
(Srisurapanont et al., 2001).  
As well as these diagnostic differences, the patterns of drug use and the cultural, health 
service and legal context of drug use also differ substantially between Asian and Western 
countries. Cannabis use is less frequent in Asian countries than Western countries (United 
Nations Office on Drugs and Crime, 2011b), and this is reflected in different patterns of 
drug use in clinical populations (Colfax et al., 2010) . For example a Taiwanese case-
control study of adolescent amphetamine users found no cannabis use but a high 
proportion of comorbid betel-nut abuse (Yen and Chong, 2006). A study of more than 300 
Taiwanese adults in detention with amphetamine abuse found less than 1% also used 
cannabis (Lin et al., 2004). In a Japanese cohort, less than half of injecting stimulant users 
had a lifetime history of cannabis use (Matsumoto et al., 2002). Therefore, while these 
studies provide important insights into possible mechanisms underlying psychosis in 
methamphetamine use, it is difficult to generalise from these studies to understand the 
correlates or impacts of stimulant use in people with psychosis who misuse amphetamines 
in combination with cannabis and other substances, such as are commonly encountered in 
North American, English and Australian mental health systems.  
The overlap between cannabis and stimulants described in this section creates a 
significant methodological challenge for understanding the relationship between stimulants 
and psychosis. If the majority of people with psychosis who use stimulants also use 
cannabis, it is very difficult to separate the associations and impacts of stimulants from 
those of cannabis. Even very large clinical studies may not have sufficient statistical power 
to examine stimulant drugs. For example, several recent clinical studies have reported on 
samples of more than 300 young people with first episode psychoses (Petersen et al., 
2007; Wobrock et al., 2013; Van Mastrigt et al., 2004; Lambert et al., 2005; Larsen et al., 
2006). However, none have reported on the characteristics of those young people who 
used stimulants.  
Stimulants and psychosis 
The first clinical descriptions of psychosis associated with amphetamine abuse appeared 
in the 1930s, within five years of the commercialisation of amphetamines (Angrist et al., 
1974; Curran et al., 2004). Connell’s seminal 1958 Maudsley Monograph (Connell, 1958) 
described 200 cases of amphetamine-related psychosis. Since that time, it has become 
18 
 
clear that amphetamine abuse may trigger psychotic experiences and states (Angrist et 
al., 1974; Caplehorn, 1990; Harris and Batki, 2000; McKetin et al., 2006b; Curran et al., 
2004; Darke et al., 2008). Amphetamine-related psychoses have therefore been studied 
as important phenomena in their own right and also as a possible model for understanding 
the mechanisms of psychosis and the development of schizophrenia (Hermens et al., 
2009; Machiyama, 1992; Sato et al., 1992; Snyder, 1973).  
The evidence that stimulants may precipitate or worsen psychotic symptoms comes from 
several types of study. First, in experimental challenges, high dose amphetamines can 
induce acute reversible psychotic symptoms in volunteer subjects who do not have any 
apparent vulnerability to psychosis (Angrist et al., 1974; Griffith et al., 1972).  
Second, there are high rates of brief and transient psychotic symptoms reported by 
recreational stimulant users. Hall (Hall et al., 1996) examined 301 recreational 
amphetamine users: around 60% reported brief hallucinations or paranoia following 
stimulant use, compared with less than 20% who reported such symptoms prior to their 
first amphetamine use. In another large sample of recreational stimulant users, three 
quarters reported at least one psychotic symptom over a 12-month period, and nearly one 
quarter  reported at least one clinically significant psychotic symptom (18% after excluding 
a people with a diagnosis of psychotic disorders) (McKetin et al., 2006b). Amongst 
homeless youth in Canada, more than half of methamphetamine users reported auditory 
hallucinations, a significantly higher rate than in other vulnerable young people (Martin et 
al., 2006). It has been estimated that recreational amphetamine users have a more than 
ten-fold increase in psychotic symptoms compared with general population (McKetin et al., 
2006b) and up to a threefold increase in risk of psychotic symptoms compared to other 
young people (McKetin et al., 2010). These symptoms are dose-related, being associated 
with more frequent use, use of high potency forms (Hall et al., 1996), dependent use 
(McKetin et al., 2006b), or use in combination with other drugs (McKetin et al., 2010).  
Third, regular amphetamine use is associated with hospital admission for brief psychotic 
syndromes such as drug-induced psychosis. A study of Australian hospital admission data 
suggested that amphetamine users had a significantly higher risk of admission to hospital 
for psychosis than cannabis users, and that this risk increased with age: for drug users 
aged over 30, the estimated risk of hospital admission with drug-induced psychosis was 
more than eight times higher for amphetamine users than for cannabis users (Degenhardt 
et al., 2007d).  
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Fourth, amphetamines increase psychotic symptoms in people with schizophrenia and 
other psychotic disorders (Lieberman et al., 1990; Angrist et al., 1980). Curran (Curran et 
al., 2004) reviewed 26 studies which reported on experimental amphetamine challenge in 
persons with schizophrenia. These found an increase in positive psychotic symptoms 
(such as hallucinations), especially for those who were already experiencing 
hallucinations: 28% of persons in remission at the time of the challenge experienced a 
recurrence of psychotic symptoms, and 51% of people with current symptoms 
deteriorated.  
Fifth, the evidence reviewed above provides a plausible theoretical link between stimulant 
use and worsening of psychotic symptoms. Stimulants act to increase synaptic dopamine, 
and increased dopamine activity is particularly associated with positive psychotic 
symptoms (Insel, 2010; Di Forti et al., 2009). In experimental challenges, psychotic 
symptoms are associated with increased levels of the dopamine metabolite homovanillic 
acid (Angrist et al., 1974; Angrist and Gershon, 1974) and are blocked by the antipsychotic 
haloperidol, a dopamine receptor blocker (Angrist et al., 1974). Animal studies also provide 
indirect support for this link: amphetamine administration in rats and primates produces 
abnormalities of motor activity and behaviour which have some parallels to psychosis and 
which are also blocked by administration of haloperidol (Curran et al., 2004; Sato et al., 
1992; Ujike, 2002).  
Summary 
This introduction has highlighted issues relevant to the design of the studies presented in 
this thesis, rather than attempting to systematically review all the evidence on the 
relationship between psychosis and stimulants or other substances. In summary, the key 
issues relevant to the design of the current research are:   
Psychosis is a significant problem and it is important to understand any factors that might 
help to prevent its onset or modify its course. Substance disorders are one such factor, 
and are amongst the few risk factors which may be amenable to modification at the time of 
a person’s first contact with mental health services.   
Psychoses are increasingly seen as a heterogeneous spectrum of disorders which evolve 
through clinical stages and are influenced by social as well as personal and genetic 
factors. In understanding possible impacts of substance abuse on psychosis at a 
population level it is important to take a broad, multi-diagnostic and multi-stage approach 
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and to measure and control for personal and social factors such as age, gender, urban 
location, migration and disadvantage which may confound the relationships between 
psychosis and substances.  
Most research on substance comorbidity in psychosis has focused on cannabis because it 
is the most commonly used drug both in the population and in people with psychosis. 
However stimulant use is also common and there are good reasons to be concerned about 
the potential role of stimulants in precipitating or worsening psychosis.  
Studies of transient psychotic symptoms in recreational stimulant users have provided very 
important evidence about the relationship between stimulants and psychosis. However in 
understanding severe or enduring harms, it is important to complement these studies by 
examining (i) more severe and enduring psychotic syndromes and (ii) more severe or 
dependent stimulant use.  
Evidence about the impact of stimulants on the onset and progression of psychotic 
disorders is limited, in part because of the substantial overlap of stimulants with cannabis 
disorders. This means that studies of very large samples are required in order to examine 
the effects of stimulants separately from those of cannabis. It also implies that any 
examination of stimulants in psychosis should also measure and control for concurrent 
cannabis use.  
A role for epidemiological approaches? 
This combination of challenges means that an epidemiological approach using linked data 
sets may be of particular value in examining the relationship between stimulants and 
psychosis. Using large, representative, population-based datasets it may be possible to 
measure many relevant confounding factors and to have sufficient scale and power to 
examine these complex relationships. Two types of dataset are likely to be of relevance: (i) 
household surveys of drug or mental health problems and (ii) large administrative data 
collections or registers drawn from routine mental health service data.  
Household surveys of substance and/or mental health problems have formed the basis for 
some of the evidence already reviewed above. Advantages of these surveys include their 
large scale, control over sampling, representativeness, and use of standardised measures 
to allow comparison between jurisdictions or over time. These studies are discussed 
further in Chapter 3. They include the US Epidemiological Catchment Area (ECA) study 
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(Regier et al., 1990), US National Comorbidity Survey (Kessler et al., 2001) and its 2001-
2003 replication (Degenhardt et al., 2007a), International Consortium on Psychiatric 
Epidemiology (Vega et al., 2002), WHO World Mental Health Survey Initiative studies 
(Gureje et al., 2006; Jacobi et al., 2004; Lee et al., 2007; Stein et al., 2008), UK National 
Substance Use Survey (Coulthardt et al., 2002) and New Zealand Mental Health (Wells et 
al., 2006) and National Drug Surveys (Wilkins and Sweetsur, 2008). Many of these studies 
include estimates of stimulant use. However, few measure stimulant dependence, and 
even fewer measure psychotic symptoms or syndromes. Using data from the early 1980’s 
the ECA study (Regier et al., 1990) reported a lifetime prevalence of amphetamine 
dependence or abuse of 1.7%. Since that time, no population study has reported on rates 
of stimulant dependence diagnosed according to standardised diagnostic criteria.   
Health service data collections provide a second source of epidemiological data. The low 
prevalence of psychotic disorders makes them difficult to study in household surveys. 
However, most people living with psychotic illnesses have contact with health services 
(Jablensky et al., 2000; Morgan et al., 2011) and therefore health service data may be 
particularly helpful in research into psychotic disorders (Morgan and Jablensky, 2010; 
Byrne et al., 2005). As well as traditional case registers there is increasing scope to derive 
this information from electronic health records and administrative databases (Perera et al., 
2009).  
Three studies using population-level health service data demonstrate the particular 
potential for this approach in examining stimulant disorders in psychosis. Degenhardt and 
colleagues (Degenhardt et al., 2007d) examined data for all Australian hospital admissions 
over the decade to 2004 and calculated admission rates for cannabis and amphetamine-
induced psychoses. They estimated that amphetamine users had a greater risk of 
admission with drug-induced psychosis than cannabis users and that this difference in risk 
increased with age. Callaghan and colleagues (Callaghan et al., 2012) used hospital 
discharge records from California to identify 42,412 people with methamphetamine-related 
conditions. Their risk of a later diagnosis of schizophrenia was significantly greater than 
matched controls with no substance disorders or with cocaine, alcohol and opioid 
disorders but similar to the risk for those with cannabis disorders. Niemi-Pynttari and 
colleagues (Niemi-Pynttari et al., 2013) used the Finnish Hospital Discharge Register to 
examine 18,478 people with diagnoses of drug-induced psychosis. They found that people 
with diagnoses of stimulant-induced psychosis had lower risk of receiving a later diagnosis 
of schizophrenia than people with a cannabis-induced psychosis.  These last two studies 
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are currently the only published studies examining whether cannabis and stimulant 
disorders are associated with different risks of progression to a diagnosis of schizophrenia. 
The differing findings of these studies underline the need for further examination of this 
issue.  
Epidemiological approaches can complement clinical studies, but also have important 
limitations. They are powerful tools for identifying candidate risk factors, and contributing to 
hypotheses about the causes and development of psychosis (McGrath, 2007), but cannot 
by themselves demonstrate causation (McGrath, 2008).  
The current research  
This research examines the relationship between stimulant dependence and psychotic 
disorders. It examines the rate and correlates of stimulant disorders in people with 
psychosis, and the potential impact of stimulant disorders on progression to successive 
stages of psychosis. The specific research questions that are addressed are summarised 
at Figure 1.1.  
The research uses epidemiological approaches. Chapters 3 and 4 use data from a 
national household survey, the second Australian National Survey of Mental Health and 
Wellbeing (NSMHWB), (Slade et al., 2009). This nationally representative household 
survey was conducted in 2007 by the Australian Bureau of Statistics (ABS). It collected 
data on common mental disorders and substance use disorders using standardised 
diagnostic criteria. The survey also collected data on other personal and family risk factors 
for psychosis, and included screening questions on psychotic symptoms and experiences.  
Chapters 5 to 9 use health service administrative data for state-operated hospital 
admission and community mental health contacts for the state of New South Wales 
(NSW), Australia. The organisation of Australian health services means that state-
operated services have primary responsibility for the care of psychosis, and therefore this 
data includes most people with psychotic disorders in a population of more than 7 million 
people over a period of more than ten years.  
The design of each component study will be described within each chapter. However, all 
studies were designed to address the specific methodological issues described in this 
introduction. They focus on severe stimulant use, including people with diagnoses of 
stimulant abuse or dependence. They focus on psychotic syndromes rather than 
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symptoms, and take a broad, multi-diagnostic approach including brief, atypical and drug-
induced psychoses, affective psychoses and schizophrenia. They consider different stages 
of psychosis, and separately examine the prevalence, correlates and impacts of stimulant 
disorders in the general population, in early psychosis and in enduring psychoses such as 
schizophrenia. They measure rates of cannabis use disorders, and seek to control for the 
effects of cannabis disorders and to assess the additive effects of cannabis and stimulants 
on psychosis outcomes. They measure personal and social factors which may confound 
the relationship between stimulants and psychosis (age, sex, migration, urban location, 
social disadvantage) and seek to control for these where relevant. 
All studies examined stimulant disorders as a group, combining amphetamine, 
methamphetamine, MDMA and cocaine into a single “stimulant” category. The principal 
reason for combining stimulant drugs in this way us that most of the data sources used in 
this research do not consistently or reliably distinguish individual stimulant drugs.  Chapter 
2 reviews studies examining rates of stimulant use in people with psychosis: up to a third 
of such studies report on stimulant use as a combined category rather than reporting on 
specific stimulant drugs. Chapters 3 and 4 examine data from Australia’s National Survey 
of Mental Health and Wellbeing (NSMHWB). That survey asks about individual stimulant 
drugs when quantifying substance use. However, it combines stimulant drugs when 
examining abuse, dependence and impacts, reporting only on a combined “stimulant” 
category. Chapters 5 to 9 examine administrative data from NSW hospital and community 
mental health services, using ICD-10 diagnoses recorded by mental health clinicians and 
medical records coders. Diagnostic precision is an important limiting factor in using large 
administrative datasets (Morgan and Jablensky, 2010; Mortensen, 1995) and focusing on 
broader diagnostic groupings may be one strategy for limiting this imprecision. ICD-10 
distinguishes cocaine disorders (F14.x) from other stimulant disorders (F15.x), and allows 
the option of coding specifically for methamphetamine-related disorders at the second 
decimal place (F15.x1). However in practice, clinicians and coders rarely use the lowest 
levels of coding. Specific diagnostic codes for methamphetamine disorders are rarely 
entered and could not be used to consistently distinguish methamphetamine use disorders 
from other stimulant disorders (such as MDMA use disorders). While ICD-10 distinguishes 
cocaine-related disorders from other stimulant disorders, cocaine disorders were 
hypothesised to be less frequent in Australian mental health services, and anecdotal 
feedback from Australian clinicians was that many are likely to document terms such as 
“stimulant abuse” when seeing people with cocaine abuse.   
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Two further factors contribute to the decision to consider stimulant drugs as a broader 
group. First, there are significant regional differences in the type of stimulant used, with 
cocaine being the most widely used stimulant in North America and amphetamine-related 
stimulants dominating in Australia and South East Asia (United Nations Office on Drugs 
and Crime, 2011a; Degenhardt et al., 2008c; Degenhardt and Hall, 2012a). Therefore 
when comparing data globally, differences between individual stimulant drugs may also be 
confounded by other regional differences. Second, individuals often use more than one 
type of stimulant drug. In particular ecstasy use often overlaps with amphetamine and 
other drug use (Degenhardt et al., 2009b; Kinner et al., 2008; Keyes et al., 2008). 
Therefore attempting to distinguish between specific stimulant drugs would require 
research designs which compared at least four groups of people with stimulant use 
disorders; (i) those with cocaine use disorders (ii) those with methamphetamine or ecstasy 
use disorders (iii) those with multiple stimulant use disorders and (iv) those with 
unspecified stimulant use disorder. All planned analyses in these studies aimed to 
examine the overlap of stimulant use disorders with cannabis disorders and to compare 
these with people with no substance disorders. Adding four or more subcategories of 
stimulant disorder would add substantially to the complexity of planned analyses, while 
reducing their statistical power. Because a large proportion of people would be likely to be 
in mixed or unspecified stimulant disorder groups, this increase in complexity would be 
unlikely to be accompanied by additional explanatory power. Combining amphetamine, 
MDMA and cocaine use disorders into single stimulant use category does create 


























Figure 1.1. Overview of research questions.  
PART 1: THE AUSTRALIAN POPULATION 
What is the prevalence of stimulant use disorders in the Australian population? 3 
What are the characteristics of people with stimulant use disorders in Australia?  4 
Are stimulant use disorders more common in people with other risk factors for 
psychosis? 4 
PART 2: EARLY PSYCHOSIS 
Is greater stimulant availability in the community associated with more frequent 
admission for psychosis? 5 
What is the prevalence of stimulant use disorders in people with first admission 
psychosis? 6 
What are the correlates of stimulant use disorders in people with first admission 
psychosis? 6 
Are stimulant use disorders associated with readmission in the first two years of 
psychosis? 7 
PART 3: SCHIZOPHRENIA 
Are stimulant use disorders associated with increased risk of progression to 
schizophrenia over five years? 8 
What is the prevalence of stimulant use disorders in people with schizophrenia? 9 
What are the correlates of stimulant use disorders in people with schizophrenia? 9 
In people with schizophrenia, are stimulant use disorders associated with frequent 
service use, physical health problems or housing instability? 9 
         = Chapter number.   n
Internationally, what is the prevalence of stimulant use disorder in people with 
psychosis? 2 
LITERATURE REVIEW 
Are there regional or national differences in the prevalence of stimulant use disorders 
in people with psychosis? 2 
What person or service factors are associated with variations in prevalence? 2 
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ABSTRACT   
Objective 
Stimulant abuse and dependence often complicate the care of people with psychotic 
disorders. This study systematically reviews prevalence estimates reported for stimulant 
abuse and dependence in people with psychotic disorders, and examines personal, 
clinical, regional and methodological factors which explain variation in these rates.  
Methods 
PsychINFO, EMBASE and MEDLINE (1946 - 2013) were searched systematically for 
studies reporting on stimulant drug use disorders in representative samples of people with 
psychotic disorders. Random effects models estimated the pooled rate of a stimulant use 
disorder, defined to include stimulant abuse and stimulant dependence. Study 
characteristics associated with heterogeneity in rates of stimulant use disorder were 
examined by subgroup analyses for categorical variables, by meta-regression for 
continuous independent variables and by multiple meta-regression.  
Results 
64 studies provided 68 estimates of lifetime or recent stimulant use disorders in 22,500 
people with psychosis. The pooled rate of stimulant use disorder was 8.9% (95% CI 7.4% - 
10.5%). Higher rates of stimulant use disorders were reported in studies of affective 
psychosis, studies from inpatient settings, studies from the USA and Australia, and studies 
with higher rates of cannabis disorder; in multiple meta-regression analysis these factors 
This chapter is based on the manuscript: Sara G, Large M, Matheson S, Burgess PM, 
Malhi G, Whiteford H, Hall W (2014). Stimulant use disorders in people with 
psychosis: a meta-analysis of rate and factors affecting variation. 
Australian and New Zealand Journal of Psychiatry. In press. 
Reproduction of the submitted original within a book or thesis is permitted by the Sage 
Publications Author rights policy. www.sagepub.com/journalgateway/authorGateway.htm 
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explained 68% of between-study variance. Rates of stimulant use disorder were stable 
over time, and unrelated to age, gender, stage of psychosis, type of stimulant drug or 
study methodology factors.  
Conclusions 
Reported rates of stimulant use disorder in people with psychosis are much higher than in 
the general population but vary widely and are associated with regional, service setting 
and clinical differences between studies. It is likely that stimulants contribute to the overall 
burden of psychosis, and that social and environmental factors combine with drug and 





Amphetamines, cocaine and other stimulants are the most widely used illicit drugs after 
cannabis in developed countries (United Nations Office on Drugs and Crime, 2011a). They 
are most commonly used by males in their late teens and early twenties, who are also the 
group most at risk for the development of psychotic disorders (Adlaf et al., 2005; 
Degenhardt et al., 2007b; Durell et al., 2008; Substance Use and Mental Health Services 
Administration, 2010; Wilkins et al., 2006). In 2007, around 3% of Australians, including 
more than 8% of men aged 16 to 29, met criteria for a lifetime stimulant use  disorder 
(Sara et al., 2011a).   
Stimulants may have harmful effects across the spectrum of psychotic disorders and, 
along with cannabis, may play a causal role in some episodes of psychosis (Sara, 2012). 
Many regular stimulant users report transient and dose-dependent psychotic symptoms 
(McKetin et al., 2006b). Stimulants can precipitate brief syndromes of drug-induced 
psychosis (Bramness et al., 2012; Crebbin et al., 2009), sometimes diagnosed as 
“methamphetamine psychosis” (Kittirattanapaiboon et al., 2010; Yui et al., 2000b). 
Stimulant exposure can worsen existing psychotic symptoms or precipitate relapse among 
people with established psychotic disorders such as schizophrenia (Curran et al., 2004). 
The effects of stimulants on psychosis are more common in people with patterns of severe 
or dependent stimulant use (McKetin et al., 2013; Chen et al., 2003), and stimulants such 
as methamphetamine may be more potent than cannabis in precipitating psychotic 
symptoms (McKetin et al., 2013). Therefore, knowing the rate of severe or dependent 
stimulant use in people with psychosis may help in understanding whether stimulant drugs 
contribute significantly to the overall burden of psychosis. 
Studies of people with psychosis have reported rates of stimulant use disorder which 
range from below 4% (Compton et al., 2005; Hambrecht and Häfner, 1996; Martins and 
Gorelick, 2011) to more than 30% (Gearon and Bellack, 2000; Sevy et al., 1990). In a 
population cohort of people with a diagnosis of schizophrenia in NSW, 14% also had a 
diagnosis of a stimulant use disorder (Sara et al., 2014c). This wide variation between 
studies may reflect differences in the personal, clinical or social characteristics of the 
people with psychosis who were included in the study. Delineating these factors would 
help in understanding which groups of people with psychosis may be at greater risk of 
stimulant-related harms. There are also significant regional differences in stimulant use in 
the general population (United Nations Office on Drugs and Crime, 2011a; Agar and 
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Reisinger, 2004; Degenhardt et al., 2008c). If stimulants contribute to the overall burden of 
psychosis then stimulant use disorders in people with psychosis may be more common in 
regions where stimulant use is also more common in the general population.  Rates of 
stimulant use may also be influenced by the subtype or stage of psychosis; several studies 
of people with a first episode of schizophrenia-spectrum or affective psychosis have 
reported rates of stimulant use or dependence between 15% and 30% (Hides et al., 2006; 
Mauri et al., 2006; Rabinowitz et al., 1998; Ruiz-Veguilla et al., 2009; Sara et al., 2013; 
Wade et al., 2005).  Cannabis use often precedes or accompanies stimulant use 
(Degenhardt et al., 2009a; Power et al., 2014) and cannabis disorders are one of the 
strongest predictors of later stimulant disorder (Degenhardt et al., 2007c). Therefore in 
examining stimulant use disorders it is also important to measure and control for cannabis 
use disorders.  
The wide between-study variation in rates of stimulant use disorder in people with 
psychosis may also be due to methodological differences between studies: rates of 
stimulant use disorder are likely to be influenced by issues including the period examined 
(lifetime or recent stimulant use), the inclusion or exclusion of specific stimulant drugs 
(amphetamine, cocaine, ecstasy), or whether drug-induced psychoses were included or 
excluded. 
The first aim of this study is to synthesize the results of primary research through meta-
analysis, in order to derive a pooled estimate and range for the rate of stimulant use 
disorder in people with psychosis. The second aim of this study is to identify whether 
between-study variation in the rate of stimulant use disorder is systematically influenced by 
personal, clinical or social factors, or whether this heterogeneity is better explained by 
methodological differences between studies.  
METHODS 
The methods conformed to the guidelines for Meta-analysis of Observational Studies in 
Epidemiology (Stroup et al., 2000).  
Data Sources 
PsychINFO (1967 - 2013), EMBASE (1974 - 2013) and MEDLINE (1946 - 2013) were 
searched systematically for peer-reviewed English-language publications reporting rates of 
substance use in people with psychosis. To identify potential studies for examination in full 
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text, titles, abstracts and keywords were searched for “Schizophrenia OR Psychosis OR 
Psychotic OR Bipolar OR Mania OR Manic OR Prodrome OR Prodromal” AND “Substance 
OR Dual Diagnosis OR Drug Abuse OR Cannabis OR Amphetamine OR 
Methamphetamine OR Stimulant OR Cocaine”.  The search strategy was broad, including 
any substance use disorder or cannabis disorder, because rates of stimulant use disorder 
are often reported as incidental findings without mention of stimulants in the study’s title, 
key words or abstract. The reference lists of identified studies and key literature reviews 
were hand-searched for further relevant studies. 
Study selection and data extraction 
Studies were included if they reported the recent or lifetime prevalence of stimulant use 
disorders in people with a diagnosed psychotic disorder. We accepted the diagnostic 
method used by the original study to identify and define stimulant use disorders and 
psychosis. Stimulant Use Disorders were defined to include DSM or ICD categories of 
abuse and dependence, or, where these were not applied, levels of use characterised by 
the original study as “abuse”, “problem use”, “severe use” or “harmful use”. Studies that 
reported stimulant use but did not report on rates of stimulant use disorder were excluded. 
Stimulants included unspecified stimulants or any specific stimulant drug identified through 
chemical or common names including amphetamine, methamphetamine, ice, 
cocaine/crack, or ecstasy/MDMA. Psychoses included commonly used diagnostic 
categories (schizophrenia, schizo-affective disorder, affective psychosis, brief, atypical and 
drug-induced psychoses) or prodromal states.  
Studies were included if they described rates of stimulant use disorder in representative 
clinical populations of people with psychosis, such as successive admissions or referrals 
from a defined catchment area or population. We excluded studies whose sampling 
framework rendered them non-representative or were likely to systematically influence the 
estimated prevalence of substance use disorders, such as clinical samples from dual 
diagnosis programmes, groups with only drug-related psychoses (such as 
“methamphetamine psychosis”), studies where groups were selected to obtain matched 
samples of people with and without substance comorbidity, and studies excluding people 
with substance use or dependence. Some studies had inclusion or exclusion criteria which 
were ambiguous or had the potential to distort prevalence estimates, such as referrals 
from clinical services to specialist treatment trials or imaging studies. If the study authors 
explicitly excluded people with substance use disorders, then these studies were excluded 
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from this review. However, even where substance use disorders were not explicitly 
excluded, people with comorbid substance use disorders may have been less likely to be 
referred for these studies. Therefore these studies were flagged for subgroup analysis 
rather than being excluded.  Some representative samples allowed the inclusion of people 
with drug-induced psychoses within a larger multi-diagnostic sample: these studies were 
included in this review, but were flagged for subgroup analysis. In order to reduce the 
probability of chance results from very small samples, we defined an arbitrary minimum 
sample size of 15 people.  
Two authors selected the studies according to our inclusion criteria and extracted data 
independently. These authors were a psychiatrist (GS) and a psychologist (SM) who both 
had prior experience in data extraction for systematic reviews.   Multiple published studies 
based on a single clinical sample were examined for possible overlap; a single estimate 
was obtained from the most complete study reporting on those participants. One published 
conference abstract was identified which included all relevant data and was not otherwise 
reported: this was included in the review. Differences between raters were resolved by a 
joint examination of papers.  
Definition of outcome and moderator variables 
The primary outcome measure was the rate of stimulant use disorder in each study, 
expressed as the number of people with stimulant use disorder divided by the number of 
participants with psychosis in the study. Recency of drug use was classed as either 
“Recent” (within previous 12 months) or “Lifetime” (greater than 12 months). Psychosis 
diagnoses were grouped into “Schizophrenia Spectrum” (including schizophrenia, 
schizoaffective disorder and schizophreniform psychoses), “Affective Psychoses” (bipolar 
disorder, psychotic depression), “Other Psychoses” (brief, atypical and drug-induced 
psychotic disorders), and “Mixed” (diagnostic subtype mixed or unspecified).A binary 
variable was constructed to indicate whether persons with substance-induced psychosis 
were included or excluded. Stage of psychosis was classed as “Prodromal”  (including 
prodromal, pre-psychotic, ultra high risk or comparable states), “First Episode” (first 
episode psychosis, first hospitalisation or first contact with a specialist early psychosis 
service), “Established illness” (ongoing or chronic illness, diagnoses limited to 
schizophrenia only, contact with extended care or rehabilitation services) or “Mixed” (stage 
of illness mixed or not specified). Where reported, the rate of recent or lifetime cannabis 
use disorder was recorded. Where a study collected data over several years, the year of 
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collection was taken as the midpoint of the study period. Where year of collection was not 
reported, it was estimated by calculating the average time-lag between collection and 
publication for other studies in the review where this data was available, and subtracting 
this from the publication year. Country, location within country (urban, rural, mixed or 
unspecified) and service setting (inpatient, community, mixed or not specified) were 
recorded.  
Data were extracted on study design and eight strength of reporting variables: the use of 
research interviews in (i) psychosis or (ii) substance disorder diagnosis; the use of 
standardised criteria (DSM or ICD) for (iii) psychosis or (iv) substance disorder; (v) the 
inclusion of biological assays (hair, urine or blood) in substance identification; (vi) missing 
demographic data for (sample average age or sex distribution); (vii) the use of an 
estimated year of collection and  (viii) type of recruitment method  (random/representative 
or  non-random). A composite “strength of reporting” score was constructed by simple 
addition of these eight individual scores.  
Meta-analysis 
Analysis was conducted using Comprehensive Meta-analysis (CMA) Version 3, (Biostat, 
Inc, Englewood, New Jersey, USA). An a priori choice of a random effects model was 
made for all analyses because of significant variation in study design and populations. 
Where studies reported stimulant rates for mutually exclusive diagnostic groups, these 
were treated as subgroups and examined separately.   
Subgroup analyses 
The contribution of categorical study characteristics (e.g., type of stimulant, stage of 
psychosis) to between-study heterogeneity was assessed using Q-value statistics.  The 
contribution of continuous variables (e.g., age, sex, year of publication, cannabis rate) to 
between-study heterogeneity was examined using a random effects (restricted maximum 
likelihood) meta-regression model. Continuous and categorical variables with univariate 
significance were examined together using a random effects (restricted maximum 
likelihood) meta-regression model, with Knapp-Hartung distribution. Categorical variables 
were examined and, where required, collapsed into fewer categories to ensure that no 
variable had a Variance Inflation Factor (VIF) greater than 3.  
The effect of variations in strength of reporting was measured by subgroup analysis for 
individual strength of reporting variables and after splitting studies at the median of the 
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composite strength of reporting score. To investigate possible publication bias, a funnel 
(Egger’s) plot of the main effect was examined for interaction between stimulant rate and 
standard error. Duval and Tweedie’s “trim and fill” method (Duval and Tweedie, 2000) was 
used to examine the effect on the pooled effect rate of hypothetical missing studies. 
RESULTS 
Search Results  
The search strategy identified 1,610 potentially relevant citations; 1,291 were excluded 
following abstract review and 255 were excluded after review in full text (Figure 2.1). The 
64 remaining studies had a combined sample size of 22,500 people with psychosis (per 
sample mean 331; SD 1,195; range 40-9,919). They provided 68 estimates of stimulant 
use disorder rates, since some studies included estimates for more than one diagnostic 
group. Differences between raters were resolved for rates of stimulant use disorder (20 
studies) and other study details (6 studies).  Summary details for all included studies are 






































Figure 2.1. Search strategy 
  
Search 1: PsychINFO (1967 – 2013), EMBASE (1974 – 2013) and MEDLINE (1946 
– 2013). Strategy: “Schizophrenia OR Psychosis OR Psychotic OR Bipolar OR 
Mania OR Manic OR Prodrome OR Prodromal” AND “Substance OR Dual 
Diagnosis OR Drug Abuse OR Cannabis OR Amphetamine OR Methamphetamine 
OR Stimulant OR Cocaine”).  
Search 2: Hand searching of references in published papers and systematic reviews 
of the incidence of cannabis, stimulant or other substance use in people with 
psychotic illness or high risk states.  
1,610 studies (excluding duplicates) 
identified, titles and abstracts reviewed 
1,291 excluded based on abstract  
205 excluded after review in full text 
319 studies examined in full text 
64 studies reported the rate of stimulant use disorder in a representative sample of 
people with a psychotic disorder or prodromal/at risk state for psychosis.  




Meta-analysis of studies reporting stimulant use disorder 
The pooled rate of recent or lifetime stimulant use disorder was 8.9% (95% confidence 
interval 7.4% - 10.5%, median 8.5%, interquartile range 4.0% - 15.9%). Between-study 
heterogeneity was assessed as high (I2 = 91.0%). The study with the lowest reported rate 
of stimulant use disorders (0.5%) described recent (12-month) substance abuse in 475 
medication-free young people referred to an early psychosis service in Denmark (Petersen 
et al., 2007). The highest rate was reported by study examining 67 people attending a 
psychiatry outpatient service in an inner city mental health service  in Baltimore, USA 
(Gearon and Bellack, 2000); 37.3% of that group had 12-month diagnosis of cocaine 
abuse or dependence.  
Test of possible publication bias 
Examination of the funnel plot showed asymmetry (Figure 2.1). The trim and fill method 
identified and removed 10 studies, producing a revised pooled estimate of 10.5% (95% CI 



































Subgroup analyses of clinical study characteristics are summarised in Table 2.1. The 
highest rates of recent or lifetime stimulant use disorder were reported in studies which 
examined affective psychosis (Miller and Tanenbaum, 1989; Mueser et al., 1992; 
Rabinowitz et al., 1998; Strakowski et al., 1996), having a pooled estimate of 15.2% (95% 
CI  6.9% - 30.2%). Studies of people with schizophrenia also reported higher rates of 
stimulant use disorder than studies of people with mixed or unspecified psychosis 
diagnoses. The pooled estimate of stimulant use disorder was non-significantly higher in 
studies examining lifetime rather than recent periods. The inclusion or exclusion of drug-
induced psychosis, the stage of psychosis or the type of stimulant drug did not contribute 
to between-study heterogeneity.  
 
The influence of service and setting factors is summarised in Table 2.2. Higher rates of 
stimulant use disorder were reported in studies from hospital settings than in studies from 
community or mixed settings. There were significant regional or national differences, with 
the highest rates of stimulant use disorder being reported by studies from the USA and 
Australia, and lower rates reported by studies from Western and Southern Europe, 
Scandinavia, the UK and Ireland. There were differences between regions in the type of 
stimulant drug examined: most studies from the USA (19 of 29 studies) reported cocaine 
use disorders, UK studies reported a mix of amphetamine (3 studies) and ecstasy use 
disorders (2 studies), European studies reported cocaine (7 studies) or unspecified 
stimulant use disorders (5 studies). Australian studies reported 









95% CI   
Between sample 






limit   Q df P I2   Q df P 
Type of stimulant drug                           
  Amphetamine 14 8.4% 5.5% 12.5% 
 
107.8 13 <0.001 87.9 
 
1.5 3 0.692 
  Cocaine 32 8.6% 6.5% 11.4% 
 
327.8 31 <0.001 90.5 
   
  
  Ecstasy 2 4.7% 1.4% 14.9% 
 
3.5 1 0.060 71.6 
   
  
  Stimulants mixed/unspecified 20 9.7% 6.9% 13.4%   245.8 19 <0.001 92.3        
Period of estimate                           
  Lifetime (>12 months) 41 9.8% 7.7% 12.4% 
 
315.6 40 <0.001 87.3 
 
2.4 1 0.120 
  Recent (<12 months) 27 7.2% 5.2% 9.8%   416.9 26 <0.001 93.8        
Type of psychosis 
            
  
  Schizophrenia spectrum 38 10.4% 8.1% 13.4% 
 
316.3 37 <0.001 88.3 
 
11.7 3 0.008 
  Affective psychosis 4 15.2% 6.9% 30.2% 
 
10.9 3 0.012 72.6 
   
  
  Other psychoses 4 10.4% 4.5% 22.0% 
 
28.0 3 <0.001 89.3 
   
  
  Mixed or unspecified 22 5.2% 3.6% 7.5% 
 
373.1 21 <0.001 94.4 
   
  
Drug-induced psychosis                            
  Excluded from sample 53 8.8% 7.1% 10.8% 
 
492.5 54 <0.001 89.0 
 
0.0 1 0.961 
  Included in sample 15 8.7% 5.7% 12.9%   151.2 14 <0.001 90.7         
Stage of psychosis                           
  Early and prodromal psychosis 26 7.8% 5.7% 10.5% 
 
290.6 25 <0.001 91.4 
 
2.1 2 0.345 
  Established psychosis 28 8.6% 6.4% 11.4% 
 
291.4 27 <0.001 90.7 
   
  











95% CI   
Between sample 






limit   Q df P I2   Q df P 
Type of service                           
  Hospital 27 13.9% 10.8% 17.7% 
 
152.9 26 <0.001 83.0 
 
20.1 3 <0.001 
  Community 13 7.6% 5.2% 10.9% 
 
118.2 12 <0.001 89.9 
   
  
  Mixed 24 6.4% 4.8% 8.5% 
 
236.3 23 <0.001 90.3 
   
  
  Other / unspecified 4 3.8% 0.9% 15.2%   11.1 3 0.011 73.1        
Location within country                           
  Urban 36 9.5% 7.3% 12.2% 
 
349.8 36 <0.001 89.7 
 
0.9 2 0.652 
  Mixed urban/rural 23 7.8% 5.7% 10.7% 
 
317.2 23 <0.001 92.8 
   
  
  Not specified 3 5.6% 2.2% 13.6% 
 
9.3 2 0.009 78.5 
   
  
Country or region                           
  USA 29 11.9% 9.1% 15.3% 
 
225.0 28 <0.001 87.6 
 
17.4 6 0.008 
  UK 7 6.8% 3.8% 11.7% 
 
57.8 6 <0.001 89.6 
   
  
  Europe 10 8.3% 4.9% 13.5% 
 
84.2 9 <0.001 89.3 
   
  
  Scandinavia 5 4.7% 2.4% 9.3% 
 
40.0 4 <0.001 90.0 
   
  
  Australia 9 10.8% 6.8% 16.9% 
 
85.2 8 <0.001 90.6 
   
  





Meta-regression was used to examine whether individual continuous variables predicted 
differences between studies in the reported rate of stimulant use disorder (Table 2.3). 
Higher rates of stimulant use disorder were associated with higher rates of cannabis use 
disorder. Stimulant use disorder rates were not related to the average age or proportion of 
males in study samples. There was no significant change in stimulant use disorder rates 
over the period covered by the studies, from 1971 (McLellan and Druley, 1977) to 2009 
(Sara et al., 2013).  
 
Table 2.3. Univariate meta-regressions: association of continuous variables with prevalence of 













Average age of sample 61 0.003 0.020 -0.037 0.043 0.13 0.898 
Percent of sample male 66 0.012 0.009 -0.005 0.029 1.39 0.170 
Percent cannabis 
use/disorder 63 0.036 0.007 0.022 0.049 5.36 <0.001 
Year of data collection 68 -0.027 0.017 -0.062 0.007 -1.58 0.118 
 
Study methodology variables had little impact on estimated stimulant use disorder rates 
(Table 2.4). Studies with missing demographic (age or sex) data reported higher rates of 
substance use disorder. Studies which used biological assays to define recent substance 
use had a higher pooled estimate of stimulant use disorder rates than studies which did 
not use assays. Differing rates of stimulant use were not explained by whether studies 
used operational criteria or research interviews for defining psychosis or stimulant use 








95% CI   
Between sample 






limit   Q df P I2   Q df P 
Sampling and selection                           
  Representative or random sample 59 9.1% 7.6% 11.0% 
 
633.6 58 <0.001 90.8 
 
0.6 1 0.431 
  Non-random sample 9 7.5% 4.6% 11.8%   60.7 8 <0.001 86.8        
Diagnostic criteria for psychosis                           
  DSM or ICD criteria used 57 9.3% 7.7% 11.2% 
 
577.2 56 <0.001 90.3 
 
0.4 1 0.516 
  Criteria not used or unclear 9 7.9% 4.9% 12.4%   86.6 8 <0.001 90.8        
Diagnostic criteria for stimulant disorder                         
  DSM or ICD criteria used 51 8.9% 7.3% 10.9% 
 
532.4 50 <0.001 90.6 
 
0.0 1 0.942 
  Criteria not used or unclear 17 8.8% 6.2% 12.3%   159.5 16 <0.001 90.0        
Psychosis diagnosis method                           
  Research diagnostic interview 40 7.7% 6.1% 9.9% 
 
369.4 39 <0.001 89.4 
 
2.4 1 0.120 
  Routine clinical diagnoses 28 10.4% 7.8% 13.7%   337.7 27 <0.001 92.0        
Substance diagnosis method                           
  Research diagnostic interview 38 8.2% 6.4% 10.5% 
 
364.8 37 <0.001 89.9 
 
0.6 1 0.429 
  Routine clinical diagnoses 30 9.5% 7.2% 12.5%   355.7 29 <0.001 91.8        
Substance estimate includes biological assay   
  Uses assay (hair, urine etc) 12 13.1% 8.7% 19.3% 
 
89.3 11 <0.001 87.7 
 
4.3 1 0.038 
  No assay 56 8.1% 6.6% 9.8%   652.6 55 <0.001 91.6        
Sample demographic data complete  
  Data complete 56 8.0% 6.6% 9.8% 
 
658.3 55 <0.001 91.6 
 
4.2 1 0.040 
  Sample age or sex missing 12 12.9% 8.6% 18.9%   82.6 11 <0.001 86.7        
Collection period data complete                           
  Period reported 38 9.6% 7.6% 12.0% 
 
505.0 37 <0.001 92.7 
 
1.1 1 0.285 
  Period estimated  30 7.8% 5.9% 10.4%   224.7 29 <0.001 87.1        
Composite strength of reporting score                         
  Below median 18 8.6% 6.1% 12.0% 
 
185.4 17 <0.001 90.8 
 
0.0 1 0.837 
  Median or higher 50 8.9% 7.3% 10.9%   510.7 49 <0.001 90.4        
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Multiple meta-regression  
Significant univariate predictors of between-study heterogeneity were examined by 
multiple meta-regression (Table 2.5). To avoid unacceptable inflation of variance, two 
categorical variables (region, service setting) were collapsed to a smaller number of 
categories.  Five studies (8%) had no data for rates of cannabis use and were excluded 
from this analysis. The rate of cannabis use disorders was the strongest predictor of 
stimulant use disorder rates, accounting for 43% of between-study variance. After 
controlling for cannabis use disorders, the period of observation (lifetime or 12-month) and 
the type of psychosis diagnosis did not contribute to between-study heterogeneity. 
Significant differences between regions remained in the multivariate model. Higher rates of 
stimulant use disorder were reported in studies from the USA and Australia.  The 
combined model explained 67% of between-study variance (Goodness of fit: Tau² = 
0.8646, I² = 91.37%, Q = 718.81, df = 62, p = < 0.0001).  
 
Table 2.5. Multiple meta-regression, predictors of variation in rate of stimulant use disorder in 
studies of people with psychosis.  
 
        95% CI       
    Coefficient SE Lower Upper t p   
Cannabis disorder rate a 0.034 0.006 0.022 0.046 5.500 0.000   
Hospital setting 0.443 0.192 0.057 0.829 2.300 0.025   
Psychosis diagnosis b         
  Affective psychosis 0.645 0.426 -0.208 1.499 1.520 0.135 F=2.24, 
df=3,53, 
p=0.094 
  Schizophrenia 0.561 0.221 0.118 1.004 2.540 0.014 
  Other psychoses 0.472 0.462 -0.455 1.398 1.020 0.312 
Region c          




  Australia 0.572 0.385 -0.200 1.345 1.490 0.143 
  Europe d 0.111 0.323 -0.537 0.759 0.340 0.733 
  UK 0.454 0.362 -0.272 1.181 1.250 0.215 
 
Notes. (a) Reference group is mixed/unspecified psychosis. (b) Reference group is other countries, including 
studies from mixed or multiple countries, Canada, Israel and Morocco. Pooled estimates from Canada were 
significantly lower than those from the USA: grouping Canada with USA or examining separately resulted in 
unacceptable inflation of variance.  (c) Includes studies from Belgium, Germany, Switzerland, France, Italy, 






The first aim of this study was to estimate the rate and range of stimulant use disorders in 
people with psychosis. We found a pooled estimate (including recent and lifetime 
disorders) of 8.9% (95% CI 7.4% - 10.5%). Estimates varied widely between studies, and 
factors contributing to this variation are discussed below. The overall rate of stimulant use 
disorders in people with psychosis was substantially higher than estimated rates in the 
general population. The Global Burden of Disease study estimated the 12-month 
prevalence of amphetamine or cocaine use in the general population to be 0.3%-1.3% 
(Degenhardt and Hall, 2012b), and the point prevalence of stimulant dependence to be 
0.10-0.25% (Degenhardt et al., 2014). The current study cannot directly demonstrate the 
effect of stimulants, however there is substantial evidence that stimulants may precipitate 
or worsen psychotic symptoms (Hermens et al., 2009; Curran et al., 2004).The high 
prevalence of stimulant use in people with psychosis therefore suggests that stimulants 
may make a significant contribution to the overall burden of psychosis.  
The second aim of this study was to examine whether between-study variation in the rate 
of stimulant use disorder reflected factors that may be relevant to clinical care or health 
service planning, or was merely due to methodological differences between studies. There 
was very wide variation in rates of stimulant use disorder in people with psychosis: 
estimates ranged from 0.5% to 37.3%, with an interquartile range of 4.0% - 15.9%. We 
found that in a multiple meta-regression model, a combination of clinical and setting 
factors together accounted for nearly 70% of observed variation. Higher rates of stimulant 
use disorders were reported in studies with higher rates of cannabis disorder and studies 
from the USA and Australia. In univariate analyses higher rates were also reported in 
studies of affective psychosis and from inpatient settings.  Studies which included 
biological assays in the diagnosis of substance disorders reported higher rates of stimulant 
use or disorder, but other study methodology factors such as the period examined (lifetime 
or recent), the inclusion or exclusion of drug-induced psychosis or the use of structured 
diagnostic interviews had little impact on reported rates of stimulant use disorder. 
Cannabis use disorders were the strongest correlate of the prevalence of stimulant use 
disorders. A meta-analysis cannot examine whether cannabis and stimulant disorders co-
exist in the same individuals, but evidence from many other sources demonstrates such 
overlap. In the Australian population, 73% of people with lifetime stimulant use disorders 
also had lifetime cannabis use disorders (Sara et al., 2012). In clinical studies, most 
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people with psychosis who used stimulants also used cannabis (Degenhardt et al., 2010b; 
Power et al., 2014; Sara et al., 2014c: ). This is clinically significant because stimulants 
and cannabis may act synergistically in worsening psychotic symptoms (Paparelli et al., 
2011).  
Australian clinicians have expressed concern that stimulant abuse has contributed to 
increased demand for acute mental health services (Australian Senate Select Committee 
on Mental Health, 2006). We found that after controlling for differences in diagnostic mix 
and service setting, rates of stimulant use disorder in people with psychosis were higher in 
studies from Australia and the USA than in studies from the UK and Europe. Studies from 
the USA mainly reported cocaine use disorders and Australian studies mainly reported 
abuse of amphetamine-related stimulants. These findings mirror regional differences in 
stimulant use in the broader population: the Global Burden of Disease study (Degenhardt 
et al., 2014) found high rates of stimulant dependence in North America, South East Asia 
and Australasia, with cocaine being the main stimulant used in in North America and 
amphetamines being more prevalent in Australasia and South East Asia. This suggests 
that people with psychosis may be influenced by the same social and environmental 
drivers of drug use and choice as other people in their community. It also suggests that the 
impact of stimulant drugs on people with psychosis might be greater in the USA and 
Australia than in some other regions. 
In univariate analyses, higher rates of stimulant use disorder were reported by studies of 
people with affective psychoses. There are several possible explanations for this finding. 
First, it is based on a small number of studies, and may be a chance finding or influenced 
by other characteristics of those studies. Second, people with affective psychoses may 
use stimulants as self-medication for experiences of depression or dysphoria (Mueser et 
al., 1998; Barch and Carter, 2005). Third, recent evidence suggests a strong relationship 
between affective disorders and psychotic experiences in the general population (van Os, 
2014), and it is possible that stimulants and other substances interact with vulnerabilities to 
both mood disturbance and psychotic experience. Finally, substance use disorders can 
cause diagnostic uncertainty in psychosis (Mathias et al., 2008; Sara et al., 2014a) and it 
is possible that stimulant misuse causes overactivity or elation, contributing to 
misdiagnoses of an affective disorder. On the other hand, our findings are less consistent 
with “reward deficiency” models which focus on anhedonia, negative symptoms and 
antipsychotic medication as primary causes of stimulant and other substance comorbidity 
in psychosis (Blum et al., 1996; Bedard et al., 2013; Green et al., 1999). These would 
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predict higher rates of stimulant use disorder in studies of schizophrenia and in studies of 
established or chronic psychosis: we found that studies of schizophrenia reported lower 
rates than those of affective psychosis, and rates of stimulant use disorder did not differ 
between studies of early psychosis and those of established or chronic psychoses (Blum 
et al., 1996; Bedard et al., 2013; Green et al., 1999; van Os, 2014) 
We did not find a significant change in the rate of stimulant use disorder in people with 
psychosis between 1974 and 2009. It is likely that this negative finding may have been due 
to the substantial between-study heterogeneity observed. However the finding is also 
consistent with the Global Burden of Disease study, which found no discernible increase in 
the prevalence of stimulant dependence in the general population between 1990 and 2010 
(Degenhardt et al., 2014).   
Finally, we also found higher rates of stimulant use disorder in studies of people in hospital 
settings than in community or mixed settings. This may reflect better detection and 
diagnosis of substance comorbidity in hospital settings, a greater level of severity and 
acuity in hospital settings, or selection of people more likely both to use substances and to 
require inpatient care (e.g., younger males or people with fewer personal or social 
supports). However, higher rates of stimulant use disorder in inpatient settings would also 
be consistent with stimulants playing a role in precipitating or worsening psychosis. We 
have previously found that admissions to NSW Mental health units with stimulant related 
psychosis occurred more often during periods of greater amphetamine availability (Sara et 
al., 2011b).   
Limitations of the study 
This study aimed to examine factors contributing to between-study variation in stimulant 
use disorder estimates, however the high degree of heterogeneity in these estimates is 
also a limitation of this study. Many of the pooled estimates in subgroup analyses had wide 
confidence intervals, and therefore some negative findings in this study may reflect type II 
error. For example, estimates of lifetime abuse of any drug would be expected to be higher 
than estimates of recent abuse: we found lifetime rates of stimulant use disorder were non-
significantly higher than recent rates.  
We found that rates of stimulant use disorder were low in studies with higher variance, 
suggesting that the pooled estimate of the rate of stimulant use disorder has not been 
inflated by publication bias. We excluded studies whose selection criteria appeared likely 
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to bias the estimated rate of stimulant or other drug use, and found that studies with 
potentially non-representative samples did not have systematically higher rates than those 
with more clearly representative samples. However there may have been other sources of 
selection or reporting bias in the studies included. All studies examined were in English, 
and there were more estimates and higher precision in estimates from English-speaking 
countries. There were few studies from many individual countries; lower estimates from 
those countries may reflect less complete capture of studies or systematic differences in 
studies from those countries published in English compared with other languages. Self-
reported drug use may differ systematically between countries, and is likely to be 
underestimated in countries where drug use may lead to more serious criminal sanctions.  
We examined stimulant use disorders as a group since few studies reported on stimulant 
abuse or dependence as separate disorders. The strong correlation between stimulant use 
disorders and cannabis use disorders also suggests that some of the univariate 
associations found may be non-specific associations of substance use disorder rather than 
specific associations of stimulant use disorder. As in any meta-analysis, the associations 
found are ecological associations, and may not be reflected in individuals.  
CONCLUSIONS 
People with psychosis abuse stimulants at much higher rates than the general community. 
The type of psychosis, service setting and country all affect estimates: higher rates of 
stimulant use disorder are reported in studies of affective psychosis, from inpatient settings 
or from the USA and Australia. Methodological factors contribute little to between-study 
variation in rates of stimulant use disorder. Increased rates of stimulant use disorder are 
not limited to younger people or earlier stages of psychosis, suggesting that stimulants 
may contribute to the burden of psychosis at all stages of illness, from early psychosis to 
established schizophrenia. Cannabis use disorders are the strongest correlate of stimulant 
use disorders in studies of people with psychosis. Further research is required to 
disentangle the adverse effects of stimulants and cannabis: clinical or population-based 





Table 2.6: Details of included studies 
 











(Arndt et al., 
1992) USA 1986 Lifetime Stimulant 
Schizophrenia 
spectrum Established 9 145 6.2% 31 71 19.3% 
(Barbee et al., 
1989) USA 1983 Lifetime Amphetamine 
Schizophrenia 
spectrum Mixed 6 53 11.3%  66 35.8% 
(Barry et al., 
1995) USA 1989 Lifetime Amphetamine Mixed Established 8 253 3.2% 44 51 15.8% 
(Bersani et al., 
2002) Italy 1996 Lifetime Stimulant 
Schizophrenia 
spectrum Established 23 125 18.4% 32 100 26.4% 
(Brown, 1998) England 1992 Recent Amphetamine Mixed Established 3 185 1.6%  68 9.2% 
(Buckley et al., 
1994) USA 1988 Lifetime Cocaine 
Schizophrenia 
spectrum Established 3 118 2.5% 34 66 9.3% 
(Cantor-Graae 
et al., 2001) Sweden 1998 Lifetime Amphetamine 
Schizophrenia 
spectrum Established 6 87 6.9% 48 62 17.2% 
(Carr et al., 
2009) Canada 2002 Recent Cocaine Mixed 
Early 
psychosis 2 243 0.8% 25 78 29.2% 
(Chouljian et 
al., 1995) USA 1987 Recent Cocaine 
Schizophrenia 
spectrum Established 11 100 11.0% 27 81 11.0% 
(Compton et 
al., 2005) USA 1999 Lifetime Cocaine 
Schizophrenia 
spectrum Mixed 16 248 6.5% 43 61 6.5% 
(Condren et 
al., 2001) Ireland 1995 Lifetime Amphetamine 
Schizophrenia 
spectrum Established 13 99 13.1% 45 61 42.4% 
(Coulston et 
al., 2007) Australia 2001 Lifetime Amphetamine 
Schizophrenia 
spectrum Established 6 59 10.2% 26 100  
(DeQuardo et 
al., 1994) USA 1989 Lifetime Cocaine 
Schizophrenia 
spectrum Established 3 67 4.5% 29 63 28.4% 
(Dervaux et 
al., 2001) France 1995 Lifetime Cocaine 
Schizophrenia 
spectrum Established 1 100 1.0% 34 68 27.0% 
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(Dixon et al., 
1991) USA 1988 Lifetime Cocaine 
Schizophrenia 
spectrum Established 14 83 16.9% 31  31.3% 
(Duke et al., 
2001) England 1990 Lifetime Stimulant 
Schizophrenia 
spectrum Established 23 265 8.7% 50 53 19.2% 
(El Omari et 
al., 2011) Morocco 2005 Lifetime Cocaine 
Schizophrenia 
spectrum Mixed 1 77 1.3% 32 72 35.1% 
(Elangovan et 
al., 1993) USA 1991 Recent Cocaine 
Schizophrenia 
spectrum Mixed 4 48 8.3% 32 49  
(Elangovan et 
al., 1993) USA 1991 Recent Cocaine 
Other 
psychoses Mixed 12 40 30.0% 32 49  
(Farrelly et al., 
2007) Australia 2002 Recent Stimulant Mixed Established 5 182 2.7% 31 68 11.0% 
(Fowler et al., 
1998) Australia 1992 Lifetime Amphetamine 
Schizophrenia 
spectrum Established 26 194 13.4% 36 72 36.1% 
(Gearon and 
Bellack, 2000) USA 1994 Recent Cocaine 
Schizophrenia 
spectrum Established 25 67 37.3% 38 57 40.3% 
(Green et al., 
2004) 
USA and 
Europe 1998 Lifetime Cocaine Mixed 
Early 
psychosis 17 262 6.5% 23 82 28.2% 
(Helseth et al., 
2009) Norway 2001 Recent  Stimulant Mixed Mixed 12 60 20.0% 28 58 30% 
(Hides et al., 
2006) Australia 2000 Recent Amphetamine Mixed 
Early 
psychosis 25 81 30.9% 24 73 70.4% 
(Hides et al., 
2009) Australia 2005 Recent Amphetamine Mixed 
Early 
psychosis 27 214 12.6% 20 66 37.4% 
(Jimenez-






2003 Lifetime Cocaine Schizophrenia spectrum Established 16 518 3.1% 38 66 11.6% 
(Kamali et al., 
2000) Ireland 1994 Lifetime Ecstasy Mixed Established 2 102 2.0% 38 67 16.7% 
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(Kamali et al., 
2009) Ireland 2003 Lifetime Ecstasy Mixed 
Early 
psychosis 13 166 7.8% 28 57 29.5% 
(Katz et al., 
1991) Israel 2005 Lifetime Stimulant 
Schizophrenia 
spectrum Mixed 21 237 8.9%  65 11.4% 
(Khalsa et al., 
1991) USA 1989 Lifetime Cocaine 
Schizophrenia 
spectrum Mixed 36 144 25.0%  96  
(Kwapil, 1996) USA 1990 Lifetime Cocaine UHR/ Prodrome 
UHR/ 
Prodrome 7 182 3.8% 30 48 7.7% 
(Lambert et al., 
2005) Australia 1999 Recent Amphetamine Mixed 
Early 
psychosis 34 625 5.4% 22 67 43.5% 
(Larsen et al., 
2006) 
Norway, 
Denmark 1999 Recent Amphetamine Mixed 
Early 
psychosis 11 300 3.7% 28 59 13.0% 
(Linszen et al., 
1994) Netherlands 1988 Recent Stimulant Mixed 
Early 
psychosis 2 93 2.2% 21 72 25.8% 
(Margolese et 
al., 2004) Canada 1998 Recent Cocaine 
Schizophrenia 




USA 2002 Lifetime Cocaine Schizophrenia spectrum Mixed 30 386 7.8%   7.8% 
(Mata et al., 




psychosis 6 132 4.5% 27 65 46.2% 
(Mauri et al., 




psychosis 23 99 23.2% 28 62 67.7% 
(McLellan and 
Druley, 1977) USA 1971 Lifetime Amphetamine 
Schizophrenia 
spectrum Established 16 141 11.3% 36 100  
(Miles et al., 
2003) England 2000 Recent Stimulant Mixed Established 55 1271 4.3% 39 83 6.4% 
(Miller et al., 
1989) USA 1983 Recent Cocaine Affective Mixed 6 60 10.0% 37 28 8.3% 
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USA 1987 Recent Cocaine Schizophrenia spectrum Established 8 55 14.5% 28 100 23.6% 
(Modestin et 
al., 2001) Switzerland 1994 Recent Cocaine 
Schizophrenia 
spectrum Established 35 525 6.7% 40 53 12.0% 
(Mueser et al., 
1992) USA 1988 Lifetime Stimulant 
Schizophrenia 
spectrum Established 38 159 23.9% 32 62 32.1% 
(Mueser et al., 
1992) USA 1988 Lifetime Stimulant Affective Established 12 41 29.3% 32 62 34.1% 
(Petersen et 
al., 2007) Denmark 1999 Recent Stimulant Mixed 
Early 
psychosis 3 547 0.5% 26 59 12.1% 
(Phillips et al., 




Prodrome 4 100 4.0% 19 49 18.0% 
(Potvin et al., 
2008) Canada 2002 Recent Cocaine Mixed Mixed 5 53 9.4% 34 74 35.8% 
(Rabinowitz et 




psychosis 26 224 11.6%  65 29.9% 
(Rabinowitz et 




psychosis 11 65 16.9%  45 16.9% 
(Rabinowitz et 
al., 1998) USA 1992 Lifetime Stimulant Affective 
Early 
psychosis 50 252 19.8%  50 28.2% 
(Ringen et al., 
2013) Norway 2008 Recent Stimulant 
Schizophrenia 
spectrum Established 16 364 4.4% 31 57 11.8% 
(Ruiz-Veguilla 




psychosis 26 92 28.3% 27 64 55.4% 
(Sara et al., 
2013) Australia 2009 Recent Stimulant Mixed 
Early 
psychosis 1542 9919 15.5% 23 66 29.9% 
(Sevy et al., 
1990) USA 1984 Lifetime Cocaine 
Schizophrenia 
spectrum Established 16 51 31.4% 33 94 51.0% 
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(Sevy et al., 




psychosis 11 118 9.3% 26 52 14.4% 
(Shaner et al., 
1993) USA 1990 Recent Cocaine 
Schizophrenia 
spectrum Mixed 27 100 27.0% 42 96 14.0% 
(Siris et al., 
1988) USA 1982 Lifetime Cocaine 
Schizophrenia 
spectrum Mixed 6 46 13.0% 32 52 34.8% 
(Sorbara et al., 
2003) France 1997 Recent Cocaine Mixed 
Early 
psychosis 1 58 1.7% 31 57 15.5% 
(Steele et al., 
2003) 
Ireland, 
Scotland 1993 Lifetime Amphetamine 
Schizophrenia 
spectrum Established 30 169 17.8% 36 88 42.6% 
(Strakowski et 
al., 1993) USA 1987 Recent Cocaine Mixed 
Early 
psychosis 5 102 4.9% 30 49 6.9% 
(Strakowski et 
al., 1994) USA 1988 Lifetime Cocaine Mixed Mixed 15 412 3.6% 34 63 12% 
(Strakowski et 
al., 1996) USA 1990 Lifetime Cocaine Affective 
Early 
psychosis 4 59 6.8% 25 63 32% 
(Veen et al., 
2002) Netherlands 1998 Recent Amphetamine Mixed 
Early 
psychosis 1 179 0.6% 30 70 14.5% 
(Wade et al., 
2005) Australia 1999 Lifetime Stimulant Mixed 
Early 
psychosis 23 126 18.3% 22 71 63.5% 
(Wobrock et 




psychosis 9 68 13.2% 27 66 45.6% 
(Wobrock et 




psychosis 21 498 4.2% 25 63 23.1% 
 
Notes. Data year:  Year of data collection (midpoint if range specified, estimated from publication year if not provided - see Methods).Recency: Period of stimulant 
estimate – Lifetime or Recent (within last 12 months). Drug: Type of stimulant drug. “Amphetamine” includes methamphetamine. “Stimulant” recorded where specific 
drug not specified. Num: Numerator, number of study sample with stimulant use or disorder. Denom: Denominator, size of study sample. Stim rate: 
Numerator/Denominator. Age: Average age of study sample. Male (%): Percent of study sample male. Cann rate: Rate of cannabis disorder in sample for same 




















To describe the prevalence of lifetime and 12-month stimulant use disorders in the 
Australian population, and to compare the prevalence estimates from a population survey 
with prevalence estimates derived using indirect methods. 
Methods 
Data were drawn from the National Survey of Mental Health and Wellbeing 2007, which 
sampled 8,841 residents of private dwellings in Australia in 2007. Interviews were 
conducted by lay interviewers using the Composite International Diagnostic Interview 
(CIDI). Main outcome measures were lifetime and 12-month rates of stimulant use and 
stimulant use disorders (abuse, dependence) diagnosed according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV).  
Results 
Lifetime prevalence of stimulant disorders was 3.3%, and 12-month prevalence was 0.6%, 
equating to more than 97,000 Australians. Nearly half of those who had used stimulants on 
more than five occasions met criteria for a lifetime disorder. More than 8% of men aged 
16-29 met criteria for a lifetime stimulant use disorder. Prevalence estimates were 
consistent with recent estimates using indirect methods.  
Conclusions 
Stimulant use disorders affect a significant number of Australians, and are most common 
in the age groups at greatest risk for development of psychosis.  
This chapter is based on the publication: Sara, G., P. Burgess, M. G. Harris, G. Malhi 
and H. Whiteford (2011). Stimulant use and stimulant disorders in Australia: 
findings from the National Survey of Mental Health And Wellbeing. Medical Journal 
of Australia 195 (10): 607-610. 
© Copyright 2011 The Medical Journal of Australia - reproduced with permission. 
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INTRODUCTION 
Stimulant use in Australia has increased over the last two decades (Degenhardt et al., 
2008c; Ministerial Council on Drug Strategy, 2008). Regular stimulant use may be 
associated with serious morbidity (Darke et al., 2008). A balanced policy and service 
response requires reliable data about stimulant use disorders in the general population. 
This study examines the prevalence of stimulant use disorders (including amphetamine-
type stimulants, ecstasy and cocaine) in the Australian population in 2007.  
Population surveys are the most frequent method for estimating rates of illicit drug use. 
The Australian National Drug Strategy Household Drug Survey (NDSHDS) has sampled 
persons aged 14 and over every three years from 1993 to 2007 (Australian Institute of 
Health and Welfare, 2008). Over this period, methamphetamine was the most commonly 
used stimulant, with prevalence of lifetime use averaging 7.4% (from 5.4% in 1993 to 9.1% 
in 2004). The NDSHDS 2007 reported a significant decline in lifetime amphetamine use, to 
6.3%. The surveys report a steady increase in the lifetime use of ecstasy (3.1% in 1993, 
8.9% in 2007) and cocaine (2.5% in 1993, 5.9% in 2007). Rates of recent (12-month) use 
were around one third of lifetime rates and followed a similar trend over time. Prevalence 
of recent methamphetamine use was 2.3% in 2007 (down from 3.7% in 1998). Recent 
ecstasy and cocaine use increased steadily to 2007 (ecstasy 3.5%, cocaine 1.6%).  
Differences in methodology make direct comparison difficult, but rates of stimulant use in 
Australia appear consistent with or slightly higher than those reported in population 
surveys in the USA (Substance Use and Mental Health Services Administration, 2007; 
Substance Use and Mental Health Services Administration, 2010), Canada (Adlaf et al., 
2005), UK (Coulthardt et al., 2002) and New Zealand (Wilkins and Sweetsur, 2008).   
Harm associated with stimulant use does not affect all users. It is associated with higher 
frequency of use, higher potency forms and riskier routes of administration such as 
intravenous injection (Degenhardt et al., 2008c). Those stimulant users who have features 
of a stimulant use disorder (abuse or dependence) are at highest risk. Therefore “we need 
to know the size of the population of dependent methamphetamine users in order to 
understand their impact on public health and order, and to estimate the services that are 
needed to reduce this impact” (McKetin et al., 2005) (Page v). 
Compared to estimates of stimulant use in the general population, less is known about 
rates of stimulant disorder. In the early 1980’s the US Epidemiological Catchment Area 
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study (Regier et al., 1990) reported lifetime prevalence of Dependence/Abuse of 
amphetamine (1.7%) and cocaine (0.2%).  However no recent population surveys have 
reported prevalence of stimulant dependence using standardised diagnostic criteria.  The 
NHS National Substance Use Survey UK (Coulthardt et al., 2002) reported rates of 
"stimulant dependence" but this was based on a single positive answer to a screening 
questionnaire. Teesson (Teesson et al., 2006) examined the US National Comorbidity 
Survey (1990-96) and Australian National Survey of Mental Health and Wellbeing 
(NSMHWB) (1997), reporting 12-month prevalence of DSM-diagnosed stimulant disorders 
of 0.2% in the US and 0.5% in Australia. However to allow comparison of the two surveys, 
these figures excluded cocaine.  
The 1990-1996 US National Comorbidity Survey (Kessler et al., 2001) and its 2001-2003 
replication (Degenhardt et al., 2007a) reported only cocaine and prescription stimulants.  
The International Consortium on Psychiatric Epidemiology (Vega et al., 2002) reported 
lifetime use of cocaine and stimulants, but not rates of abuse or dependence. WHO World 
Mental Health Survey Initiative studies (Gureje et al., 2006; Jacobi et al., 2004; Lee et al., 
2007; Stein et al., 2008)  reported use of alcohol or any illicit drug but did not describe 
specific drug classes, or diagnoses of abuse or dependence. The New Zealand Mental 
Health Survey (Wells et al., 2006) and National Drug Survey (Wilkins and Sweetsur, 2008) 
did not report stimulant disorders.  
In Australia the prevalence of stimulant disorders has been estimated by indirect methods. 
McKetin (McKetin et al., 2005)  used multipliers from regular amphetamine users in 
Sydney and benchmark data for substance treatment, admissions and arrests in 2002/03. 
Among persons aged 15-49 years they estimated a 12-month prevalence of monthly 
amphetamine use of 1.0%, and dependent amphetamine use of 0.7%. They estimated that 
this represented more than 70 000 dependent amphetamine users, comparable to the 
number of dependent heroin users during the peak period of Australian heroin use in the 
late 1990s and early 2000s.  
Both survey and indirect methods have limitations in estimating the prevalence of stimulant 
disorders. Population surveys may underestimate prevalence as they sample conventional 
households, under-represent “hotspots” and high risk subgroups, and may be sensitive to 
stigma (McKetin et al., 2005). Indirect methods use samples of identified substance users 
such as treatment populations. They may over-represent more disadvantaged users and 
under-represent employed users who are not in contact with treatment services. Rates of 
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help-seeking may differ by sex or cultural background (McKetin et al., 2005). Therefore, it 
is useful to compare prevalence estimates using both direct and indirect methods. 
The 2007 NSMHWB (Slade et al., 2009) collected information on substance use and 
substance use disorders. It provides the only population data on stimulant (amphetamine, 
ecstasy and cocaine) use disorders in Australia diagnosed according to standardised 
diagnostic criteria. This study aims to describe the prevalence of lifetime and 12-month 
stimulant use and disorder in the Australian population, and to compare estimates from a 
population survey with previous estimates derived using indirect methods. 
METHODS 
National Survey of Mental Health and Wellbeing 
The 2007 NSMHWB was a nationally representative household survey conducted in 2007 
by the Australian Bureau of Statistics (ABS). Slade  (Slade et al., 2009) provides a detailed 
description of its methodology. The population in scope was usual residents of private 
dwellings in Australia, aged 16 to 85 years. A stratified, multi-stage probability sample of 
dwellings (excluding very remote areas) was selected by the ABS. Interviewers used 
household composition questions to identify eligible adults in each household. One person 
in each household was randomly selected to be interviewed. Younger (16-24 years) and 
older people (65-85 years) were oversampled. In total 8,841 respondents from 14,805 
eligible households completed the interview (a response rate of 60%). Interviews were 
conducted in English by trained interviewers, and took an average of 90 minutes to 
complete. 
Stimulant use variables 
The NSMHWB asked about stimulant use in five categories: (i) Amphetamine/Speed, (ii) 
Methamphetamine/Base/Ice, (iii) Ecstasy, (iv) Cocaine and (v) Any stimulant. Lifetime 
stimulant use was assessed by asking whether respondents had used any of these drugs 
(i) at any time and (ii) more than five times in their lifetime. Respondents who reported 
lifetime stimulant use on more than five occasions were asked whether they had used any 




Diagnostic variables  
The NSMHWB used a modified Composite International Diagnostic Interview (CIDI). This 
provides lifetime and 12-month diagnoses of Stimulant Abuse and Stimulant Dependence. 
The NSMHWB reported ICD-10 and DSM-IV diagnoses. For consistency with recent 
studies of the prevalence of cannabis and other substances, DSM-IV criteria and hierarchy 
rules were used in this study. 
Data analysis 
Data from the 2007 NSMHWB Basic Confidentialised Unit Record File (CURF), April 2009 
version (Australian Bureau of Statistics, 2009) were analysed using PASW Statistics v18 
(SPSS Inc. 2009. PASW for Windows, Version 18. Chicago, SPSS Inc.) and Stata v11 
(StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX, StataCorp 
LP). Data were weighted using the factors within the CURF which adjust  for the 
differential probability of survey selection and for the age and sex distribution of the 
Australian population (Slade et al., 2009). Standard errors and 95% confidence intervals 
(CIs) were calculated using jackknife repeated replication to take account of the complex 
survey design.  
Prevalence was calculated for the whole NSMHWB age range (16-85). For comparison 
with indirect estimates (McKetin et al., 2005) it was also calculated for persons aged 16-49 
only. Following ABS conventions, estimates with a Relative Standard Error (RSE) of 
between 25% and 50% were considered possibly unreliable. Estimates with RSE greater 
than 50% were suppressed.  
RESULTS 
The prevalence of lifetime stimulant use was 12.2% (7.2% on more than five occasions) 
(Table 3.1). Amphetamine/speed was the most commonly used stimulant (9.3% any use, 
5.4% more than five occasions), followed by Ecstasy (7.9%, 4.5%), Cocaine (5.2%, 2.8%) 






Table 3.1. Lifetime use of individual stimulant drugs in Australia.  
 Lifetime use Lifetime use > 5 times 
 Rate per 100 (95% CI) Rate per 100 (95% CI) 
Amphetamine/Speed 9.3 (8.6 – 10) 5.4 (4.7 - 6.1) 
Methamphetamine/Base/Ice 3.0 (2.6 - 3.4) 1.9 (1.6 - 2.3) 
Ecstasy 7.9 (7.1 - 8.7) 4.5 (3.9 - 5.2) 
Cocaine 5.2 (4.5 - 5.9) 2.8 (2.2 - 3.4) 
Any stimulant 12.2 (11.5 - 12.9) 7.2 (6.5 – 8.0) 
Note: Rate per 100 population. Source: National Survey of Mental Health and Wellbeing 2007 
 
The lifetime prevalence of DSM-IV stimulant disorders was 3.3% (Table 3.2), with abuse 
(1.9%) more common than dependence (1.4%). The 12-month prevalence of stimulant 
disorders was 0.61% (abuse 0.35%, dependence 0.26%). For persons aged 16-49 years, 
12-month stimulant disorder rates were higher: any disorder 0.97%, abuse 0.55%, 
dependence 0.42%. Of the 7.2% of persons who had used stimulants on more than five 
occasions, 46% (3.3% of the population) met criteria for a lifetime stimulant use disorder. 
Table 3.2. Lifetime and 12-month stimulant use and disorder in Australia.  
 Lifetime 12-month 12-month 
(Persons 16-49 years) 
 Rate per 100  
(95% CI) 
Rate per 100  
(95% CI) 
Rate per 100  
(95% CI) 
Abuse 1.93 (1.57 - 2.29) 0.35 (0.21 - 0.49) 0.55 (0.32 - 0.78) 
Dependence 1.41 (0.92 - 1.91) 0.26 (0.12 - 0.41) 0.43 (0.19 - 0.66) † 
Any stimulant disorder 3.34 (2.76 - 3.93) 0.61 (0.41 - 0.81) 0.97 (0.66 - 1.29) 
Stimulant use, no disorder 3.90 (3.36 - 4.45) 3.30 (2.70 - 3.90) -  
Note: Rate per 100 population, for persons 16-85 years and 12-month prevalence for persons 16-49 
years, National Survey of Mental Health and Wellbeing 2007.  † Relative standard error of estimate 
(RSE) between 25% and 50%: estimate may be unreliable   
 
Table 3.3 shows the prevalence of stimulant disorders by age group and gender.  
Stimulant disorders were more common in males (lifetime 4.6%, 12-month 0.9%) than 
females (lifetime 2.1%, 12-month 0.3%). Stimulant disorders declined with age, with the 
highest rate in persons aged 16-29 (lifetime 7.0%, 12-month 1.6%). The highest 
prevalence rates were among males aged 16-29 (lifetime 8.4%, 12-month 2%). Estimates 






Table 3.3. Stimulant disorder prevalence, by gender and age-group.  
 Female Male All Persons 
 
Rate per 100 
(95% CI) 
Rate per 100 
(95% CI) 
Rate per 100 
(95% CI) 
Lifetime stimulant disorder 
16-29 5.5 (3.7 - 7.3) 8.4 (4.7 - 12.1) 7.0 (4.9 - 9.2) 
30-39 2.7  (1.3 - 4.0) † 7.2 (4.9 - 9.6) 4.9 (3.5 - 6.3) 
40+ 0.5  (0.2 - 0.7) † 2.1 (1.3 - 2.8) 1.3 (0.8 - 1.7) 
All ages 2.1 (1.6 - 2.6) 4.6 (3.6 - 5.7) 3.3 (2.8 - 3.9) 
12-month stimulant disorder 
16-29 1.1  (0.3 - 1.9) † 2.0 (1.0 – 3.0) 1.6 (1.0 - 2.2) 
30-39 s  1.1 (0.1 - 2.1) † 0.7 (0.1 - 1.2) † 
40+ s  s  s  
All ages 0.3 (0.1 - 0.5) 0.9 (0.6 - 1.3) 0.6 (0.4 - 0.8) 
Note: Rate per 100 population Source: National Survey of Mental Health and Wellbeing 2007. 
†  Relative standard error of estimate (RSE) between 25 and 50%: estimate may be unreliable   




This study provides the only current estimate of the prevalence of diagnosed stimulant 
disorders in a large population sample. We found that 12.2% of the Australian population 
aged over 16 have used illicit stimulants, and 7.2% have used on more than five 
occasions. Amphetamine and ecstasy were the most commonly used substances. Of 
those using stimulants more than five times, nearly half (3.3% of the population) met 
criteria for a lifetime DSM-IV stimulant abuse or dependence disorder. The lifetime 
prevalence of stimulant disorders was 3.3%. The 12-month prevalence of stimulant 
disorders was 0.61%, equating to more than 97,000 Australians.  
These figures are consistent with those obtained using indirect estimation methods.  
McKetin (McKetin et al., 2005) used 2002/03 data to estimate prevalence of amphetamine 
dependence amongst 15-49 year olds as between 0.6% and 1.1%. For persons aged 16-
49 years we found a 12-month prevalence of 0.97% (95% CI 0.66% -1.29%). A population 
survey may be expected to produce a lower prevalence estimate than indirect methods 
based on drug-using populations.  
Stimulant use is more common in younger adults and men (Substance Use and Mental 
Health Services Administration, 2007; Adlaf et al., 2005; Australian Institute of Health and 
Welfare, 2008 ; Degenhardt et al., 2007b). We found a similar pattern for stimulant 
disorders. More than 8% of men aged 16-29 met criteria for a lifetime stimulant disorder. 
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Younger men are the group most vulnerable to the development of psychosis. This finding 
is of concern given that stimulants may interact with other risk factors in the development 
of psychosis.  
Limitations 
Population-based studies are likely to underestimate prevalence of the use of illicit drugs, 
for reasons discussed above.  The NSMHWB was designed primarily for the study of high 
prevalence mental health and substance conditions. Disorders of relatively low prevalence 
such as stimulant use disorders are at the lower limits of resolution of the NSMHWB, 
especially when considering 12-month prevalence rates. This means that there are higher 
levels of uncertainty in the estimates of prevalence, particularly when examining 
subgroups by age or sex. The response rate for the 2007 survey was lower than in the 
previous (1997) NSMHWB, and this may have introduced a selection or sampling bias 
which may account for some differences from other surveys. 
Conclusions  
More than 12% of Australians over 16 have used illicit stimulants. Of those using 
stimulants on more than five occasions, nearly one half meet criteria for a lifetime 
substance use disorder. While 12-month prevalence of stimulant disorders is less than 1%, 
this represents nearly 100 000 persons. Men aged 18-29 had the highest prevalence 
rates, with 8.4% having a lifetime stimulant disorder and 2.0% having a twelve-month 
disorder. It follows that stimulant use disorders are most common in those that are most 
vulnerable to the development of psychosis.  Prevalence estimates obtained by this direct 
population survey are consistent with recent estimates using indirect methods.   
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To describe the correlates of stimulant use disorders (abuse, dependence)  in an 
Australian population sample, to compare the characteristics of stimulant users with and 
without stimulant disorders and to describe the patterns of service use and help-seeking in 
people with stimulant use disorders.  
Method  
Data were drawn from the 2007 National Survey of Mental Health and Wellbeing, which 
sampled 8,841 residents of private dwellings in Australia in 2007. Lifetime DSM-IV 
substance use and mental disorder diagnoses were obtained from interviews conducted 
by lay interviewers, using the Composite International Diagnostic Interview (CIDI). Socio-
demographic, socio-economic and clinical correlates of stimulant use disorders were 
identified using binary logistic regression models. Stimulant users with and without 
stimulant use disorders were compared to non-stimulant users via multinomial logistic 
regression models.  
Results   
Compared to Australians without stimulant use disorder, people with stimulant use 
disorders were younger, more likely to be male, of non-heterosexual orientation and born 
in Australia, but were not more socially disadvantaged. Lifetime comorbidity rates were 
high: 79% of persons with stimulant use disorders had a lifetime alcohol use disorder, 73% 
a lifetime cannabis use disorder, and more than one third a lifetime mood or anxiety 
disorder. Stimulant use disorders were associated with a family history of substance use, 
This chapter is based on the publication: Sara, G., P. Burgess, M. G. Harris, G. Malhi, H. 
Whiteford and W. Hall (2012). Stimulant disorders: characteristics and correlates in 
an Australian population sample. Australian and New Zealand Journal of Psychiatry 
46: 1165-1172. 
Reproduction of the submitted original within a book or thesis is permitted by the Sage 
Publications Author rights policy. www.sagepub.com/journalgateway/authorGateway.htm. 
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affective disorders and psychosis. One in five people with lifetime stimulant disorders had 
been imprisoned, homeless or hospitalised for substance or mental health problems, and 
13% reported at least one symptom of psychosis.  Nearly half had sought help for 
substance or mental health problems, primarily from general practitioners (GPs), 
psychologists or psychiatrists. 
Conclusions   
Stimulant use disorders in a representative population sample are associated with 
significant comorbidity and harm. Many persons with stimulant use disorders had sought 






 INTRODUCTION  
Stimulants may cause serious physical and mental health problems (Darke et al., 2008), 
more often in regular or dependent users than in those who use less frequently (McKetin 
et al., 2006a; Degenhardt et al., 2008c). In Australia the 12-month prevalence of stimulant 
use disorders (abuse or dependence) is estimated to be at least 0.6%-0.7% (McKetin et 
al., 2005; Sara et al., 2011a), a rate comparable to the prevalence of dependent heroin 
use at the height of Australia’s heroin “epidemic” in the late 1990s (Hall et al., 2000).  
Understanding the characteristics and comorbidities of individuals with stimulant use 
disorders may assist in planning health system responses for this group.  
The first aim of this study is to describe people with stimulant use disorders in a 
representative Australian population sample. Most descriptions of stimulant use disorders 
are based on treated or convenience samples such as injecting drug users or high risk 
populations. These studies find that stimulant use disorders are associated with very 
significant comorbidity. Dependent stimulant users are often dependent on other drugs, 
and have high rates of depression, anxiety, psychotic symptoms, suicidal ideation and 
suicide attempts (Glasner-Edwards et al., 2009; Kalechstein et al., 2000; Stafford and 
Burns, 2010; Wallace et al., 2009; Zweben et al., 2004; McKetin et al., 2010; McKetin et 
al., 2006b).  Individuals with stimulant use disorders are significantly disabled or 
marginalised, with fewer years of education and significantly increased rates of 
unemployment, homelessness, criminal activity and imprisonment compared with those 
without stimulant use disorders (Copeland and Sorensen, 2001; Degenhardt et al., 2008c; 
Korte et al., 2011; Stafford and Burns, 2010; Zweben et al., 2004; Farrell et al., 1998). 
However treatment and convenience samples are likely to include a more severely 
dependent or disabled group, who may differ systematically from persons with stimulant 
use disorders in the general population. 
Population surveys of drug use can complement studies based on treatment or 
convenience samples. Most population surveys report only on stimulant use, and do not 
apply diagnostic criteria for stimulant abuse or dependence. Surveys from the US, UK, 
Canada, Australia and New Zealand (Adlaf et al., 2005; Durell et al., 2008; Substance Use 
and Mental Health Services Administration, 2007; Substance Use and Mental Health 
Services Administration, 2010; Wilkins and Sweetsur, 2008) find that stimulant use is more 
common in men, peaks in the 20s, and is usually preceded by the use of other drugs,  
particularly cannabis. Australia’s National Drug Strategy Household Survey (NDSHS) 
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found that stimulant use is usually infrequent; only 36% of those who had used any 
stimulant in the preceding year had done so monthly or more often. Few population 
surveys have examined regular stimulant users or those diagnosed with stimulant use 
disorders. The US National Epidemiological Survey of Alcohol and Related Conditions 
(Conway et al., 2006) found high rates of lifetime depressive disorders (51%) and anxiety 
disorders (39%) in individuals with amphetamine abuse or dependence.  
The second aim of this study is to compare stimulant users who do not have stimulant use 
disorders with those who do. We have previously reported that nearly half (46%) of people 
who have used stimulants on more than five occasions met criteria for a lifetime stimulant 
use disorder (Sara et al., 2011a). For an individual, the vulnerability to develop abuse or 
dependence is likely to reflect a mix of  genetic, psychological and environmental factors 
(Kendler et al., 2003; Yucel et al., 2007) along with drug-related factors (McKetin et al., 
2006a). To our knowledge, no study has compared the personal, family and social 
correlates of persons with stimulant use disorders against those of stimulant users who do 
not have features of abuse or dependence.  
The third aim of this study is to examine help-seeking in people with stimulant use 
disorders. Australians with substance use disorders seek help less often than people with 
other mental disorders, and rates of help seeking are lowest in younger adults and males 
(Burgess et al., 2009b), who are the group most likely to have stimulant use disorders.  
Understanding the extent of unmet need for treatment in this group may assist in 
identifying opportunities for prevention or intervention.  
This study addresses these three aims by examining stimulant use disorders in the 2007 
Australian National Survey of Mental Health and Wellbeing (NSMHWB) (Australian Bureau 
of Statistics, 2008), which provided information about a representative sample of the 
Australian population. It collected diagnostic information on substance use and high 
prevalence mental disorders diagnosed using ICD-10 and DSM-IV criteria, along with 
information about personal and household characteristics and family history.  
METHOD  
Setting and participants 
The 2007 NSMHWB was conducted by the Australian Bureau of Statistics (ABS) in late 
2007. Respondents aged 16 to 85 years were identified from private dwellings selected by 
64 
the ABS using a stratified, multi-stage area sample. One individual was selected from the 
pool of eligible adults in each dwelling, using a randomising algorithm implemented by 
computer-assisted interview schedule, and invited to participate in an interview. Younger 
(16-24 years) and older people (65-85 years) were over-sampled to improve the reliability 
of estimates for these groups. The sampling process yielded 8,841 fully-responding 
households, a response rate of 60%. 
Stimulant use variables 
The 2007 NSMHWB reported the use of stimulant drugs in five categories: (i) 
Amphetamine/Speed, (ii) Methamphetamine/Base/Ice, (iii) Ecstasy, (iv) Cocaine and (v) 
Any stimulant (any of i – iv). For each of these drug types respondents were asked 
whether they had ever used; if so they were asked their age at first use and whether they 
had used more than five times in their lifetime. Persons who reported using any stimulant 
more than five times in their lifetime were asked whether they had done so in the last 
twelve months.  
Diagnostic variables  
The 2007 NSMHWB used a modified version of the Composite International Diagnostic 
Interview (CIDI) to provide lifetime and twelve month diagnoses of Stimulant Abuse and 
Stimulant Dependence. The derived variable “Any Stimulant Use Disorder” was positive if 
an individual met criteria for Stimulant Abuse or for Stimulant Dependence. NSMHWB did 
not report diagnoses of abuse or dependence for individual stimulants (e.g. 
methamphetamine, ecstasy, cocaine). DSM-IV criteria were used in this study.  
Other variables 
Variables from the NSMHWB measuring demographics, harms and service use were 
extracted and are listed in more detail in the results section below. Service use variables 
included help sought for any problem, not only specific help sought for stimulant or other 
substance use disorders.  
Data analysis 
Data from the 2007 NSMHWB Basic Confidentialised Unit Record File (CURF), April 2009 
version (Australian Bureau of Statistics, 2009) were analysed using PASW Statistics v18 
(SPSS Inc. 2009. PASW for Windows, Version 18. Chicago, SPSS Inc.) and Stata v11 
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(StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX, StataCorp 
LP.). Data were weighted using factors within the CURF which adjust for the differential 
probability of survey selection and for the age and sex distribution of the Australian 
population. For all analyses standard errors and 95% confidence intervals (CIs) were 
calculated using jackknife repeated replication to take account of the complex survey 
design. Because of the low prevalence of stimulant use disorders in the past 12 months, 
analyses were conducted on correlates of lifetime stimulant use disorders only.   
Analysis was conducted in two stages. Firstly, binary logistic regression was used to 
compare people with and without lifetime stimulant use disorders.  Secondly, people 
without lifetime stimulant use disorders were divided into two groups; stimulant users and 
non-stimulant users. Multinomial logistic regression was then used to examine whether 
stimulant users with a lifetime disorder differed from stimulant users without disorder and 
from people who had never used stimulants.  
For the first analysis, personal correlates and comorbidities of stimulant disorders were 
examined by comparing persons with a lifetime history of DSM-IV stimulant disorder 
against those with no stimulant disorder. Odds ratios and CIs were calculated using binary 
logistic regression analyses conducted separately for a range of potential predictors, which 
included demographic variables and lifetime mental health and substance (alcohol, 
cannabis) disorders. Lifetime harms were not included in the multivariate analysis, as 
these are consequences of rather than risk factors for stimulant use disorders. Where 
necessary, variables with low frequency values and high standard errors were 
dichotomised or categories were combined. 
Multiple logistic regression was then performed using those variables with significant 
associations (P<=0.05) and acceptable standard errors of estimate in univariate 
associations. Multicollinearity was tested by examination of variance inflation factors and 
condition number. Highly collinear variables were removed to yield a final model with a 
condition number less than 30 and with no condition index loading more than 0.4 for more 
than one individual variable (Belsley, 1991). 
The distributions of age at first reported use of alcohol, cannabis and stimulants were 
skewed and censored. Therefore we examined the proportion using each drug, and the 
median and interquartile range of age at first use. 
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In a second analysis, to examine differential risk factors for stimulant use and stimulant 
disorders, we separated persons without stimulant use disorders into two groups; stimulant 
users and stimulant non-users, as described above. This produced an outcome variable 
with three mutually exclusive categories; (i) non-users (lifetime stimulant use on five 
occasions or less), (ii) users without disorder (lifetime stimulant use but no stimulant use 
disorder) and (iii) users with disorder (lifetime stimulant use and stimulant use disorder). 
Multinomial logistic regression was used to compare these groups. Multicollinearity was 
tested using the approach described above. Because of high relative standard errors for 
many of the estimates, we limited the variables entered to those identified in the earlier 
multiple logistic regression. Odds ratios were considered to differ significantly from each 
other if their 95% confidence intervals did not overlap (Schenker and Gentleman, 2001).  
 To examine service use, persons with stimulant use disorders were compared with 
persons meeting criteria for any other lifetime DSM substance use disorder or mental 
health disorder. Lifetime rates of hospitalisation, consultation with health professionals and 
self-management were described.  
Persons with stimulant disorders were also compared with those with other substance use 
disorders. Rates of seeking help for substance problems, and the perceived effectiveness 
of that help were described for those groups.  
RESULTS 
Associations with lifetime stimulant use disorders 
263 of the 8,841 respondents to NSMHWB met criteria for a lifetime DSM stimulant use 
disorder, yielding a weighted prevalence estimate of 3.3% (CI 2.8% - 3.9%).  
Table 4.1 describes the correlates of lifetime DSM-IV stimulant use disorders. Compared 
to Australians without stimulant use disorders, those with a stimulant use disorder were 
younger, 76% (CI 75%-76%) were under 30, and were more likely to be male (69%, CI 
62%-76%). There were no significant associations between lifetime stimulant use 
disorders and education, household measures of income or disadvantage, or urban/rural 
location. Stimulant use disorders were more common in those who reported a non-
heterosexual orientation (OR 3.8, CI 1.9 – 7.4) and less common in persons born outside 
Australia (OR 0.4, CI 0.3 – 0.8), but both estimates had a relative standard error (RSE) 
between 25% and 50% and so should be interpreted with caution. 
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Table 4.1. Associations of lifetime DSM-IV stimulant use disorder 
 
  
Proportion of persons 








  % (95% CI) OR 95% CI OR (95% CI) 
Personal and Household       
  Age < 30 75.6 75.0 - 76.2 3.4 ** 2.2 - 5.3 3.0 ** 1.9 - 4.8 
  Male gender 68.8 61.5 - 76.1 2.3 ** 1.6 - 3.3 1.3 0.8 - 2.0 
  Not heterosexual 6.1 2.4 - 9.8 3.8 ** 1.9 - 7.4 † 3.3 ** 1.5 - 7.0 † 
  Country of birth non-Australia 14.6 8.0 - 21.2 0.4 ** 0.3 - 0.8 † 0.9 0.5 - 1.5 † 
  Parent(s) born non-Australia 39.3 28.2 - 50.5 0.8 0.5 - 1.2   
  Non-school qualification  43.9 33.4 - 54.4 0.9 0.6 - 1.5   
  Major urban location 73.0 65.1 - 80.9 1.4 0.9 - 2.1   
  Income       
    Deciles 1-3 (low income) 24.5 16.6 - 32.3 0.9 0.6 - 1.5   
    Deciles 4-7 19.4 13.4 - 25.5 0.7 0.5 - 1.1   
  Disadvantage       
    Deciles 1-3 (low disadvantage) 32.9 23.4 - 42.4 1.3 0.8 - 2.2 †   
    Deciles 4-7 26.2 18.5 - 34.0 1.0 0.6 - 1.7 †   
Family History       
  Alcohol or drug problem 31.7 23.1 - 40.3 2.7 ** 1.8 - 4.0   
  Anxiety disorder 30.6 21.8 - 39.3 1.8 * 1.2 - 2.6   
  Depression 40.7 30.1 - 51.3 2.2 ** 1.4 - 3.3   
  Schizophrenia or Bipolar 20.2 12.7 - 27.6 2.1 ** 1.3 - 3.4   
Comorbid substance disorders       
  Alcohol 78.6 71.3 - 85.8 14.5 
 
9.2 - 22.8 4.4 ** 2.5 - 7.8 † 
  Cannabis  73.0 66.1 – 80.0 66.9 
 
44.8 - 99.9 27.8 ** 18.1 - 42.7 
Comorbid mental disorders       
  Any affective disorder 38.8 29.2 - 48.4 3.8 ** 2.5 - 5.7 2.3 ** 1.5 - 3.5 
  Bipolar disorder 9.4 5.1 - 13.7 9.7 ** 5.6 - 16.8 
 
  
  Depression  36.1 27.1 - 45.1 3.4 ** 2.3 - 5.1   
  Anxiety disorder 42.0 32.8 - 51.2 3.0 ** 2.0 - 4.3   
Lifetime harms       
  Ever homeless 21.9 13.9 - 29.9 11.5 
 
7.0 - 19.0 
 
  
  Ever in jail 17.2 10.8 - 23.5 10.7 
 
6.5 - 17.7   
  Suicide attempts 14.1 8.9 - 19.3 5.5 ** 3.5 - 8.9   
  Suicidal ideas 31.7 23.1 - 40.2 3.2 ** 2.1 - 4.9   
  Psychotic experiences 13.2 8.0 - 18.3 4.9 ** 3.0 - 8.1 †   
Note: Comparison to persons with no lifetime stimulant use disorder .1: N = 263 of 8,841 respondents with 
lifetime stimulant disorder, weighted prevalence 3.3% (CI 2.8% - 3.9%), 2: Odds ratios from logistic 
regression where DV is presence/absence of any lifetime DSM-IV stimulant use disorder. 3: Comparison 
group for income is Decile 8-10 (highest income), and for disadvantage is Decile 1-3 (lowest disadvantage). 
Lifetime harms not included in multivariate comparisons. † Relative Standard Error (RSE) of estimate is 
between 25 and 50%: estimate may be unreliable. * p < 0.05. ** p < 0.005.  
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Lifetime stimulant use disorders were strongly associated with the diagnosis of another 
substance use disorder. Most people with lifetime stimulant use disorder also met criteria 
for lifetime alcohol use (79%, CI 71% - 86%) or cannabis use disorders (73%, CI 66%-
80%). They had more than a 60-fold higher risk of cannabis use disorders (OR 67, CI 45-
100) and more than a 10-fold higher risk for alcohol use disorders (OR 15, CI 9 – 23) than 
people without lifetime stimulant disorders.  
More than one third of those with a lifetime stimulant use disorder also had a lifetime 
history of an affective disorder (39%, CI 29% - 48%) or anxiety disorder (42%, CI 33% - 
51%). These rates were three to four times higher than rates in those without a lifetime 
stimulant use disorder.  
There were associations between lifetime stimulant use disorder and self-reported family 
history of substance use or psychiatric problems. There was an approximately two-fold 
higher risk of stimulant dependence in those with a family history of alcohol and drug 
problems (OR 2.7, CI 1.8-4.0), depression (OR 2.2, CI 1.4-3.3) or anxiety (OR 1.8, CI 1.2 – 
2.6). 
The final multivariate logistic regression model identified five variables that retained 
significant associations with lifetime stimulant use disorder after controlling for other 
variables. When compared to persons with no lifetime stimulant disorder, the strongest 
predictor of a stimulant disorder was a lifetime history of cannabis use disorder (OR 27.8, 
CI 18.1 – 42.7). There were also smaller but still significant associations with lifetime 
alcohol use disorder (OR 4.4, CI 2.5 – 7.8), being under 30 years of age (OR 3.0, CI 1.9 – 
4.8) and a history of any affective disorder (OR 2.3, CI 1.5 – 3.8).  The association with 
non-heterosexual sexual orientation also remained after controlling for other variables (OR 
3.3, CI 1.5 – 7.0) but the RSE of this estimate was between 25% and 50%. Family history 
variables were excluded from the final model because of their close co-variation with 
individual substance, mood and anxiety disorders.  
Persons with a lifetime history of stimulant use disorder reported significant psychosocial 
harms. One in five reported having been in prison (OR 10.7, CI 6.5 – 17.7) or homeless 
(OR 11.5, CI 7.0 – 19.0, RSE 25-50%). Around one third (32%, CI 23%-40%) reported 
suicidal ideation and nearly half of these (14%, CI 9% - 19%) reported a suicide attempt. 
Persons with stimulant disorders had increased rates of family history of schizophrenia or 
bipolar disorder (OR 2.1, CI 1.3 – 3.4) compared to those without stimulant disorders. 
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Thirteen percent (13%, CI 8% - 18%) reported one or more psychotic experiences on the 
NSMHWB psychosis screener, almost five times the rate of those without stimulant 
disorders (OR 4.9, CI 3.0 – 8.1, RSE 25%-50%).    
Differentiating the correlates of stimulant use and lifetime stimulant use disorder 
 In the second set of analyses, multinomial logistic regression was used to compare the 
three outcome groups; (i) stimulant non-users, (ii) stimulant users without disorder and (iii) 
stimulant users with disorder. Table 4.2 shows the results of this regression; stimulant non-
users were the comparison group and results for that group are not shown. Stimulant 
users without disorder comprised 322 of 8,841 NSMHWB respondents (weighted 
prevalence 3.9%, CI 3.4%-4.5%). They did not differ from stimulant users with disorders 
on age, gender, sexual orientation or in the proportion with comorbid affective, anxiety or 
alcohol use disorders.  Only comorbid lifetime cannabis disorder distinguished between 
stimulant users without disorder (OR 3.8, CI 2.1 – 6.6) and stimulant users with disorder 
(OR 33.2, CI 21.4 – 51.6).  
Table 4.2. Multivariate associations of stimulant use and disorder 
 
Stimulant users with  no 
DSM disorder 
Stimulant users with  
DSM disorder 
 OR (95% CI) OR (95% CI) 
Age <30 2.8 ** 2.0 - 4.0 3.7 ** 2.4 - 5.8 
Male gender 1.3 1.0 - 1.8 1.3 0.8 - 2.1 
Not heterosexual 3.7 ** 2.2 - 6.3 † 4.3 ** 2.1 - 8.8 † 
Alcohol disorder 3.6 ** 2.5 - 5.1 5.4 ** 3.1 - 9.3 † 
Cannabis disorder 3.8 ** 2.1 - 6.6 † 33.2 ** 21.4 - 51.6 
Affective or anxiety disorder 1.9 ** 1.4 - 2.6 2.5 ** 1.6 - 3.9 
Note: Multinomial Logistic Regression comparing stimulant users with and without lifetime DSM-IV stimulant 
use disorder (abuse, dependence) to a reference group with no lifetime stimulant use. Reference group is 
stimulant non-users, i.e. persons who have used stimulants less than five times in their lifetime. N = 322 of 
8,841 respondents reported stimulant use with no DSM disorder, weighted prevalence 3.9% (CI 3.4%-4.5%). 
† Relative standard error of estimate between 25 and 50%: estimate may be unreliable. * p < 0.05, ** p  < 
0.005  . 
 
Table 4.3 summarises age at first drug use and rates of lifetime use of alcohol and 
cannabis. Rates of lifetime cannabis use were much higher for stimulant users, whether 
with disorder (86%, CI 80% - 92%) or without disorder (83%, CI 77% - 88%), when 
compared to stimulant non-users (14%, CI 13% - 15%). For all groups the median age at 
first drug use was youngest for alcohol, intermediate for cannabis and oldest for 
stimulants. Stimulant users (with or without disorder) had a lower median age of first use 
of alcohol and cannabis than stimulant non-users. Stimulant users with disorder had a 
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lower median age of first use of cannabis and stimulants than stimulant users without 
disorder.  
Table 4.3. Age at first drug use and lifetime use of other drugs 
   Alcohol Cannabis  Stimulants 
Age at first drug use Median years (Interquartile range) 
   Stimulant non-users 16 (14-18) 17 (16-19) - 
   Stimulant users without 
 
14 (13-16) 16 (15-18) 20 (18-23) 
   Stimulant users with disorder 14 (12-15) 15 (14-17) 18 (16-20) 
Lifetime drug usage Proportion (95% CI) 
   Stimulant non-users 93.6% (92.9% - 94.4%) 14.2% (13.0% - 15.4%) 0.0%  
   Stimulant users without 
 
93.2% (92.4% - 94.0%) 82.7% (77.3% - 88.2%) 100.0% 
   Stimulant users with disorder 99.8% (99.5% - 100.0%) 86.0% (80.3% - 91.7%) 100.0% 
 
Service use  
Table 4.4 shows rates of help-seeking and service use. It includes help sought by 
stimulant users for any problem (i.e. stimulant use or any other mental health or drug and 
alcohol problem). The comparison group is persons with any DSM mental health or 
substance disorder other than stimulant use disorder. Nearly one in five persons (19%, CI 
11%-27%) with a lifetime stimulant use disorder reported having been hospitalised for a 
mental health or substance use condition, approximately twice the rate of persons with 
other lifetime disorders (10%, CI 8% - 11%). 
 




Lifetime stimulant use 
disorder 
  % 95% CI % 95% CI 
Hospitalisation 
   Hospitalised for any  mental health condition 9.5 7.9 - 11.1 19.2 11.5 - 27.0 
Self-management  
   Used internet for help or information 11.0 9.6 - 12.3 11.9 7.3 - 16.4 
   Self-help group 6.8 5.5 - 8.1 6.2 3.4 - 8.9 
   Telephone counselling 7.8 6.2 - 9.4 8.6 5.6 - 12 
Consultations with health professionals  
   Any professional consultation 47.5 44.9 - 50.1 57.5 48.9 - 69.5 
   Any mental health professional 32.2 30.1 - 34.3 40.1 27.0 - 53.2 
   General practitioner / primary care physician 38.1 35.4 - 40.8 45.7 35.1 - 56.3 
   Psychiatrist 15.8 13.8 - 17.8 19.6 13.6 - 25.6 
   Psychologist 20.3 18.4 - 22.2 23.4 16.3 - 30.6 
   Mental Health Nurse 3.5 2.6 - 4.5 6.2 † 2.9 - 9.5 
   Other general health professionals 7.5 5.8 - 9.1 10.4 5.5 - 15.4 
   Alternative therapists 3.8 2.9 - 4.8 7.2 † 2.7 - 11.6 
Note: Compares people with lifetime DSM-IV stimulant use disorders to those with other lifetime DSM mental 
health disorders. †: RSE of estimate is between 25% and 50%, estimate may be unreliable 
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More than half of those with a lifetime stimulant use disorder (57%, CI 47%-68%) reported 
a professional consultation for a mental health or substance use problem. The most 
common contacts were with General Practitioners (GPs) (46%, CI 35% - 56%), followed by 
Psychologists (23%, CI 16%-31%) and Psychiatrists (20%, CI 14% - 26%). The type of 
professionals did not differ substantially between those with lifetime stimulant use 
disorders and those with other disorders. Those with lifetime stimulant use disorders 
reported similar rates of use of internet information or self-help sites (12%, 7%-16%) and 
telephone counselling services (9%, CI 6%-12%) as persons with other disorders. 
Stimulant users with disorder had sought help for drug and alcohol problems more often 
than persons with other specific drug and alcohol use disorders: nearly half (47%, CI 37%-
58%) of stimulant users with disorder had talked to a medical practitioner or other health 
professional about drug and alcohol problems, compared to 16% (CI 14% - 19%) of people 
with other alcohol or drug use disorders. Fifty eight percent (58%, CI 40% - 76%) of 
stimulant users with disorder who had sought help considered that treatment had been 
effective, compared with 36% (CI 26% - 44%) of those with other drug and alcohol 
problems. Only 6% (CI 3% -9 %) of those with lifetime stimulant use disorders had 
participated in self-help groups for alcohol and drug problems.  
DISCUSSION  
This study is the first to report the correlates of diagnosed stimulant use disorders from a 
large, representative Australian population sample. We found high rates of comorbidity 
and harm in this group. Around three quarters of those with stimulant use disorders also 
had lifetime alcohol or cannabis use disorders. Depressive and anxiety disorders were 
common, and the risk of any affective disorder was more than twice that of the general 
population after controlling for age, gender and other disorders. The risk of suicide 
attempts, homelessness and imprisonment were between five and ten times greater than 
for the general population. These findings are consistent with those reported in treatment 
and conveniences samples, and suggest that the high rates of comorbidity and harm found 
in treated samples are not solely due to selection issues. This study does not demonstrate 
any causal link: stimulant use disorders may be a cause of other problems (such as mood 
disturbance or legal problems), an effect of such problems, or part of a broader set of 
personal and social vulnerabilities.  
72 
As expected, lifetime stimulant use disorders were more common in younger adults and in 
men. They were less common in people born outside Australia but this was not significant 
after controlling for other variables. Contrary to a number of clinical and cohort studies 
(Akiyama, 2006; Degenhardt et al., 2007b; Degenhardt et al., 2007c; Durell et al., 2008; 
Russell et al., 2008; Degenhardt et al., 2008c), we did not find a significant social gradient 
in the prevalence of stimulant use disorders. This may reflect limitations in NSMHWB 
which are discussed below. However we note also that a recent analysis of the Australian 
National Drug Strategy Household Drug Survey (Roche et al., 2008) found that 
amphetamine use was almost twice as common in those in the paid workforce as those 
not in work. Therefore those at risk of harm from dependent stimulant use may also 
include a broader group, and prevention or treatment strategies may need to consider a 
more diverse range than high risk studies suggest.  
There have been reports of increased rates of stimulant use in homosexual men in the US 
and UK (Bonell et al., 2010; Maxwell and Rutkowski, 2008). We found that stimulant 
disorders were more common in people reporting non-heterosexual sexual preference. 
This effect remained after controlling for other variables but was based on small numbers 
of individuals and so should be interpreted with caution. In this sample, people reporting 
non-heterosexual orientation were more likely to use stimulants, but had the same risk as 
other stimulant users of developing abuse or dependence.   
The second aim of this study was to compare stimulant users who do not have stimulant 
use disorders with those who do have such disorders. We found few differences between 
stimulant users with and without stimulant use disorders. Only comorbid cannabis use and 
younger age of first use of cannabis and stimulants distinguished the two groups. This 
finding is consistent with recent evidence for the role of early cannabis use as a gateway 
to later use of other illicit drugs (Degenhardt et al., 2009a; Degenhardt et al., 2010b). It 
suggests that strategies for the prevention of stimulant use disorders need to be broad 
based.   
In this population sample, individuals with stimulant use disorders were twice as likely to 
report a family history of Bipolar Disorder or Schizophrenia than those without stimulant 
use disorders. The precipitation or worsening of psychosis is one of the most serious 
harms associated with stimulant use disorders (Curran et al., 2004; Darke et al., 2008). 
Many risk factors interact in the development of psychosis (McGrath et al., 2004) and the 
role of stimulants should not be overstated. However for some individuals interactions 
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between genetic liability and substance abuse, including stimulants, may increase the risk 
of psychosis (McGorry et al., 2008). Our findings suggest that those with stimulant use 
disorders may be vulnerable not only due to exposure to substances but also due to a 
higher rate of family history of psychosis.  
This study’s third aim was to describe help-seeking and service use in people with 
stimulant disorders. Around half of those with a lifetime stimulant use disorder had sought 
help for a substance or mental health problem (although not necessarily for stimulant use).  
Most had done so by consulting a GP, a psychologist or psychiatrist. This suggests the 
importance of GPs and mental health professionals screening for comorbid stimulant use 
disorders. Intervention and information strategies often target internet and social media but 
only 12% of those with stimulant use disorder reported using those media for help or 
information. In this study people with stimulant disorders who sought care were more likely 
to report that this had been helpful than persons with other substance problems, 
underlining the opportunity for effective intervention in this group. The rate of help-seeking 
in those with lifetime stimulant disorders was higher than that reported from NSMHWB for 
people with any 12-month substance use disorder (24%)  (Burgess et al., 2009b). These 
higher rates partly reflect differences between lifetime and 12-month measurement 
periods, but may also reflect the high rate of comorbid conditions in people with stimulant 
use disorders. Help-seeking is more common where substance use disorders are 
comorbid with other mental disorders (Burgess et al., 2009b).  
This study has a number of limitations. First, the NSMHWB 2007 had a response rate of 
60%. Respondents to population surveys are more likely to be older, female, better 
educated, healthier and less socially disadvantaged than non-respondents (Knudsen et al., 
2010; Galea and Tracy, 2007). Rates of illicit drug use may be particularly understated by 
population health surveys which may not recruit from unconventional households, 
marginalised groups or drug “hotspots” (Degenhardt et al., 2011). The NSMHWB weights 
data for the age and gender distribution of the Australian population, but cannot correct for 
other sources of bias. These factors may contribute to the lack of association between 
stimulant use and measures of social disadvantage in this study.  
Second, the NSMHWB was designed for the study of high prevalence conditions. 
Stimulant use disorders, being infrequent, are at the lower limit of the survey’s resolution. 
Therefore we have focused on lifetime rather than twelve month disorder. This limits the 
conclusions which can be drawn. Persons with comorbid lifetime conditions cannot be 
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assumed to have had these disorders at the same time, or in any particular sequence. 
There was also insufficient power to allow examination of some potentially important 
issues, such as comparison of those with stimulant dependence and stimulant abuse 
separately. Furthermore, the NSMHWB did not report diagnoses of abuse or dependence 
for individual stimulant drugs. We therefore could not examine individual stimulant drugs, 
when there is evidence that personal correlates, harms and risks of dependence do differ 
amongst different types or forms of stimulants (Conway et al., 2006; Grant, 1995; McKetin 
et al., 2006a). 
Conclusions 
Australians who met criteria for lifetime DSM-IV stimulant use disorders in the NSMHWB 
had high rates of comorbid substance use, mood and anxiety disorders, suicide attempts, 
homelessness and imprisonment.  These findings from a representative population sample 
underline findings from treatment and convenience samples that stimulant use disorders 
are associated with significant comorbidity and harm.  
Only comorbid cannabis disorders and earlier drug use distinguished stimulant users 
without disorder from those with abuse or dependence.  Many people with stimulant use 
disorders had sought help, especially from GPs and mental health professionals, and 
many had found treatment helpful. Therefore health professionals need to be made aware 
of the scope for intervention. Prevention of stimulant use disorders may require a broad 
focus on younger people at risk, including those with cannabis use disorders. Treatment 
for stimulant use disorders may also need to address comorbid substance use disorders, 






















Clinicians have raised concerns about the impact of amphetamines on demand for mental 
health services. However, evidence for this link is limited. This study explores whether 
changes in the availability of amphetamines in NSW in the last decade have been 
associated with variations in admission to mental health units for amphetamine related 
conditions and for psychoses more generally.  
Method 
The study examined admissions from community settings to NSW acute mental health 
units from 2000 to 2009. Quarterly rates of hospital admission with primary or comorbid 
diagnoses of stimulant use disorders, stimulant-induced psychoses and non-drug-related 
psychoses were compared to quarterly rates of criminal incidents of amphetamine 
possession and use, which provide an indirect measure of the community availability of 
amphetamines. Analysis was confounded by increases in mental health beds over the 
period. Linear regression predicted admission rates on the basis of amphetamine 
availability, adjusting for changing mental health bed numbers.   
Results  
Amphetamine availability and admissions for psychoses increased steadily from 2000 to a 
peak in early 2007, but have declined since. Regression models including both 
amphetamine availability and bed numbers predicted 34% of variation in stimulant use 
disorders admission rates and 50% of variation in stimulant induced psychosis admission 
rates. There was no significant effect of amphetamine availability on admissions for 
This chapter is based on the publication: Sara, G., P. Burgess, G. Malhi and H. Whiteford 
(2011). Amphetamine availability and admissions for psychosis in New South Wales, 
2001-2009. Australian and New Zealand Journal of Psychiatry 45(4): 317-324. 
Reproduction of the submitted original within a book or thesis is permitted by the Sage 
Publications Author rights policy. www.sagepub.com/journalgateway/authorGateway.htm 
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schizophrenia and other non-drug-induced psychoses after controlling for changing bed 
numbers.  
Conclusions 
Increased amphetamine availability appears to have been one factor increasing demand 
for mental health admission in NSW over the last decade. However, there appears to have 
been a recent downward trend in both amphetamine availability and amphetamine-related 
admissions. Policies which reduce the community availability of amphetamines may result 
in reduced admissions for amphetamine related mental health conditions, including 
amphetamine-induced psychoses. Further research is needed regarding effects of 




Over the last decade Australian mental health services have experienced a significant 
increase in demand, especially for acute inpatient care (Department of Health and Ageing, 
2007). Many mental health professionals have argued that increased use of 
amphetamines has been a significant driver of this demand (Australian Senate Select 
Committee on Mental Health, 2006). 
Amphetamines are associated with physical and psychological harm (Darke et al., 2008). 
They may trigger episodes of acute psychosis in vulnerable individuals, and worsen 
symptoms in persons with pre-existing psychotic disorders (Curran et al., 2004; Hall and 
Degenhardt, 2006; Darke et al., 2008).  However, Degenhardt and colleagues 
(Degenhardt et al., 2008c) have cautioned against overstatement of the extent of 
amphetamine related harm. They reviewed Australian drug use and health indicators to 
2005-2006 and reported that health-related “indicators of meth/amphetamine-related harm 
did not show the dramatic increases that might have been expected given recent media 
attention, with indicators stabilising over the past few years” (p 250).  
From 1993 to 2004 there was a five-fold increase in admissions to Australian hospitals 
with a primary diagnosis of drug-induced psychosis, increasing from 56 admissions per 
million population aged 10-49 to 253 admissions per million population (Degenhardt et al., 
2007d). Amphetamine induced psychoses accounted for an increasing proportion of these 
admissions (55% in 2003-04, up from 41% five years earlier). There have been several 
reports of increased amphetamine-related presentations to hospital Emergency 
Departments (ED) (Fulde and Wodak, 2007; Gray et al., 2007). In New South Wales 
(NSW) the number of ED admissions for amphetamines and related substances increased 
139% between 2002 and 2007 (Snowball et al., 2008). While proportionally large, these 
are increases from a low base rate, and specific amphetamine-related disorders remain a 
small percentage of overall mental health service or Emergency Department activity.  
This study examines relationships between amphetamine availability and admissions for 
psychosis in NSW from 2000 to 2009. If amphetamines are a significant driver of changes 
in mental health service demand, then there should be a relationship between community 
availability of amphetamines and admissions for amphetamine-related mental health 
problems.  Increased incidence of amphetamine-related episodes of psychosis is likely to 
result in increased admissions for psychosis. It is also likely to result in a change in the mix 
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of persons admitted to inpatient units, increasing the acuity of those units by increasing the 
proportion of admissions that are due to psychotic disorders.  
Arrests for drug possession have been shown to be a valid measure of community drug 
availability (Rosenfeld and Decker, 1999), although they are likely to be influenced both by 
supply factors (fluctuations in drug availability) and policing factors (changes in police 
resources and focus). A recent study (Snowball et al., 2008) has shown a steady increase 
in amphetamine arrests in NSW over the last decade, and also shown that over this same 
period arrests for narcotics and amphetamines were strongly correlated with emergency 
department presentations for  problems related specifically to  these drugs.   
We hypothesize that greater community availability of amphetamines will be associated 
with an increase in admissions for stimulant use disorders (abuse, dependence etc) and 
stimulant-induced psychoses. In addition amphetamine use may lead to exacerbations of 
illness in persons with schizophrenia or other psychotic disorders.  
The diagnosis of specific drug-related conditions is often imprecise due to lack of 
recognition of the role played by specific drugs, or by systematic under-recording of 
secondary or co-morbid diagnoses even when they are clinically recognised. Therefore the 
current study also examines for a relationship between amphetamine availability and 
admissions for non-drug-related psychoses. 
This study aims to add to the existing evidence in several ways. First, no published study 
has examined for a direct relationship between a measure of community amphetamine 
availability and admissions for mental health care. Second, Australian national hospital 
data collections include only a single “primary” diagnosis for each admission. A study 
using a large state-based data collection can also examine additional “secondary” or 
comorbid diagnosis. In routine mental health care, substance-related conditions are often 
recorded as secondary diagnoses, and therefore examination of these diagnoses may be 
more sensitive than examination of primary diagnoses alone. Third, the most recent 
publication of an Australian time series (Degenhardt et al., 2007d) examines hospital 
admissions from 1993 to 2004, and changes in both drug availability and admissions for 




Data sources  
Aggregated data was obtained from routinely collected crime and health datasets, and was 
used with permission of the relevant data custodians. No data on individual admissions or 
arrests was obtained.   
Amphetamine supply 
Amphetamine supply data was provided by NSW Bureau of Crime Statistics. This 
comprises the total number of “criminal incidents” of amphetamine possession and/or use 
detected by or reported to NSW Police, and recorded in the NSW “COPS” database.  
“Criminal incidents” differ from arrests in that they also include cautions and persons 
diverted from court through use of infringement notices or youth justice conferences. 
Criminal incidents of amphetamine dealing and supply are not included in this analysis as 
these are smaller in number, more variable and are likely to be more influenced by policing 
rather than supply factors. It is also possible that substantial amphetamine seizures for 
possession or supply could be a cause of reduced community drug availability rather than 
a marker of increased availability.  
Demand for mental health care 
Mental Health admissions data was extracted from Inpatient Statistics Collection, NSW 
Health Information Exchange (HIE). It included all same day and overnight episodes of 
inpatient care where the person was aged 14 – 65 and admission occurred to a 
designated acute adult mental health unit in NSW. Specialist acute Child and Adolescent 
Mental Health Units (CAMHS) were not included because of difficulties in separation of 
mental health from general medical admissions at several hospital sites. The study 
focuses on admission for acute or emergency care from community settings where 
exposure to amphetamines may have been a risk factor and where the timing of admission 
to a mental health unit could be influenced by that exposure. Therefore the following were 
excluded: (i) psychogeriatric units, non-acute adult and non-acute CAMHS units; (ii) acute 
adult units with a specialist or tertiary role (e.g. forensic units, neuropsychiatry units, day 
programs and admissions for electro-convulsive therapy); (iii) admissions following transfer 
from another hospital, a nursing home or due to statistical type-change within a facility; 
and (iv) episodes where greater than one week elapsed between admission to hospital 
81 
and transfer to an acute mental health unit. Admissions to Psychiatric Emergency Care 
Centres (PECCs) were included.  
Diagnosis 
NSW Health inpatient data records primary and additional ICD-10 diagnoses for all 
inpatient episodes. ICD includes amphetamines within stimulant use disorders (F15). ICD-
10 introduced coding of a 5th digit to specify methamphetamine within these disorders. 
However this additional coding was present in only a minority of records and has not been 
examined. Diagnosis codes were grouped into three broad diagnostic groupings: stimulant 
use disorders, stimulant-induced psychoses and non-drug-related psychoses (Table 5.1).  
Table 5.1. Mapping of ICD diagnostic codes 
Diagnoses ICD-10 codes included  
Stimulant use disorders F15.0 to F15.99, excluding stimulant-related 
psychoses codes below   
Stimulant-related psychoses F15.5, F15.50, F15.51, F15.59, F15.7, F15.70, 
F15.71, F15.79   
Non-drug-related psychoses   
  Brief and acute psychoses F23- F23.91   
  Schizophrenia and related psychoses F20- F22.9    
  Schizoaffective disorder F25-F25.9 
  Mania with psychosis F30.2, F31.2    
  Other psychoses F31.5, F32.3, F32.30, F32.31, F06.0, F06.1, F06.2, 
F28, F29      
Note. ICD-9 diagnoses recorded in earlier years of this series have been mapped to corresponding ICD-10 
codes. 
 
For each admission, each diagnosis of interest was recorded as present if it occurred as 
either a primary or an additional diagnosis. The unit of counting was the hospital episode, 
not the diagnosis. More than one diagnosis of the same group was often made in a single 
episode: for example, many episodes recorded more than one diagnosis in the stimulant 
use disorders group (eg stimulant intoxication and stimulant dependence). These were 
counted as a single episode with amphetamine use disorders rather than as two episodes.  
Time period and incident/admission rates 
Monthly data for both sources was available from June 2000 to September 2009 inclusive. 
Monthly data was aggregated to produce quarterly rates. As quarters differ in length, 
amphetamine incident and admissions data were calculated using daily rates (quarterly 
total / days in quarter).  
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Over the period studied, there was a 34% increase in public mental health beds in NSW, 
increasing from 1861 beds in July 2000 to 2491 beds in July 2009 (NSW Health 
Department, 2009; NSW Health Department, 2002). Over the same period there has been 
an overall upward trend in amphetamine arrests in NSW  
Statistical Analysis 
The major independent variable (amphetamine possession) was examined to exclude 
seasonal effects: dummy variables were created for quarter (1-4) and sequence (1-37), 
and a linear regression calculated for predicted amphetamine possession over time. 
Variance on the distribution of residuals was analysed (one way ANOVA, factored by 
quarter). There were no significant differences between quarters (F=0.17, df=36, p=0.916). 
Therefore subsequent analyses did not consider possible seasonal effects.  
Linear regression was conducted separately for each of the three major dependent 
variables: (i) admissions with stimulant use disorders, (ii) admissions with stimulant-related 
psychoses; and (iii) admission with non-drug related psychosis (i.e., schizophrenia, brief 
psychoses, schizoaffective disorders, mania).    
Initial data analysis and descriptive statistics were conducted using PASW Statistics v18 
(SPSS Inc. 2009. PASW for Windows, Version 18. Chicago, SPSS Inc.). Regression 
analyses were conducted using Stata v11 (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX, StataCorp LP.).  
RESULTS 
Summary data  
Data was obtained for 111 months (37 quarters) from July 2000 to September 2009. In this 
period there were 19,897 incidents of amphetamine possession or use recorded.  
In the study period 187,161 admissions to acute mental health units met the inclusion 
criteria for the study, of which 90,296 (48%) included at least one primary or secondary 
diagnosis of psychosis. Diagnoses of non-drug-related psychoses (82,684, 44% of 
admissions) were more frequent than drug-related psychoses (10,167, 5% of admissions).  
There were 10,423 admissions with a stimulant use disorder recorded, comprising 5.6% of 
all admissions. There were 3,557 stimulant-induced psychoses recorded (1.9% of 
admissions). Table 5.2 summarises the main dependent and independent variables. 
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Table 5.2. Amphetamine possession and admissions. 
 Distribution Confidence 
Interval 
 






       (Possession incidents per day) 5.99 0.005 1.04 0.56 5.98 6.00 
Stimulant use disorders  
      (Admissions per day) 3.11 0.004 0.69 -0.02 3.10 3.12 
Stimulant-induced psychoses 
      (Admissions per day) 1.07 0.003 0.33 0.34 1.07 1.07 
Non-drug-related psychoses 
       (Admissions per day) 24.80 0.011 2.23 -1.08 24.78 24.82 
 
Trends over time  
Figure 5.1 shows trends in amphetamine possessions and amphetamine-related 
admissions. Amphetamine possessions increased from 2002, peaking in the first quarter of 
2007. There was an apparent steady decline after 2007. Stimulant-induced psychoses and 
stimulant use disorders appeared to follow a similar trend to amphetamine possessions, 
with an overall gradual increase from 2002 to 2007 but a consistent decline from a peak in 
early 2007; rates in the first three quarters of 2009 were between one third and one 
quarter of that recorded in late 2006 and early 2007.  
Admissions for non-drug-related psychosis were more frequent and had less variability. 
They appeared to show a similar but less marked trend, with an apparent reduction of 

























Figure 5.2. Amphetamine possessions and schizophrenia admissions, 2000-2009 
 
85 
Analysis of admission rates was complicated by an increase in acute mental health beds in 
NSW over the period being studied, largely due to the construction of new acute beds. For 
the acute units in scope for this study, average occupied beds rose steadily from 682 at 
the beginning of the period to 1114 in the third quarter of 2006 (Figure 5.3). The increase 
was not constant over the period examined: after late 2006 average occupied beds in the 
units included in this study levelled off, fluctuating between 1,114 and 1,069 occupied 
beds. A small proportion of this increase in occupied beds may also have been due to 











Figure 5.3. NSW acute mental health beds, 2000-2009. 
 
As increasing bed numbers leads to increased admissions it is also possible that any 
increase in admissions for stimulant related disorders over the period may simply have 
reflected greater bed access rather than greater demand. Therefore analyses also 
included occupied bed days as a second dependent variable. As the increase in bed 
numbers was not linear, a “bed peak” dummy variable was also created, dividing the time 
series into a component prior to July-Sept 2006 where beds increased in a linear fashion 
and a component after that period where bed numbers were steady.  
This analysis treated increased bed numbers as if they were independent of and preceded 
increased presentations and admissions. The relationship between bed numbers and 
admissions is of course likely to be complex and recursive: the increased construction of 
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beds in NSW during this decade was itself driven by community, consumer and clinician 
concerns about increased rates of admission and occupancy. However, for this analysis it 
was not possible to model the relationship in this way.  
Association between possession and admissions 
Linear regression was conducted separately for each of the three main dependent 
variables. The regression model included three variables: (i) amphetamine possession 
incidents per day, (ii) average occupied beds in in-scope units and (iii) a binary “bed peak” 
variable indicating whether the month examined was during or after the period of 
increasing bed numbers. Results of these regressions are summarised in Table 5.3.  
Table 5.3. Relationship between amphetamine possession, beds and admissions. 
 Coefficient SE t P 95% CI (lower) (upper) 
Stimulant use disorders       
  Amphetamine possessions 0.44 0.13 3.24 0.003 0.16 0.71 
  Average Beds 0.00 0.00 1.96 0.059 -0.00 0.00 
  Pre/post bed peak -1.20 0.30 -3.9 <0.001 -1.82 -0.58 
  Constant  -0.93 0.93 -1.0 0.325 -2.81 0.96 
Stimulant induced psychoses  
   Amphetamine possessions  0.11 0.03 4.12 <0.001 0.06 0.17 
   Average Beds 0.00 0.00 2.9 0.007 0.00 0.00 
   Pre/post bed peak -0.33 0.06 -5.4 <0.001 -0.46 -0.21 
   Constant -0.09 0.19 -0.5 0.638 -0.47 0.29 
Non-drug-induced psychoses  
  Amphetamine possessions 592.10 419.35 1.41 0.167 -261.08 1445.28 
  Average Beds 26.68 3.05 8.76 <0.001 20.49 32.89 
  Pre/post bed peak -3253.56 950.52 -3.42 0.002 -5187.40 -1319.72 
  Constant -13016.15 2895.38 -4.50 <0.001 -18906.84 -7125.45 
 
Admissions for stimulant-use disorders and stimulant-induced psychoses showed a 
significant association with incidents of amphetamine possession. These associations 
remained after adjustment for changes in bed numbers. The overall regression model, 
including possession rates and bed number/period variables accounted for 34% of 
variance in admissions for stimulant-use disorders (F(3,33) = 7.28, p = 0.0007, R2 = 0.398, 
Adj R2 = 0.343) and 50% of the variance in stimulant-induced psychoses ( F(3,33) = 13.17, 
p < 0.0001, R2 = 0.545, Adj R2 = 0.506).  
Examination of admissions for non-drug-related psychoses was complicated by the non-
normal distribution of this variable. Of standard transformation options only a cubic 
transformation produced a distribution marginally suitable for regression (Chi-square of 
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original v transformed distribution=4.08, P=0.130). Using this transformation the combined 
regression model accounted for 77% of variation in admissions (F(3,33) = 41.74, p < 
0.0001, R2 = 0.791, Adj R2 = 0.773), however amphetamine possession made a non-
significant contribution to this model, and nearly all variance in admissions was accounted 
for by changes in bed numbers.  
DISCUSSION 
Summary of findings 
In this NSW data, from 2000 to 2009, there was a relationship between amphetamine 
availability (as measured by police incidents of amphetamine possession) and admissions 
to acute mental health units for amphetamine use and amphetamine related psychoses. 
From 2000 to 2007 there was a steady increase in amphetamine possession incidents and 
in amphetamine-related admissions. Acute mental health beds also increased in this 
period, however the relationship between amphetamine availability (possession incidents) 
and amphetamine-related admissions remained when this bed increase was controlled for.  
An unexpected finding was an apparent downward trend in both amphetamine availability 
and amphetamine-related admissions from a peak in the first quarter of 2007 to a low in 
late 2009. Over this period amphetamine possession incidents reduced by 33% (from 749 
in Q1 2007 to 503 in Q3 2009), stimulant use disorders by 62% (from 399 to 153 
admissions per quarter), stimulant related psychoses by 75% (from 167 to 41 admissions 
per quarter) and admissions for schizophrenia by 18% (from 1625 to 1334 admissions per 
quarter). Mental health bed numbers have remained stable during this period.  
Limitations  
The current study has the limitations of ecological studies in comparing two sets of 
aggregate, state level data (Wakefield, 2008), and we cannot demonstrate that the 
individuals who were admitted were exposed to stimulants, or that increased amphetamine 
availability and increased admissions occurred in the same geographical regions of NSW.  
The study compares two imprecise measures. Amphetamine-related criminal incidents 
provide an indirect measure of community drug availability, but are clearly subject to 
influence from other factors. Diagnostic information collected from routine administrative 
collections reflects diagnoses made by many hundreds of clinicians using diverse 
diagnostic practices rather than structured diagnostic instruments. In considering 
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substance-related disorders in particular, the reliability of routine clinical diagnoses is 
limited, and there is frequent under-recognition and under-diagnosis of substance-related 
disorders in routine clinical practice. These factors clearly limit the conclusions that can be 
drawn from the current study. However, the imprecision of the available measures is likely 
to bias against finding an association in this study.  
Both drug use and admissions may be influenced by broader social factors, including 
broad trends in economic activity and employment over the period being studied. 
Increased arrests for amphetamine possession due to increased police activity may result 
in increased detection and diversion of individuals with psychosis to mental health services 
by police. Therefore we cannot conclude that the association found between varying 
amphetamine availability and admissions is a causal one.  
Both health and police data may have been influenced coincidentally by changes in 
practice and procedure or coding within their respective systems: there were changes to 
NSW Police resources and the introduction of new diversion and cautioning systems within 
NSW within this period. NSW Health services moved from ICD-9 to ICD-10 coding: the 
current study has mapped ICD-9 codes where present to equivalent ICD-10 codes, but 
these changes, or changes in NSW documentation requirements or source systems over 
the period, may have resulted in changes in diagnostic recording or coding.  
Regarding the recent downward trend in criminal incidents and admissions, both sets of 
data are subject to underestimation for recent time periods and may be revised upwards 
as time elapses. Diagnosis in NSW Health data is not completed until after separation from 
hospital and following a further period required for coding and data entry: diagnosis 
completion may continue to increase for 3-6 months after the close of a period. Data for 
the current study were extracted approximately 4 months after the close of the last period 
being analysed, and so data for the last quarter may be underestimated by up to 5-10%. 
However, the decline since 2007 was steady and consistent, and the overall trend seen 
was unlikely to be an artefact of diagnostic coding delays.  
The study sought to examine for a relationship between amphetamine availability and 
admission for non-drug-related psychoses including schizophrenia. The confounding 
effects of changing bed numbers over this period made it difficult to examine this question 
statistically. When comparing amphetamine availability with admissions for non-drug-
related psychoses, including schizophrenia (Figure 5.2) there appeared to be similarities 
between these two data series: since early 2007 the reduction in overall admissions for 
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psychosis mirrored that for amphetamine-related disorders. If increased drug-related 
presentations for psychosis were themselves a driver for increases in bed numbers, our 
approach of adjusting for bed numbers as an independent variable may have prevented 
demonstration of an association. We think that the issue requires further study, examining 
a longer time-series of data for the period after bed numbers have stabilised. Even a minor 
impact of amphetamines on admission rates for schizophrenia and related psychoses may 
have significant personal and service impact; in the period studied there were 
approximately 10,000 admissions per year to acute mental health units with diagnoses of 
psychotic disorders, comprising 48% of all admissions to those units.  
Conclusions  
Within the limitations described above, increased amphetamine availability and use appear 
to have been one factor increasing demand for mental health admission in NSW over the 
last decade. Conversely, there appears to have been a significant downward trend in 
amphetamine availability and admissions for amphetamine-related disorders from early 
2007 to the end of the study period (September 2009).   
Policies and strategies which reduce the community availability of amphetamines may 
result in reduced admissions for amphetamine related mental health conditions, including 
amphetamine-induced psychoses. These psychoses result in significant trauma and 
morbidity, and for some vulnerable individuals may represent the first phase of a 
continuing or recurrent psychotic disorder. Therefore limiting community amphetamine 
availability may be one strategy contributing to the prevention of psychosis.  
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Substance use in early psychosis is associated with male gender and earlier onset. 
Evidence about other correlates of substance use is less consistent. Stimulants (e.g. 
methamphetamine, cocaine) may precipitate psychosis. However the associations of 
stimulant disorders in early psychosis are difficult to examine because of lower prevalence 
and overlap with cannabis disorders. 
Methods  
Hospital records were used to identify 9919 persons aged 15-29 with a first hospital 
admission with psychosis in New South Wales (NSW), Australia.  Correlates of illicit drug 
disorders, cannabis disorders and stimulant disorders were examined using univariate and 
multivariate logistic regression.  
Results 
Half of first psychosis admissions had comorbid substance diagnoses. Cannabis and 
stimulant disorders were increased more than ten-fold compared to the age-matched 
Australian population. Stimulant disorders were equally common in women and men and 
associated with urban location, social advantage and older age at first admission. 
Cannabis disorders were associated with male gender, younger age and non-metropolitan 
location. Diagnoses of drug-induced psychoses were more strongly associated with 
stimulants than with cannabis. Compared to people with cannabis diagnoses alone, those 
with both cannabis and stimulant disorders were older, more likely to have a diagnosis of 
drug-induced psychosis and more likely to have comorbid alcohol disorders. 
This chapter is based on the publication: Sara, G., P. Burgess, G. Malhi, H. Whiteford 
and W. Hall (2013). Differences in associations between cannabis and stimulant 
disorders in first admission psychosis. Schizophrenia Research 147: 216-222. 
Inclusion of the published original in a thesis or dissertation is permitted by the Elsevier 




Cannabis is the most commonly used substance in psychosis, and the associations of illicit 
drug use in psychoses are largely those of cannabis disorders. There are significant 
differences between the personal, socio-economic and diagnostic correlates of cannabis 
and stimulant disorders in young people with first admission psychosis.   
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INTRODUCTION 
Substance use in psychosis is associated with male gender (Cantor-Graae et al., 2001; 
Crebbin et al., 2009; Rabinowitz et al., 1998; Wade et al., 2005) and earlier onset (Cantor-
Graae et al., 2001; Compton et al., 2011; Wade et al., 2005; Large et al., 2011). There are 
conflicting findings about associations between substance use and symptom severity, 
urban location, disadvantage, migration and diagnostic subtype (Rabinowitz et al., 1998; 
Sevy et al., 2001; Wade et al., 2005). Some studies report no relationship with diagnostic 
subtype (Wade et al., 2005; Wade et al., 2006a), some report more substance use in 
affective psychoses than in other psychosis subtypes (Rabinowitz et al., 1998) while 
others report more substance use in non-affective psychoses (Cantwell et al., 1999).  
More than one in five young people with psychosis may abuse stimulants (Wade et al., 
2005; Rabinowitz et al., 1998; Genetic Risk Outcome in Psychosis Investigators, 2011). 
Amphetamines stimulate dopamine activity (Hermens et al., 2009) and can trigger 
psychotic symptoms in healthy volunteers (Angrist et al., 1974), recreational drug users 
(McKetin et al., 2006b) and people with psychotic disorders (Curran et al., 2004). The 
effects of amphetamines and other stimulants on people with psychosis may be different 
from or additive to those of cannabis. However, most persons who use stimulants have 
also used cannabis. Therefore even very large studies of young people with psychosis 
have not had sufficient power to examine the correlates of stimulant disorders and to 
assess whether they differ from those of cannabis disorders.  
Using a large, population-based dataset it may be possible to examine a range of possible 
associations of substance use disorders in early psychosis, and to have sufficient power to 
examine the associations of stimulant use disorders while controlling for comorbid 
cannabis disorders. This study identified all first admissions with psychosis for young 
people aged 15-29 in the state of New South Wales (NSW), Australia, over a seven year 
period.  
METHOD 
The study was approved by the NSW Population and Health Services Research Ethics 
Committee. NSW had an estimated population of 7.27 million persons in 2012, 1.47 million 
(20%) of whom were aged 15-29 (Centre for Epidemiology and Evidence, 2012).   
 
93 
First admissions with psychosis 
Admissions to NSW state operated hospitals were examined using the NSW Health 
Information Exchange. The first admission per individual was identified.  
Inclusion criteria were (i) the person’s first psychosis admission occurred during the study 
period (July 2005 to June 2012) and (ii) age 15 - 29 at that admission. Psychosis was 
identified by ICD-10 diagnosis codes. Drug-induced and affective psychoses were 
included. Where episodes had multiple psychosis codes a single psychosis diagnosis was 
derived using the following diagnostic hierarchy: schizophrenia, delusional disorder, 
schizoaffective disorder, affective psychosis, brief psychosis, drug induced psychosis and 
atypical/unspecified psychosis. 
The period July 2000 to June 2005 served as a baseline for identification of incident cases. 
We excluded (i) persons with admissions for psychosis in the baseline period, (ii) same-
day admissions, (iii) residents of another country or Australian state/territory, (iv) Organic 
Psychosis and (v) Schizotypal Disorder.  
Individual substance disorders 
Substance disorders were identified by diagnosis codes for abuse, dependence, 
intoxication or poisoning by alcohol or illicit drugs. Drug induced psychoses were counted 
as both psychosis and substance use disorder. Amphetamines and cocaine were grouped 
into a single stimulant category.  All individual substance diagnoses were recorded; 
polydrug disorder was recorded only where this was specifically diagnosed.  
Overlap between cannabis, stimulants and other drug disorders  
A composite “Illicit Drug Use Group” variable was created based on the presence of 
cannabis and/or stimulant diagnoses. This had five mutually exclusive categories; (i) No 
illicit drug diagnoses, (ii) Cannabis, (iii) Stimulants, (iv) Cannabis plus Stimulants or (v) 
Other/ Polydrug only. Some persons in groups (ii) - (iv) had additional substance 
diagnoses, including opiate or hallucinogen disorders, however the “Other/Polydrug only” 






Migration status was based on country of birth recorded at index admission. Rurality and 
disadvantage measures were based on Australian Bureau of Statistics reference data for 
the statistical local area of residence at index admission.   
Binary variables were constructed indicating whether persons had prior hospital 
admissions with non-psychotic mental health or substance disorders, or prior recorded 
contact with a NSW public community mental health team. Persons were defined as 
having acute entry into care if they had no prior hospital or community care for mental 
health or substance disorders, or only had community mental health contacts in the 7 days 
preceding their first admission with psychosis.  
Analysis 
Analyses were conducted using SPSS v20 (IBM Corporation, 2011) and Stata v11 
(StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX, StataCorp 
LP). Demographic variables and substance disorder prevalence were compared to NSW 
population rates. Twelve month prevalence rates of substance disorders in the Australian 
population aged 15-29 were estimated from the Australian National Survey of Mental 
Health and Wellbeing, 2007, using methods described elsewhere (Australian Bureau of 
Statistics, 2009; Slade et al., 2009; Sara et al., 2011a).  
Associations of illicit drug use were examined in two stages. First, univariate Odds Ratios 
and 95% CIs were calculated using binary logistic regression analyses conducted 
separately for candidate demographic, diagnostic and prior care variables, with the 
presence of any illicit drug diagnosis as the binary dependent variable. Multiple logistic 
regression was then performed entering all variables with significant univariate 
associations (P<=0.05) and including alcohol use disorders as a covariate.  
Second, the associations of cannabis and stimulants with these independent variables 
were examined using multinomial logistic regression, with the five-category “Illicit Drug Use 
Group” as the dependent variable. The first category (No illicit drug use) was the reference 
group. Possible confounding effects of hallucinogen or polydrug diagnoses were examined 
by sensitivity analysis. 
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Multicollinearity for all regressions was tested by examination of variance inflation factors 
and condition index, achieving a final condition index less than 30 and no condition index 
loading more than 0.4 for more than one individual variable (Belsley, 1991). 
Mean age at first admission for different drug types was compared using one-way ANOVA, 
with post hoc testing using Tukey’s Honestly Significant Difference test.  
RESULTS  
We identified 9,919 individuals who met the study criteria. Two thirds (66%) were male 
(Table 6.1). The most common diagnoses at first admission were schizophrenia or 
delusional disorder (35%), drug induced psychosis (22%), affective psychosis (13%) and 
atypical or unspecified psychosis (13%). 
Table 6.1. Sample characteristics, people with first psychosis admissions (n = 9,919).  
  N % a 
Gender     
  Male 6,529 65.8% 
Age     15-19 2,390 24.1% 
  20-24 3,732 37.6% 
  25-29 3,797 38.3% 
Psychosis subtype at first episode d     Schizophrenia and Delusional Disorder 3,434 34.6% 
  Schizoaffective 463 4.7% 
  Affective Psychosis 1,293 13.0% 
  Brief Psychosis 1,244 12.5% 
  Drug induced psychosis 2,193 22.1% 
  Other/Atypical/NOS 1,292 13.0% 
Comorbid substance diagnoses e     Any substance diagnosis 4,951 49.9% 
  Alcohol 1,352 13.6% 
  Sedative 104 1.0% 
  Any illicit drug diagnosis 4,570 46.1% 
Illicit drug diagnosis group   
  Cannabis  2,107 21.2% 
  Cannabis & stimulants 857 8.6% 
  Stimulants 685 6.9% 
  Other drug / polydrug only 921 9.3% 
Care prior to first psychosis admission 
  Previous hospital admissions 3,556 35.9% 
  Previous community mental health care 6,498 65.5% 
  Acute entry to care f 4,882 49.2% 
Note.  (a) Percentages are of non-missing data. (b) Country of birth data missing for 267 (2.7%). (c) 
Area of residence missing for 372 (3.8%). (d) Single psychosis diagnosis per person, hierarchy rule 
applied in order listed. (e) Multiple substance diagnoses per person, no hierarchy rule. (f) No prior 
mental health admissions and not more than 7 days of community mental health care prior to first 
psychosis admission.  
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Half of the group had a comorbid substance use disorder (Figure 6.1), especially cannabis 
(30%), stimulant (16%) and alcohol (14%) disorders. Cannabis and stimulant disorders 
overlapped; 857 persons had both cannabis and stimulant diagnoses, representing 29% of 
2964 persons with cannabis diagnoses and 56% of 1542 persons with stimulant 
diagnoses. The Other/Polydrug group (n=921) included 752 persons with a diagnosis of 
polydrug disorder without specifying other individual substances, hence the estimates for 
specific individual drugs are under-estimates.    
 
Figure 6.1. Comorbid drug diagnoses in persons aged 15-29 with first admission psychosis, 
showing derivation of drug use group based on cannabis and stimulant use. 2964 (30%) persons 
had a cannabis diagnosis and 1542 (16%) had a stimulant diagnosis. All percentages are of total 
sample (n=9,919). 
 
By comparison with the aged-matched NSW population young people with first admissions 
for psychosis were more likely to be male, to be migrants, to reside in more disadvantaged 
areas and to live outside of major cities (Table 6.2). Young people admitted with psychosis 
had nearly eight times the odds of having a substance use disorder compared to the 
Australian population of the same age. There was a greatly increased rate of cannabis 
disorders and, to a slightly lesser degree, of stimulant disorders when compared to the age 
matched population. Alcohol disorders were moderately increased. Confidence intervals 
for these three estimates did not overlap, indicating that these differences were significant 
(Schenker and Gentleman, 2001).  
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n = 9,919 n = 1,451,029 (95% CI) 
Personal characteristics       
  Male gender 65.8% 49.6% 1.90 (1.82 - 1.98) 
  Born outside Australia  19.8% 17.7% 1.15 (1.09 - 1.21) 
  Most disadvantaged 40% 45.6% 37.6% 1.39 (1.33 - 1.44) 
  Regional/remote residence 42.1% 40.5% 1.07 (1.03 - 1.11) 
Substance use disorders a     
  Any substance disorder 49.9% 11.1% 7.95 (7.64 - 8.27) 
  Alcohol disorder 13.6% 9.7% 1.47 (1.39 - 1.56) 
  Cannabis disorder 29.9% 2.5% 16.76 (16.03 - 17.52) 
  Stimulant disorder 15.5% 1.5% 11.85 (11.20 - 12.53) 
Note: (a) Population rates for substance use disorders are rates for 12-month Abuse/Dependence for the 
Australian population, from the National Survey of Mental Health and Wellbeing 2007.  
 
Table 6.3 shows univariate and multivariate associations of illicit substance disorders. 
Comorbid substance use was associated with male gender, younger age, being born in 
Australia and non-metropolitan residence. The association with younger age was less 
marked in the multivariate model. There was no univariate association with disadvantage 
or acute entry to care; these variables were excluded from multivariate analysis. Comorbid 
substance diagnoses were more prevalent in Schizophrenia (36%), Schizoaffective 
Disorder (31%) and Brief Psychoses (29%) than in Affective Psychoses (25%). Comorbid 
illicit substance diagnoses were by definition most common in persons with drug-induced 
psychosis. A small group (n=54) had diagnoses of drug-induced psychosis with alcohol or 
sedative diagnoses only but no illicit drug diagnoses. These may reflect alcohol-induced 
hallucinoses, delirium, or incomplete coding of comorbid substances. As they are small in 
number, these subjects have not been excluded.   
Examining the composite “Illicit Drug Use Group” variable with multinomial logistic 
regression, the correlates of cannabis and stimulant disorders differed significantly (Table 
6.4).  Cannabis disorders declined with age, and were associated with male gender and  
rural location but not social disadvantage. By contrast, stimulant disorders increased with  
age, were unrelated to gender or rural location and were more common in less 
disadvantaged areas. Stimulant disorders were associated with a greater likelihood of 
acute entry into mental health care. Compared to people with cannabis diagnoses alone, 
those with both cannabis and stimulant disorders were older, more likely to have a 







Table 6.3. Associations of any illicit drug use disorder in first admission psychosis 





   n = 5,349 (53.9%) n = 4,570 (46.1%) OR (95% CI) OR (95% CI) 
Age group   
 
15-19 1,242 (52.0%) 1,148 (48.0%) 1.24 (1.11 - 1.37) 1.13 (0.99 - 1.29) 
20-24 1,935 (51.8%) 1,797 (48.2%) 1.24 (1.13 - 1.36) 1.20 (1.07 - 1.35) 
25-29  2,172 (57.2%) 1,625 (42.8%) 1.00 a 1.00 a 
Sex 
 
Female  2,167 (63.9%) 1,223 (36.1%) 1.00 a 1.00 a 
Male 3,182 (48.7%) 3,347 (51.3%) 1.86 (1.71 - 2.03) 1.80 (1.61 - 2.02) 
Migration status 
 
Born in Australia  3,867 (50.0%) 3,872 (50.0%) 2.34 (2.10 - 2.61) 1.89 (1.64 - 2.18) 
Not born in Australia  1,340 (70.0%) 573 (30.0%) 1.00 a 1.00 a 
Urban location Major cities  3,208 (58.1%) 2,316 (41.9%) 1.00 a 1.00 a 
Regional and remote 1,971 (49.0%) 2,052 (51.0%) 1.44 (1.33 - 1.56) 1.20 (1.08 - 1.33) 
Disadvantage Least disadvantaged 2,821 (54.3%) 2,377 (45.7%) 1.00 a - 
Most disadvantaged 2,358 (54.2%) 1,991 (45.8%) 1.00 (0.92 - 1.09) - 
Acute entry into 
care  
No  2,755 (54.7%) 2,282 (45.3%) 1.00 a - 
Yes 2,594 (53.1%) 2,288 (46.9%) 1.06 (0.98 - 1.15) - 
Diagnosis Affective psychosis 964 (74.6%) 329 (25.4%) 1.00 a 1.00 a 
Schizophrenia 2,192 (63.8%) 1,242 (36.2%) 1.66 (1.44 - 1.92) 1.50 (1.29 - 1.76) 
Schizoaffective 321 (69.3%) 142 (30.7%) 1.30 (1.03 - 1.64) 1.25 (0.97 - 1.61) 
Brief 883 (71.0%) 361 (29.0%) 1.20 (1.01 - 1.43) 1.24 (1.03 - 1.50) 
Drug induced 54 (2.5%) b 2,139 (97.5%) 116.06 (86.18 - 156.30) 107.80 (79.39 - 146.37) 
Other / NOS 935 (72.4%) 357 (27.6%) 1.12 (0.94 - 1.33) 1.08 (0.90 - 1.31) 
Note: (a) Reference groups for regression analysis (b) 54 subjects with a diagnosis of drug-induced psychosis had alcohol or sedative use disorders as the only 








































Other illicit drug / 
polydrug  
n=921 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Age group     
  15-19 1.00 a 1.00 a 1.00 a 1.00 a 
  20-24 0.96 (0.83 - 1.11) 1.22 (0.98 - 1.51) 1.61 (1.23 - 2.10) 1.14 (0.92 - 1.42) 
  24-29 0.67 (0.57 - 0.78) 0.93 (0.74 - 1.16) 1.86 (1.43 - 2.42) 1.30 (1.05 - 1.61) 
Person characteristics     
  Male 2.09 (1.83 - 2.38) 1.89 (1.56 - 2.29) 1.09 (0.89 - 1.33) 1.53 (1.28 - 1.82) 
  Migrant 0.55 (0.46 - 0.65) 0.46 (0.36 - 0.60) 0.57 (0.44 - 0.74) 0.48 (0.38 - 0.60) 
  Urban location 0.67 (0.59 - 0.75) 0.84 (0.71 - 1.00) 1.17 (0.96 - 1.43) 1.32 (1.11 - 1.56) 
  Least disadvantaged 1.00 (0.88 - 1.12) 1.16 (0.98 - 1.38) 1.24 (1.02 - 1.50) 0.88 (0.75 - 1.03) 
Psychosis diagnosis     
  Affective Psychosis 1.00 a 1.00 a 1.00 a 1.00 a 
  Schizophrenia  1.13 (0.90 - 1.42) 0.95 (0.63 - 1.43) 0.79 (0.43 - 1.44) 1.18 (0.80 - 1.73) 
  Schizoaffective  1.25 (0.99 - 1.58) 1.33 (0.90 - 1.97) 1.25 (0.73 - 2.14) 1.07 (0.71 - 1.60) 
  Brief psychosis 1.04 (0.75 - 1.45) 1.31 (0.77 - 2.24) 2.21 (1.20 - 4.06) 1.47 (0.91 - 2.39) 
  Atypical / NOS  1.39 (1.14 - 1.69) 1.45 (1.04 - 2.01) 1.72 (1.11 - 2.68) 1.89 (1.38 - 2.60) 
  Drug induced psychosis b 63.53 (45.80 - 88.12) 139.14 (92.60 - 209.08) 287.91 (177.19 - 467.82) 129.34 (86.34 - 193.74) 
Acute entry into care 1.11 (0.98 - 1.25) 1.31 (1.10 - 1.55) 1.33 (1.10 - 1.62) 0.76 (0.64 - 0.89) 
Alcohol use disorder 3.49 (2.96 - 4.12) 5.25 (4.27 - 6.46) 2.51 (1.93 - 3.26) 2.13 (1.69 - 2.70) 
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Stimulants appeared more strongly associated than other drugs with diagnoses of Drug 
Induced Psychosis. Odds Ratios for these estimates were very high, being based on 
comparison with the small group with Drug-Induced Psychosis who had no illicit drug 
diagnosis.  We conducted separate analyses using Cannabis Disorders and Stimulant 
Disorders as binary dependent variables, while controlling for the other drug as a 
covariate. Detailed results are not reported here, but the findings were consistent with that 
of the multinomial regression: persons with stimulant disorders had around twice the odds 
of having a diagnosis of Drug Induced Psychosis when compared to persons with 
cannabis disorders.   
We examined the possible confounding impact of hallucinogen and polydrug diagnoses 
using sensitivity analysis. Multinomial logistic regression was repeated after excluding 
persons with these diagnoses. There was no change in the pattern of significant findings 
for cannabis or stimulant groups. Hallucinogen and polydrug diagnoses were more 
common in the “Cannabis and Stimulant” group, and when these were excluded there was 
no longer a significant association with age or atypical/unspecified psychosis for that 
group.  
Age at first admission with psychosis differed by type of drug (Table 6.5). Average age at 
first admission was approximately one year younger for persons with cannabis disorders 
than for those with no comorbid drug use, and approximately one year older for those with 
stimulant use disorders.  
 
Table 6.5. Age at first admission for psychosis, by type of drug used  
  Persons Mean (95% CI) 
Cannabis alone 2,107 22.7 (22.5 - 22.9) 
Cannabis and stimulants 857 23.1 (22.9 - 23.4) 
No drug diagnosis 5,349 23.5 (23.4 - 23.6) 
Polydrug, other drug 921 23.7 (23.4 - 23.9) 
Stimulants alone 685 24.2 (23.9 - 24.4) 





We examined first admissions for psychosis in a representative population sample of 
9,919 young people aged 15-29. Half had comorbid substance diagnoses. To our 
knowledge this is the largest reported series of first admission psychoses and the first to 
specifically examine the correlates of stimulant disorders.  
Differences in Correlates of Cannabis and Stimulant Disorders 
In NSW residents with first admission psychosis, comorbid substance disorders were 
associated with being younger, male and living in rural locations. Cannabis disorders were 
the most common substance comorbidity, and the associations of substance disorders are 
therefore largely those of cannabis disorders. By contrast, stimulant diagnoses were 
associated with older age, less social disadvantage and a more even gender balance. 
Cannabis and stimulant disorders were more common in atypical and drug-induced 
psychoses than in affective psychoses or schizophrenia.  
Stimulant disorders appeared particularly associated with diagnoses of drug-induced 
psychosis. The validity of this diagnosis is often questioned (Mathias et al., 2008). Atypical, 
brief and drug-induced psychoses comprised nearly half of diagnoses  in this study, but 
are frequently excluded from clinical studies (Compton et al., 2011; González-Pinto et al., 
2011; Gonzalez-Pinto et al., 2008; Linszen et al., 1994; Sevy et al., 2001; Veen et al., 
2004). This may underestimate the impact of cannabis and stimulants in young people 
admitted with psychosis. If these diagnoses are associated with more positive outcomes, 
then excluding  them may also influence findings regarding course and outcome, and limit 
the generalizability of research findings to clinical settings where substance comorbidity 
and brief or atypical psychoses are common.  
Notably, women were as likely as men to have stimulant diagnoses in this group, although 
stimulant disorders are four times more common in male than female Australians of this 
age (Sara et al., 2011a). This could suggest that stimulants are more likely to precipitate 
psychosis in women than in men. However, psychotic symptoms are unrelated to gender 
in recreational amphetamine users (McKetin et al., 2010) and are more common in male 
dependent stimulant users (Chen et al., 2003; Salo et al., 2011). Alternative explanations 
include that young women with psychotic symptoms and stimulant use are more likely to 
seek care, to be admitted when they do seek care or to have a comorbid stimulant 
diagnosis recognised and recorded.  
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Correlates of Drug Use Disorders in Psychosis  
First admissions for psychosis were more common in disadvantaged areas, but comorbid 
substance diagnoses were not. Therefore the excess of psychosis in disadvantaged areas 
was not due to an excess of drug-related psychoses.  
The excess of psychosis admissions amongst migrants is consistent with other reports 
(McGrath et al., 2004; Tandon et al., 2008). However, substance-related psychoses were 
around half as common in migrants as in those born in Australia, as also reported in an 
Australian clinical study (Wade et al., 2005).This may reflect lower rates of drug-use in 
migrant Australians. In population surveys, Australians whose main language is not 
English have much lower rates of use of alcohol, cannabis and stimulants than other 
Australians (Australian Institute of Health and Welfare, 2011). Alternative explanations 
include underreporting or poorer recognition of substance use in young people from 
differing cultural backgrounds.    
Cannabis and stimulant disorders were more than ten times more frequent in young 
people with first admissions for psychosis than in young Australians of the same age. 
Alcohol disorders were only moderately increased. These findings are consistent with 
evidence that cannabis and stimulants play a causal role in psychosis (Hall and 
Degenhardt, 2011; Hermens et al., 2009). However this study does not demonstrate a 
causal link between individual substances and psychosis. We cannot identify whether 
substances precipitated psychosis, whether persons used substances for self-medication 
or whether other factors explained these associations.   
We found that cannabis was more strongly associated with admission for psychosis than 
were stimulants, contrasting with findings that the risk of admission is higher for 
amphetamine users than for cannabis users (Degenhardt et al., 2007d). That study 
examined only diagnoses of drug-induced psychosis, and we found that stimulants were 
particularly associated with drug-induced psychoses.  
Limitations 
Diagnoses obtained from administrative data are less reliable than those made using 
standardised diagnostic instruments. Substance comorbidities may be particularly under-
recorded in routine clinical data (Large et al., 2012). Rates of cannabis and stimulant use 
in our sample were nonetheless similar to those reported in clinical studies.   
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Some individuals in our cannabis and/or stimulant disorder groups also had comorbid 
diagnoses of alcohol, opiate or hallucinogen disorders. We have attempted to limit 
possible confounding effects of these other drugs by including alcohol diagnoses as a 
covariant and examining the effects of exclusion of individuals with hallucinogen or 
polydrug diagnoses. However, our drug use categories do not reflect completely “pure” 
users of cannabis or stimulants, and may include people with undiagnosed use of other 
substances.    
This study examines only people admitted to hospital with psychosis.  Studies from the UK 
(Sipos et al., 2001), Denmark (Petersen et al., 2005) and Australia (Wade et al., 2006c) 
found that more than 80% of people seen by specialist early psychosis services were 
admitted over the first 12 to 36 months of care. Those not admitted had longer duration of 
psychosis, less social disadvantage and greater likelihood of a manic psychosis (Sipos et 
al., 2001; Wade et al., 2006c; Compton et al., 2011), but did not differ in positive 
symptoms or likelihood of problem substance use (Wade et al., 2006c). Therefore studying 
only admitted persons is likely to have a modest impact on our findings.  
Data on admissions to private hospitals were not available to us. In NSW, private hospitals 
are mainly located in advantaged urban areas. They do not provide involuntary care, and 
admit few young people with acute psychoses. In 2011 only 76 individuals aged 15-29 had 
a first or subsequent admission to a NSW private hospital with a diagnosis of psychosis 
(Morris-Yates, personal communication). By contrast there were 1,338 first admissions in 
our study group in that year. Exclusion of private hospitals is unlikely to explain our 
findings.  
Conclusions  
Stimulants and cannabis act through different chemical pathways and differ in their 
patterns of dependence and their clinical impacts.  There are methodological challenges in 
separating the associations of stimulant use from those of cannabis use in young people 
with early psychosis. Examining a large population sample is one approach to these 
challenges. We have identified significant differences in age, gender, demographics and 
diagnosis between cannabis users and stimulant users admitted with psychosis.  Our 
findings underline that substance comorbidity is so frequent in young people with 
psychosis that its identification and treatment should be a core component of their care.  
Strategies for comorbid stimulant disorders may need to include the needs of a slightly 
older and less disadvantaged group. 
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Future studies could examine the apparent relationship between stimulant disorders and 
diagnoses of brief or drug-induced psychoses, and whether these are associated with 
differences in outcome when compared with cannabis-associated psychoses.    
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7: Stimulant disorders and hospital readmission over two 








Few studies have examined the impact of stimulant use on outcome in early psychosis. 
Ceasing substance use may lead to positive outcomes in psychosis. 
Aims 
To examine whether baseline cannabis or stimulant disorders and ongoing drug use 
predict readmission within two years of a first psychosis admission. 
Methods 
Predictors of readmission were examined with Cox Regression in 7269 people aged 15-29 
with a first psychosis admission. 
Results 
Baseline cannabis and stimulant disorders did not predict readmission. A stimulant 
disorder diagnosis prior to index psychosis admission predicted readmission, but a prior 
cannabis disorder diagnosis did not. Ongoing problem drug use predicted readmission. 
The lowest rate of readmission occurred in people whose baseline drug problems were 
discontinued.   
 
 
This chapter is based on the publication: Sara, G., P. Burgess, G. Malhi, H. Whiteford 
and W. Hall (2014). Cannabis and stimulant disorders and readmissions 2 years 
after first episode psychosis. British Journal of Psychiatry. 204: 448-453. 
Reproduction for further personal publication is permitted by the British Journal of 
Psychiatry Copyright transfer and publication agreement. The definitive publisher-
authenticated version is available online at http://bjp.rcpsych.org 
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Conclusions 
Prior admissions with stimulant disorder may be a negative prognostic sign in first episode 
psychosis. Drug use diagnoses at baseline may be a good prognostic sign if they are 
identified and controlled. 
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INTRODUCTION 
Substance use may influence the onset and course of psychosis (Álvarez-Jiménez et al., 
2011). Ongoing substance use is associated with negative outcomes (González-Pinto et 
al., 2011; Bertelsen et al., 2009; Wade et al., 2006b) but may also be a marker for other 
factors that affect prognosis, including younger age of onset and male gender (Wade et 
al., 2006b). Many young people with psychosis abuse stimulant drugs (Hides et al., 2006; 
Sara et al., 2013) however most of these young people also abuse cannabis (Degenhardt 
et al., 2010b), making it difficult to separate the effects of these two drugs. In a large Thai 
sample, more than half of first admissions with specific diagnoses of methamphetamine 
psychosis went on to have further episodes of psychosis (Kittirattanapaiboon et al., 2010). 
We are not aware of any study examining the relationship between stimulant disorders and 
outcome in young people with broadly diagnosed psychoses. Our study used a large 
population-based sample of people aged 15-29 with a first admission with psychosis. We 
examined readmission within two years as a measure of relapse or recurrence (Gleeson et 
al., 2010). Our first aim was to examine whether baseline cannabis or stimulant disorders 
predicted later readmission. Our second aim was to examine the impact of ongoing 
problem drug use on readmission. 
METHODS 
Setting and Participants  
The study was approved by the NSW Population and Health Services Research Ethics 
Committee. NSW had an estimated resident population of 7.3 million persons in 2012, of 
which approximately 20% were aged 15-29 (Centre for Epidemiology and Evidence, 
2012).  Admissions to NSW state operated (“public”) hospitals were linked using a unique 
health identifier. 
Figure 7.1 summarises the study’s method. For all persons with a diagnosis of psychosis, 
the first ever (index) hospital admission with psychosis was identified. People aged 15-29 
whose index admission occurred within the study period (July 2005 to June 2010) were 
included. Exclusion criteria were: (i) admissions where the person was admitted and 
discharged on the same day; (ii) persons whose usual residence was another country or 
another Australian state; (iii) persons with organic psychosis or schizotypal disorder as the 
only psychosis diagnosis; (iv) persons whose index admission ended in death; and (v) 
persons not yet discharged 2 years after index admission.   
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The period July 2000 to June 2005 was used as a baseline period for determining incident 
cases. All subjects had no admissions with a psychosis diagnosis for at least five years 
prior to their index admission. Admissions in the baseline period for non-psychotic 
conditions (such as mood, anxiety, adjustment or substance disorders) were not excluded, 












Figure 7.1. Overview of study method. Admissions to all NSW public hospitals, 2000 – 
2012. Diagnostic exclusions: Schizotypal disorder (n=34), organic psychosis (n=22).  
 
We identified readmissions to any NSW public hospital with a primary or additional 
diagnosis of psychosis within 2 years of discharge from the index psychosis admission. 
We excluded readmissions due to transfer between hospitals, or occurring on the day of 
discharge of the index admission. Readmission data were available to 30 June 2012.  
Measures 
Primary and additional diagnoses were made by the treating psychiatrist and extracted 
from clinical notes by medical records coders. Psychosis was defined by the presence of a 
primary or additional ICD-10 (National Centre for Classification in Health, 2010) diagnosis 
code for a psychotic disorder, including affective psychoses (mania or depression with 
Study period 
 2005 - 2010 
Follow-up period 
 2005 - 2012 
Included in study, 2 years follow-up 
data available (n = 7269) 
Readmitted 
(n = 2715, 37%)  
Not readmitted 
(n = 4554, 63%) 
Persons 15-29 with first psychosis 
admission in study period (n = 7772) 
Not NSW resident (n = 437) 
Death in hospital (n = 7) 
Un-discharged at 2 years (n = 3) 
Diagnostic exclusions (n = 56) 
Baseline period for determination of incident cases 
 2000 - 2005 
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psychosis specified) and drug-induced psychosis. Substance related disorders were 
identified by diagnosis codes for abuse, dependence, intoxication or poisoning. Drug-
induced psychoses were counted as both a psychosis and a substance use disorder. 
Amphetamines and cocaine were grouped into a single “stimulant” disorder category. All 
individual substance diagnoses were recorded; polydrug disorder was recorded only 
where this was specifically diagnosed (ICD code F19).  
Binary variables were constructed to indicate prior hospital admissions with non-psychotic 
mental health conditions, cannabis disorders or stimulant disorders. Migration status was 
based on country of birth recorded at index admission. Australian Bureau of Statistics 
reference data for the statistical local area of residence at the index admission were used 
to obtain measures of rurality (Accessibility Remoteness Index of Australia, ARIA, 
www.abs.gov.au/websitedbs/d3310114.nsf/home/remoteness+structure) and 
disadvantage (Index of Relative Socio-Economic Disadvantage, IRSD, 
www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001 ).    
A proxy measure of ongoing problem drug use was constructed for individuals who had 
contact with community mental health services or were re-hospitalised for any reason after 
their index admission. This proxy measure could not be constructed where a person had 
no further contact with NSW hospital or community services following their index 
admission. NSW inpatient and community mental health services collect diagnoses and 
periodic ratings using the Health of the Nation Outcome Scales (HoNOS) (Wing et al., 
1998). Ratings are made by the treating clinician (case manager or psychiatrist). Ongoing 
drug problems were defined as present if, during the follow-up period, the person had 
either (i) any diagnosis of a substance use disorder in hospital or community records or (ii) 
at least one completed HoNOS with  a score of 2 (“Loss of control of drinking or drug-
taking”), 3 (“Marked craving or dependence”) or 4 (“Incapacitated by alcohol and drug 
problems”) on the HoNOS Problem Drinking or Drug-taking Scale (i.e., HoNOS Item 2) . 
HoNOS does not distinguish the type of substance used. A threshold score of 2 or more 
was chosen to define problem substance use, in keeping with expert clinician ratings of 
“clinically significant” problems on the HoNOS (Burgess et al., 2009a). Baseline and 
ongoing drug diagnosis and HoNOS measures were combined to create a composite 
variable with three possible values; No Drug Problem (baseline or ongoing), Drug Problem 
Ceased (drug diagnosis at index admission but no ongoing problem), Drug Problem 




Statistical analyses were undertaken using Stata v11 (StataCorp. 2009. Stata Statistical 
Software: Release 11. College Station, TX, StataCorp LP). Univariate Cox regressions 
were conducted on candidate variables. Proportional hazards assumptions were tested by 
visual examination of log-log survival plots and by testing for significant interactions when 
each variable was entered as a time-based covariate. Variables of interest, with univariate 
P <0.2, and which satisfied proportional hazards assumptions, were entered into a 
multivariate Cox regression. This model was stratified on local mental health service, 
because observations may have been correlated within health services due to local 
population or resource factors. Two variables failed proportional hazards assumptions and 
were therefore included as stratifiers rather than covariates: (i) admission to a non-
specialised mental health unit and (ii) psychosis as a comorbid diagnosis rather than a 
primary diagnosis for the index admission. The distribution of deviance residuals was 
examined to identify multivariate outliers.  
Differences between people with and without ongoing service contact were examined 
using binary logistic regression. The proxy measure of ongoing drug problems was 
analysed for the subset of subjects for whom the measure was available, using the same 
Cox Regression method described above.  
RESULTS 
There were 7,269 persons aged 15-29 who had a first admission in the study period (Table 
7.1). Two-thirds (66%) were male and only 24% were aged under 20. The most common 
diagnoses at first admission were schizophrenia or delusional disorders (36%) and drug-
induced psychosis (22%). Thirty percent had a comorbid cannabis disorder and 16% a 
comorbid stimulant disorder. One in six (16%) had prior admissions for mental health or 
substance-related problems but without a psychosis diagnosis.  Thirty-seven percent of 
persons were readmitted with psychosis within two years. The risk of readmission was 
highest immediately following the index admission; 17% of subjects were readmitted within 











% (95% CI) 
Total 7,269 (100) 37 (37-37) e 
Gender   
 Male 4,810 (66) 39 (38-40) 
 Female 2,459 (34) 34 (32-35) 
Age group   
 15-19 1,736 (24) 42 (40-45) 
 20-24 2,718 (37) 37 (36-39) 
 25-29 2,815 (39) 34 (32-36) 
Diagnosis   
 Schizophrenia 
a 2,602 (36) 42 (40-44) 
 Schizoaffective 343 (5) 41 (35-48) 
 Affective psychosis 
b 939 (13) 28 (25-31) 
 Brief psychosis 919 (13) 38 (35-42) 
 Drug-induced psychosis 1,570 (22) 36 (33-38) 
 Other psychosis 
c 896 (12) 36 (33-40) 
Baseline drug diagnoses  
 Cannabis 2,197 (30) 41 (38-43) 
 Stimulants 1,162 (16) 38 (35-42) 
Prior care   
 Prior admissions 
d 1,177 (16) 42 (38-45) 
 Prior cannabis 645 (9) 41 (36-45) 
 Prior stimulants 372 (5) 46 (39-53) 
Person    
 Migrant 1,332 (18) 35 (32-38) 
 Rural residence 3,013 (41) 39 (37-41) 
 Most disadvantaged 3,183 (44) 39 (38-41) 
Note: (a) Includes delusional disorder. (b) Mania or depression where psychosis specified. (c)  
Includes other non-organic psychosis (F28), Psychosis NOS (F29). (d) Prior admissions for mental 
health care but no prior psychosis diagnosis. (e) Readmission rate 37.35%, 95%CI 37.33% – 
37.38% 
 
Table 7.2 shows the results of univariate and multivariate Cox Regression. In univariate 
comparisons, readmission at two years was significantly more likely in males (HR 1.21, 
95% CI 1.11-1.31) and in younger subjects. The highest rate of readmission (42%) was for 
people with an index diagnosis of schizophrenia. By comparison with schizophrenia, the 
risk of readmission was reduced in those with affective psychosis (HR 0.61, 95% CI 0.53-
0.69), drug-induced psychosis (HR 0.83, 95% CI 0.75-0.92) and atypical psychosis (HR 
0.85 95% CI 0.75-0.97). Cannabis disorders at index admission were associated with a 
greater risk of readmission (HR 1.15, 95% CI 1.06-1.25), but cannabis disorders prior to 
the index admission were not (HR 1.11, 95% CI 0.97-1.26). This pattern was reversed for 
stimulants: baseline stimulant disorders were unrelated to risk of readmission, but people 
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with an admission with stimulant disorders prior to their index admission had a higher risk 
of readmission (HR 1.30, 95% CI 1.11-1.51).    




Multivariate  f  
 
N HR 95% CI P 
 
HR 95% CI 
Gender (male) 4,810 1.21 1.11-1.31 <0.001  1.13 1.04-1.24 
Age group        
 15-19 
a 1,736 1.00 - <0.001  1.00 - 
 20-24 2,718 0.85 0.77-0.93   0.80 0.73-0.89 
 25-29 2,815 0.76 0.69-0.83   0.72 0.65-0.80 
Diagnosis        
 Schizophrenia 
a b  2,602 1.00 - <0.001  1.00 - 
 Schizoaffective 343 0.98 0.82-1.17   1.01 0.84-1.21 
 Affective psychosis 
c 939 0.61 0.53-0.69   0.56 0.48-0.64 
 Brief psychosis 919 0.91 0.80-1.02   0.80 0.73-0.89 
 Drug-induced psychosis 1,570 0.83 0.75-0.92   1.13 1.04-1.24 
 Other psychosis 
d 896 0.85 0.75-0.97   0.81 0.71-0.92 
Baseline drug diagnoses        
 Cannabis 2,197 1.15 1.06-1.25 <0.001  1.06 0.97-1.16 
 Stimulants 1,162 1.05 0.95-1.16 NS 
e  1.02 0.90-1.14 
Prior care        
 Prior admissions  1,177 1.18 1.07-1.30 <0.001  1.22 1.08-1.37 
 Prior cannabis 645 1.11 0.97-1.26 NS  0.97 0.82-1.14 
 Prior stimulants 372 1.30 1.11-1.51 NS  1.36 1.12-1.66 
Person        
 Migrant 1,332 1.11 1.00-1.22 NS  1.04 0.93-1.16 
 Rural residence 3,013 1.10 1.02-1.19 NS  1.03 0.86-1.24 
 Most disadvantaged 3,183 1.13 1.04-1.22 <0.001  1.07 0.95-1.21 
Notes: (a) Reference group. (b) Includes delusional disorder. (c) Mania or depression where psychosis 
specified. (d) Includes other non-organic psychosis (F28), Psychosis NOS (F29). (e) NS = Not significant (p 
> 0.05). (f) P for overall model <0.001 
 
The results of multivariate analysis differed slightly: after controlling for other variables, 
affective, brief and atypical psychoses were associated with lower risk of readmission than 
schizophrenia, but drug-induced psychosis was associated with a higher risk (HR 1.13, 
95% CI 1.04-1.24). Baseline cannabis disorder was no longer associated with 
readmission. Findings regarding stimulants were unchanged in the multivariate analysis: 
prior stimulant disorders predicted readmission (HR 1.36, 95% CI 1.12-1.66) but a 
baseline stimulant diagnosis did not. There was no relationship between readmission and 
migrant status, rural location or residing in more disadvantaged localities.   
Examining multivariate outliers, 80 subjects (1.1%) had deviance residuals greater than 
2.5 standard deviations (SD) but none greater than 3.0 SD. These subjects did not differ 
significantly from other subjects on age, gender, diagnosis group, rate of substance use or 
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year of admission, but they were more likely to have had their index admission outside a 
specialist mental health unit. Index admission occurred outside a specialised mental health 
unit for 1,068 persons (15% of the study group). These admissions were more common in 
rural hospitals, and were not excluded from the study in order to avoid systematic under-
representation of rural residents. Sensitivity analysis was conducted by refitting the 
multivariate Cox regression model after removing this group; the risk of readmission for 
brief psychosis was slightly reduced, and now differed significantly from that for 
schizophrenia (HR 0.84, 95% CI 0.74-0.96) in the revised model. The model was 
otherwise unchanged.   
Sensitivity analysis was conducted on the effects of different methods for dealing with tied 
observations within a Cox regression. There was no significant difference between exact 
and approximate methods; the results presented used the Efron approximation.  
Thirty one percent (31%) of subjects had no further contact with NSW community mental 
health or inpatient services in the 2 years after their index admission, and therefore had no 
diagnostic or HoNOS information for ongoing care in the study period. People with no 
ongoing service contact were more likely to be younger, to have an index diagnosis of brief 
(OR 1.39, 95% CI 1.01 – 1.91), drug-induced (OR 1.27, 95% CI 1.02 – 1.58), or 
atypical/unspecified psychosis (OR 1.49, 95% CI 1.07 – 2.07) and to have had prior 
admissions with cannabis (OR 1.47, 95% CI 1.07 – 1.27) or stimulant (OR 1.50, 95% CI 
1.01 – 1.21) diagnoses. They were less likely to have baseline cannabis diagnoses (OR 
0.43, 95% CI 0.36 – 0.52) but did not differ from people with ongoing contact on gender, 
baseline stimulant use, urban/rural location or migration status.     
Excluding people with no further contact with NSW Health services, the proxy measure of 
ongoing drug problems was available for 69% of the study group (4,993 persons). Their 
two year readmission rate (54%) was higher than for the study group as a whole, since the 
readmission rate for those with no further contact was, by definition, zero. Those with 
ongoing contact were divided into three groups; No Drug Problem (n=2,209), Drug 
Problem Ceased (n=866) and Drug Problem Ongoing (n=1,918). Figure 7.2 shows the 
cumulative readmission curve for these groups. The readmission rate was highest for the 
Drug Problem Ongoing group (66%, 95% CI 63%-69%), intermediate for those with No 
Drug Problem (50%, 95% CI 47% - 52%) and lowest for the Drug Problem Ceased group 
(40%, 95% CI 37% - 44%). This difference was significant (Wilcoxon/Breslow test, Chi-
square = 147.92, p<0.0001). The proportional hazards assumption for Cox Regression 
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was not met: examination of the survival curves suggests that the reason for this was that 
the Drug Problem Ceased group had a lower rate of early readmission, but not of later 
readmission when compared with the No Drug Problem group. Sensitivity analysis, where 
people with an index diagnosis of drug-induced psychosis were excluded, did not change 
these results; readmission rates after exclusion of drug-induced psychosis were Drug 
Problem Ongoing 67% (95% CI 63% - 71%), No Drug Problem 50% (95% CI 48%-52%), 












Figure 7.2. Readmission following first psychosis admission, by pattern of ongoing problem drug 
use. Results for 4,993 persons (69% of total sample) for whom a proxy measure of ongoing drug 




It is clinically important to identify factors which predict outcome in first episode psychosis, 
and especially to identify prognostic factors which may be influenced by intervention. 
Some studies have found that substance use at psychosis onset predicts poorer outcomes 
(Malla et al., 2008; Addington et al., 2010). We have used health system data for a 
population of 7.3 million persons to examine the risk of readmission in young people 
following a first admission for psychosis. Neither cannabis nor stimulant diagnoses at 
baseline predicted readmission after controlling for age, gender and diagnostic subtype. 
Our findings are consistent with those suggesting that ongoing substance use is the more 
important issue (González-Pinto et al., 2011; Wade et al., 2006b; Bertelsen et al., 2009).  
Cannabis disorders and readmission 
We found univariate associations between baseline cannabis and outcome, however these 
were no longer significant after controlling for age, gender and diagnostic subtype. Our 
findings are consistent with studies reporting that baseline cannabis use did not predict 
poor outcome (Addington and Addington, 1998; González-Pinto et al., 2011). Some of the 
apparent association between baseline cannabis use and adverse outcome may be due to 
confounding of cannabis disorders with other factors which predict readmission, namely, 
being younger, male and having a primary diagnosis of schizophrenia. Baseline use of 
cannabis or other drugs may also be a predictor of ongoing drug use.   
Stimulant disorders and readmission 
Stimulant disorders at baseline were not associated with readmission, but hospital 
admissions with stimulant disorders prior to the index admission were. The finding is 
consistent with evidence that the risk of developing a drug-related psychosis after 
prolonged drug use is greater for stimulants than for cannabis (Degenhardt et al., 2007d), 
and with sensitisation models of the interaction between stimulant use and psychosis 
(Curran et al., 2004; Hermens et al., 2009).  Prior stimulant-related admissions are likely 
be indicators of severe or enduring stimulant use, since most people with stimulant abuse 
or dependence are not admitted to hospital. Severe stimulant disorders may also be 
associated with abuse of a wider range of substances, including heavier or more sustained 
cannabis use. However the same association was not found for prior cannabis use 
disorders.  
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Ongoing drug use 
We found that people with ongoing problem drug use had a rate of readmission nearly one 
third higher than people with no drug use. An association between ongoing drug use and 
poor outcome is not surprising, however our findings help to quantify the scale of this 
effect in a representative population-based sample, and underline the significant personal 
and health system impacts of ongoing drug use.  
Conversely, we found that the best outcome (as measured by hospital readmission) 
occurred in people with baseline substance diagnoses but no ongoing substance use 
problems. Several studies have found that young people with psychosis who cease 
substance use have better outcomes than those who have never used substances 
(Strakowski et al., 2007; Baeza et al., 2009; Lambert et al., 2005). A recent meta-analysis 
of this issue concluded that further and larger studies were needed (Gupta et al., 2013). 
Our findings add further evidence on this issue. 
An association between substance use and positive outcome in psychosis may seem 
counterintuitive, since substance use in people with psychosis is associated with negative 
prognostic factors including younger age, male gender and social disadvantage. However 
there is increasing evidence that comorbid drug use in psychosis is also associated with 
better neurocognitive performance, fewer negative symptoms,  fewer neurological soft 
signs and more positive symptoms (Rabin et al., 2011; Yucel et al., 2012).  
Three explanations have been proposed for these findings. First, cannabis may have 
direct neuroprotective effects (Yucel et al., 2012). Second, Meuser (Mueser et al., 1998) 
has proposed that this effect is mediated through social competence, whereby more 
“socially oriented patients with serious mental illness are more likely to come into contact 
with drugs and subsequently develop substance use disorder” (p726). Third, these findings 
may reflect varying degrees of personal vulnerability: psychosis in the absence of 
substance use is likely to reflect greater genetic or developmental diathesis in the person 
affected, whereas cannabis or other drugs may precipitate psychosis in individuals with 
less intrinsic vulnerability (Schnell et al., 2009; Loberg and Hugdahl, 2009). Our findings 
cannot distinguish between greater social competence and lesser personal vulnerability as 
explanations for positive outcome in former drug users with psychosis, and further 
research on this question is needed. The association between ongoing substance use and 
worse outcome is inconsistent with cannabis having a neuroprotective effect in psychosis.  
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Regardless of the mechanism, our findings underline an important and hopeful clinical 
message. Young people with a first episode psychosis and comorbid substance disorder 
may have the best outcomes, provided that substance disorder is properly managed.  
Other findings 
After controlling for other variables, the risk of readmission for people with an index 
diagnosis of drug-induced psychosis was higher than for those with an index diagnosis of 
schizophrenia. This is consistent with studies questioning the predictive validity of drug-
induced psychosis diagnoses (Mathias et al., 2008; Crebbin et al., 2009). In a study of 
persons with diagnoses of cannabis-induced psychosis, nearly half were subsequently 
diagnosed with schizophrenia and 77% had further psychotic episodes (Arendt et al., 
2005).  
The association between ongoing problem drug use and readmission was not constant 
over time; cessation of problem drug use appeared to be associated with a reduced risk of 
early readmission (within 90 days of discharge from index admission). Early and late 
relapse or readmission may be influenced by different processes and risk factors (Durbin 
et al., 2007). This issue warrants further study. 
Limitations 
The scale and population coverage of administrative datasets can complement clinical 
studies by allowing an examination of issues such as stimulant abuse which may be 
otherwise confounded by other clinical or personal variables in smaller clinical samples. 
However routinely collected administrative data also have a number of limitations.   
First, we have not captured all incident cases of psychosis in NSW because we have used 
hospitalisation data to define incidence. More than 80% of people seen by specialised 
early psychosis services are admitted early in their illness (Sipos et al., 2001; Petersen et 
al., 2005; Wade et al., 2006c). Those not admitted have longer duration of psychosis, less 
social disadvantage and greater likelihood of a manic psychosis (Sipos et al., 2001; Wade 
et al., 2006c; Compton et al., 2011), but do not differ in their prevalence of positive 
symptoms or the likelihood of problem substance use (Wade et al., 2006c). Our findings 
underestimate the total number of young people with psychosis, and our sample omitted 
some young people with better social support and/or a less acute onset.  
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Second, we did not have follow-up information on all study subjects. Thirty-one percent of 
subjects had neither a readmission to hospital nor a contact with NSW community mental 
health services during the follow-up period. These subjects were younger, more likely to 
have index diagnoses of brief, atypical and drug-induced psychoses and to have prior (but 
not baseline) cannabis and stimulant diagnoses. In the Australian health system, state 
operated mental health services care for most persons with psychosis. Loss of contact 
with specialised services may be a sign of resolution of symptoms and recovery from 
illness (Warner, 2009; Emsley et al., 2011). However people losing contact with 
specialised services may have equivalent rates of positive symptoms and substance use 
to those remaining in care (Stowkowy et al., 2012).  We cannot know whether those with 
no follow-up had ongoing substance use or psychosis for which they did not seek care, or 
whether they sought care from services other than NSW public inpatient or community 
mental health services.  
 
Third, we used hospital readmission as a measure of relapse. Lack of readmission does 
not equate with symptomatic or functional recovery, and many significant relapses of 
psychoses may be managed without readmission. We did not have a measure of the 
severity of psychotic symptoms nor of substance use. However hospital readmission 
remains the most widely used indicator of relapse in young people with psychosis 
(Gleeson et al., 2010), and a second hospital admission may be a very significant event for 
a young person and for their family.  
 
Fourth we have examined admissions prior to the index psychosis admission with 
stimulant or cannabis diagnoses. Most people with substance use disorders (abuse or 
dependence) are not admitted to hospital with those disorders. Therefore this measure of 
prior substance disorder is likely to be of high specificity but low sensitivity. 
 
Finally, our proxy measure of ongoing drug use was imprecise. It combined data from 
inpatient and community diagnoses with a clinician rating of problem substance use 
derived from the HoNOS. The HoNOS is not a diagnostic instrument and does not 





Cannabis or stimulant disorders at first admission with psychosis may not be negative 
prognostic signs. Young people with substance comorbidities may have both the best and 
worst of outcomes, depending on whether problematic substance use is discontinued. It is 
critical to screen and offer intervention for drug use in early psychoses. Admissions with 
stimulant disorder diagnoses prior to the first psychosis admission were associated with 
worse outcome. This suggests that it is important not only to identify current substance use 
at first admission with psychosis but also to obtain a detailed history of the type, severity 














STIMULANTS AND ONGOING PSYCHOSIS 
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8: Stimulants, diagnostic stability and progression to 








Substance abuse adds to diagnostic uncertainty in psychosis and may increase the risk of 
transition from brief and affective psychoses to schizophrenia.  This study examined 
whether comorbid substance disorder was associated with diagnostic instability and 
progression from other psychosis diagnoses to schizophrenia, and whether effects differed 
for cannabis and stimulant-related disorders. 
 
Methods 
We identified 24,306 individuals admitted to hospital with an ICD-10 psychosis diagnosis 
between 2000 and 2011. We examined agreement between initial diagnosis and final 
diagnosis over 2-5 years, and predictors of diagnostic change towards and away from a 
final diagnosis of schizophrenia.  
 
Results  
Nearly half (46%) of participants with initial brief, atypical or drug-induced psychoses were 
later diagnosed with schizophrenia.  Persisting illicit drug disorders did not increase the 
likelihood of progression to schizophrenia (OR 0.97, 95% CI 0.89 – 1.04), but increased 
the likelihood of revision of index psychosis diagnosis away from schizophrenia (OR 1.55, 
95% CI 1.40 – 1.71). Cannabis disorders predicted an increased likelihood of progression 
to schizophrenia (OR 1.12, 95% CI 1.01 – 1.24), while stimulant disorders predicted a 
This chapter is based on the publication: Sara, G., P. Burgess, G. Malhi, H. Whiteford 
and W. Hall (2014). The impact of cannabis and stimulant disorders on diagnostic 
stability in psychosis. Journal of Clinical Psychiatry.  75(4): 349-356. 
Reproduced with permission of Physicians Postgraduate Press, Inc. 
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reduced likelihood (0.81, 95% CI 0.67 – 0.97). Stimulant disorders were associated with 
greater overall diagnostic instability.  
 
Conclusions 
Many people with initial diagnoses of brief and affective psychoses are later diagnosed 
with schizophrenia. Cannabis disorders are associated with diagnostic instability and 
greater likelihood of progression to schizophrenia. By contrast, comorbid stimulant 
disorders may be associated with better prognosis in psychosis, and it may be important to 
avoid premature closure on a diagnosis of schizophrenia when stimulant disorders are 
present.   
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INTRODUCTION 
A person with psychosis may receive different diagnoses over time. “Diagnostic shifts” 
(Bromet et al., 2011) may reflect inter-rater variation, changes in available information, the 
evolution of illness or a combination of all of these (Bromet et al., 2011; Haahr et al., 
2008).  These shifts are of clinical relevance; the diagnosis first made by a person’s 
treating team may determine his or her subsequent care (Crebbin et al., 2009; Whitty et 
al., 2005) and may shape the expectations of the person, his or her family and treating 
clinicians.    
Comorbid substance use is common in psychosis (Addington and Addington, 2007; Wade 
et al., 2005; Kavanagh et al., 2004; Moore et al., 2012a; Regier et al., 1990) and may 
contribute to diagnostic shifts in several ways. First, substance use creates clinical 
uncertainty; it is difficult to judge causation of psychosis when substance use persists 
(Mathias et al., 2008). Second, substance use may influence the course of psychosis. 
Substances may trigger recurrence of symptoms and relapse of illness (González-Pinto et 
al., 2011; Wade et al., 2006a; Wade et al., 2007; Sorbara et al., 2003; Bertelsen et al., 
2009; Malla et al., 2008) and therefore may increase the likelihood of progression towards 
enduring psychoses such as schizophrenia. However, findings on this issue are conflicting; 
comorbid substance use in brief or affective psychoses has been associated with reduced 
(Schwartz et al., 2000; Bromet et al., 2011), increased (Whitty et al., 2005), or unchanged 
(Naz et al., 2003) likelihood of diagnostic shift to schizophrenia.  
Cannabis and stimulants may differ in their effects on diagnostic stability. Cannabis 
interacts with personal vulnerabilities to increase the risk of developing schizophrenia (Hall 
and Degenhardt, 2011). Therefore persistent cannabis use is likely to predict a diagnostic 
trajectory from brief psychoses to schizophrenia. Amphetamine, cocaine and other 
stimulants are used in up to 30% of young people with psychosis (Hides et al., 2006; Sara 
et al., 2013). They are powerful dopamine agonists that can induce psychotic symptoms in 
healthy volunteers (Angrist et al., 1987), and whose effects may increase with repeated 
use due to sensitization (Hermens et al., 2009; Curran et al., 2004). Dopamine over-
activity may play a role in schizophrenia (Keshavan et al., 2008; Laruelle and Abi-
Dargham, 1999), therefore persistent stimulant use may be even more likely than 
persistent cannabis use to cause diagnostic progression from other psychoses to 
schizophrenia. 
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However, the only study that examined cannabis and stimulant induced psychoses 
separately found that 46% of people with cannabis-induced psychosis later received a 
diagnosis of schizophrenia, compared with only 30% of people with amphetamine-induced 
psychosis (Niemi-Pynttari et al., 2013). That study examined people with a specific 
diagnosis of substance-induced psychosis, and when multiple substances were related to 
the psychosis episode they were classed as “other or unknown” substances. It is important 
to know whether these findings can be generalized to other clinical situations that often 
involve a wide range of psychosis diagnoses and where cannabis and stimulant use often 
co-exist.  
Our study examined admissions to mental health units in the state of New South Wales 
(NSW, population 7.2 million), Australia. This provided a population-based  sample with 
sufficient power to examine diagnostic stability in brief psychoses (including brief, atypical 
and drug-induced psychoses) and affective psychoses (bipolar disorder and psychotic 
depression), and to examine the effects of cannabis and stimulant comorbidity  separately 
and in combination. We focused on substance problems occurring during  the follow up 
period rather than at the first (index) admission, because baseline substance problems 
have been shown to have a more limited effect on outcome in psychosis than ongoing 
substance use (González-Pinto et al., 2011; Sorbara et al., 2003; Wade et al., 2006a). 
METHODS 
Sample 
Admissions of NSW residents to state operated (“public”) hospitals from 1 July 2000 to 30 
June 2011 were screened. The first (index) admission with psychosis was identified for 
each person with the use of a unique person identifier (Figure 8.1). Participants were aged 
18-50 years and had an index admission of more than one day’s duration to a designated 
mental health unit, with a primary or secondary diagnosis of psychosis. People whose 
index admissions were longer than 2 years or ended in death were excluded.  
For each participant we identified all subsequent admissions for mental health care to 
NSW public hospitals, and all subsequent contacts with specialised community mental 
health services in the five years from the end of the index admission. Diagnostic stability 
was examined only in persons with at least two years of ongoing service contact, to avoid 
overestimating diagnostic agreement where the time between assessments was limited.   
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The study was approved by the NSW Population and Health Services Research Ethics 
Committee.  
Psychosis diagnoses 
New South Wales health services record diagnosis using the International Classification of 
Diseases Tenth Revision, Australian Modification (ICD-10-AM) (National Centre for 
Classification in Health, 2010). Hospital episodes with a primary or additional ICD-10 
diagnosis of  psychosis were grouped into (i) ‘Schizophrenia’,  including schizophrenia 
(F20)  and schizoaffective disorder (F25), (ii) ‘Affective Psychoses’, including bipolar 
disorder (F30, F31) and psychotic  depression (F32.3, F32.30, F32.31, F33.3), and (iii) 
‘Other Psychoses’, including acute and transient psychoses (F23), delusional disorders 
(F22, F24), other or unspecified psychosis (F28, F29)  and drug-induced psychoses. Drug 
induced psychoses included ICD-10 substance codes (F10-F19) in which psychosis was 
specified (e.g. F10.5, F10.9). DSM-IV schizophreniform psychosis is classified with acute 
and transient psychoses in ICD-10. Organic psychoses and schizotypal disorder were 
excluded.  
Index diagnosis was obtained from the first admission for each person.  Final diagnosis 
was the mental health diagnosis at the end of the 2 to 5 year follow-up period in inpatient 
and community care episodes.  When multiple diagnoses were recorded on the last date, 
priority was given to the diagnosis identified by the treating team as being primarily 
responsible for the episode of care. Final diagnoses of mental health conditions other than 
psychosis were grouped as “Non-psychotic conditions”. Persons with no specific mental 
health diagnosis recorded in the study period were excluded from analysis.  
Binary variables were created for schizophrenia or other psychosis diagnoses at index 
admission and during ongoing community-based care. 
Substance diagnoses 
Substance disorders were identified by primary or additional diagnosis codes for abuse, 
dependence, intoxication, poisoning by specific illicit drugs, or alcohol-related liver 
disease. Drug-induced psychoses counted as both a psychosis and a substance disorder. 
Amphetamines and cocaine were grouped as stimulant disorders.  Opiate disorders 
included illicit opiates (e.g. heroin) and non-medical use of prescription opiates.  Polydrug 
disorder was recorded only where specifically diagnosed (ICD code F19). We 
distinguished between substance disorders occurring only at the index admission, and 
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substance disorders occurring in the study period (i.e. at least one substance disorder 
diagnosis occurring subsequent to the index admission). Only substance diagnoses in the 
study period were examined in analyses of diagnostic stability.  
 
A binary variable was constructed indicating the presence of any illicit drug diagnosis 
(cannabis, stimulant, hallucinogen, opiate or polydrug) during the study period (excluding 
the index admission). A composite “Illicit Drug Use Group” variable was created with five 
mutually exclusive categories: (i) No illicit drug diagnoses, (ii) Cannabis,  (iii)  Stimulants, 
(iv) Cannabis plus Stimulants, and (v) Other/Polydrug only. Some persons in groups (ii) – 
(iv) had additional substance diagnoses. People in the “Other/Polydrug only” category had 
only specific substance diagnoses (e.g. opiate disorders) or a polydrug diagnosis without 
indication of the substances involved, and no cannabis or stimulant diagnoses .   
Other variables 
Demographic variables were measured from index admission. Migration status was based 
on country of birth. Rurality and disadvantage measures were based on Australian Bureau 
of Statistics reference data for the area of residence, collapsed for rurality (major 
metropolitan vs. regional and rural residence) and disadvantage (most disadvantaged 40% 
of local areas vs. least disadvantaged 60%). Ongoing contact was defined as having at 
least one community mental health contact or admission to a mental health unit in the two 
to five years after discharge from the index admission. 
Statistical analysis 
Predictors of ongoing contact were examined using binary logistic regression. Univariate 
Odds Ratios (ORs) and 95% CIs were calculated separately for demographic, diagnostic 
and prior care variables. Multivariate analysis included all variables with significant 
univariate associations (P<=0.05). Multi-collinearity was assessed and collinear variables 
excluded (Belsley, 1991). 
Index and final diagnoses were cross-tabulated, and overall diagnostic agreement was 
calculated as the percentage of persons with both index and final diagnosis in the same 
group. Diagnostic agreement was calculated separately for persons with and without 
comorbid substance diagnoses and compared using Pearson’s Chi-square test.  For the 
binary Schizophrenia/No Schizophrenia variable, agreement between index and final 
127 
diagnosis was calculated using Cohen’s kappa, calculated separately for persons with and 
without cannabis, stimulant and alcohol disorders.  
 
Predictors of diagnostic change to or from schizophrenia were examined using binary 
logistic regression analyses, conducted separately for people with (i) schizophrenia and (ii) 
other psychoses at index admission.  Within each group, two regression models were 
constructed. The first examined the effect of any illicit drug diagnosis, and the second 
examined the effects of cannabis and stimulants separately.  Regression diagnostics were 
conducted as described above. Analyses were conducted using Stata v13 (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX, StataCorp LP.). 
RESULTS 
After exclusions, an index psychosis admission was identified for 42,205 persons aged 18-
50 years (Figure 8.1). Sixty percent were male (Table 8.1), and more than half were aged 
between 21 and 35.  The most common diagnoses at index admission were schizophrenia 
(39%) and other (brief, atypical, drug-induced and unspecified) psychoses (33%). One 
third had comorbid illicit drug diagnoses at index admission, most commonly a cannabis 
disorder (22%) and/or stimulant disorder (11%). More than half of those with stimulant 
disorders also had cannabis disorder.  
 
The rate and pattern of cannabis and stimulant disorders were similar for schizophrenia 
and affective psychoses (Table 8.2). Comorbid substance disorders were most common in 




















Figure 8.1. Overview of study method 
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Table 8.1. Characteristics of study sample and predictors of ongoing service contact over two to 
five years following an initial diagnosis of psychosis. 









Odds of  
ongoing  
contact (a) 
  n = 42,205 
n (%) 
n = 17,075 
n (%) 
n = 25,130 
n (%) 
 
OR (95% CI) 
Personal characteristics       Age: mean (SD) 32.9 (8.9) 33.2 (8.9) 32.7 (8.9) 0.99 (0.99-0.99)* 
  Male  25,410 (60) 10,158 (60) 15,252 (61) 0.96 (0.91-1.00) 
  Migrant (b) 10,111 (25) 4,397 (27) 5,714 (24) … 
  Regional and rural (b) 17,248 (43) 6,748 (42) 10,500 (43) … 
  Most disadvantaged 16,657 (42) 6,382 (40) 10,275 (43) 1.08 (1.04-1.13)* 
Psychosis Diagnoses (c)       Schizophrenia 16,602 (39) 5,077 (30) 11,525 (46) 1.00 
  Affective psychoses 11,605 (28) 5,450 (32) 6,155 (25) 0.48 (0.45-0.50)* 
  Other psychoses 13,998 (33) 6,548 (38) 7,450 (30) 0.47 (0.45-0.50)* 
Drug abuse/dependence (c)       No illicit drugs 27,774 (66) 11,105 (65) 16,669 (66) 1.00 
  Cannabis 6,862 (16) 2,713 (16) 4,149 (17) 1.05 (0.99-1.11) 
  Cannabis + Stimulant 2,601 (6) 1,066 (6) 1,535 (6) 1.07 (0.98-1.17) 
  Stimulant 2,095 (5) 1,009 (6) 1,086 (4) 0.86 (0.78-0.94)* 
  Other / Polydrug only 2,873 (7) 1,182 (7) 1,691 (7) 1.02 (0.94-1.11) 
Alcohol abuse/dependence (c) 5,628 (13) 2,284 (13) 3,344 (13) 1.05 (0.98-1.11) 
Notes: (a) Odds ratios from multivariate logistic regression. (b) Migrant status and rurality excluded from 
regression due to collinearity with other variables. Country of birth data missing for 1648 persons (3.9%), 
Address data missing for 2124 persons (5.0%). Percentages of those with valid data (c) Psychosis and 
substance diagnoses at index admission. * p< 0.05.   
 
 
Table 8.2. Psychosis type and substance disorder diagnoses in 42,205 people with an initial 
diagnosis of psychosis. 
Index psychosis diagnosis n Index substance diagnosis 
Rate (95% Confidence Interval) 
Any illicit drug Cannabis Stimulant 
Schizophrenia 16,602 25.5% (24.8% - 26.1% ) 
17.8% 
(17.2% - 18.4% ) 
5.5% 
(5.2% - 5.9% ) 
Affective Psychoses / Bipolar 11,605 23.3% (22.5% - 24.1% ) 
16.9% 
(16.2% - 17.6% ) 
5.1% 
(4.7% - 5.5% ) 
Other psychoses 13,998 53.6% (52.8% - 54.4% ) 
32.5% 
(31.7% - 33.2% ) 
22.7% 
(22.0% - 23.4% ) 
Total 42,205 34.2% 
(33.7% - 34.6% ) 
22.4% 
(22.0% - 22.8% ) 
11.1% 




Thirty-nine percent of subjects had two or fewer years of mental health service contact and 
were excluded from analysis of diagnostic stability. Ongoing contact was more likely in 
people who were younger, lived in disadvantaged areas and had index diagnoses of 
schizophrenia. Overall substance diagnoses at index admission did not predict ongoing 
contact however contact was less likely (OR 0.86, 95% CI 0.78 – 0.94) in people whose 
only substance comorbidity at index admission was a stimulant disorder. 
Diagnoses at index admission were compared with diagnosis over the following two to five 
years (Table 8.3). Only 18% of those with an index diagnosis of brief, atypical or drug-
induced psychosis retained a diagnosis within that group. Others were diagnosed with 
schizophrenia (46%), non-psychotic conditions (29%) and affective psychoses (7%). Index 
diagnoses of schizophrenia were stable: 82% retained that diagnosis in the study period.  
 
Table 8.3: Comparison of index and final diagnosis over five years in 24,306 persons with an initial 
diagnosis of psychosis. 
 
 
One third of people with ongoing service contact had at least one illicit substance 
diagnosis during the study period. Substance disorders predicted lower diagnostic stability. 
Index and final diagnoses agreed in 60% of persons without substance disorders but only 
in 47% of people with substance disorders (χ2 = 423, p < 0.001). Diagnostic agreement 
was lower for stimulant disorders (40% agreement between index and final diagnosis) than 
for cannabis disorders (47% agreement, χ2 = 57, p < 0.001).  Stability between index and 
final diagnosis was also examined by measuring kappa for agreement between index and 
final diagnosis after grouping these into binary Schizophrenia/No Schizophrenia variables. 
Diagnostic stability was lower for those with comorbid stimulant disorders and cannabis 
disorders in the study period, compared with those with alcohol disorders in the study 














Schizophrenia 9,172 (82%) 370 (3%) 579 (5%) 1,107 (10%) 11,228 (100%) 
Affective psychoses  1,196 (20%) 2,717 (46%) 245 (4%) 1,765 (30%) 5,923 (100%) 
Other psychoses 3,256 (46%) 497 (7%) 1,302 (18%) 2,100 (29%) 7,155 (100%) 
Total 13,624 (56%) 3,584 (15%) 2,126 (9%) 4,972 (21%) 24,306 (100%) 
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Figure 8.2.  Comorbid substance disorders during study period and diagnostic stability: agreement 
(kappa) between index and final study diagnosis of schizophrenia or other psychosis in 24,306 
persons over two to five years.    
 
Table 8.4.  Predictors of diagnostic change in 24,306 persons with an initial diagnosis of psychosis 
and 2-5 years of ongoing service contact.  
 
Diagnosis change to 
 schizophrenia (a) 
 
(n = 4,452 of 13,078) 
Diagnosis change from 
schizophrenia (b) 
 









OR (95% CI) (d) 
Any substance 
disorder 




OR (95% CI) (d) 
Age 0.97 (0.97-0.98)* 0.97 (0.97-0.98)* 0.98 (0.98-0.99)* 0.98 (0.98-0.99)* 
Male gender 1.69 (1.56-1.82)* 1.68 (1.55-1.81)* 0.65 (0.59-0.73)* 0.66 (0.59-0.73)* 
Years in study 1.26 (1.19-1.33)* 1.26 (1.19-1.33)* 0.80 (0.75-0.86)* 0.81 (0.75-0.86)* 
Substance disorders     
  No illicit drugs 1.00 1.00 1.00 1.00 
  Any illicit drug 0.97 (0.89-1.04) - 1.55 (1.40-1.71)* - 
  Cannabis - 1.12 (1.01-1.24)* - 1.30 (1.13-1.49)* 
  Cannabis + Stimulant - 0.99 (0.89-1.11) - 1.66 (1.41-1.95)* 
  Stimulant - 0.81 (0.67-0.97)* - 2.21 (1.67-2.93)* 
  Other / Polydrug only - 0.80 (0.71-0.90)* - 1.67 (1.45-1.92)* 
 
Note: (a) People with initial diagnoses of affective, brief, atypical or drug-induced psychosis.  (b) People with 
initial diagnoses of schizophrenia. (c) Any substance disorder in study period. (d) Specific substance disorder 
in study period by type of substance. * p< 0.05. 
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Predictors of diagnostic change were examined separately for people with diagnoses of 
schizophrenia (n=11,228) or other psychoses (n=13,078) at index admission (Table 8.4). 
In people with initial diagnoses of affective, brief or atypical psychoses, male gender and 
longer duration of observation were associated with increased odds of diagnostic change 
to schizophrenia. Conversely, in people with initial diagnoses of schizophrenia, female 
gender was associated with diagnostic revision away from schizophrenia towards other 
diagnoses. Younger age was associated with diagnostic instability in both directions.   
In people with initial diagnoses of affective, brief or atypical psychoses, illicit substance 
disorders during the study period were not associated with diagnostic change to 
schizophrenia after controlling for age, sex and duration of observation. However when 
examined separately, cannabis and stimulant disorders had significant but opposing 
effects: diagnostic change to schizophrenia was more likely with comorbid cannabis 
disorders (OR 1.12, 95% CI 1.01 – 1.24) and less likely with stimulant disorders (OR 0.81, 
95% CI 0.67 – 0.97) or other drug disorders (OR 0.80, 95% CI 0.71 – 0.90) without 
cannabis disorders. Of people with an index diagnosis of affective or other psychoses and 
no substance diagnosis, 34.0% were later diagnosed with schizophrenia, compared with 
36.6% of those with affective/other psychoses and ongoing cannabis disorders (Risk 
Difference 2.6%, Number Needed to Harm 39).  
In people with initial diagnoses of schizophrenia, all comorbid substance disorders were 
associated with greater likelihood of diagnostic change towards other diagnoses. This 
effect was greatest for those with only stimulant disorders, least for those with only 
cannabis disorders and intermediate for those with both cannabis and stimulant disorders.  
DISCUSSION  
We examined diagnostic stability in 24,306 individuals two to five years after an admission 
for psychosis.  More than 80% of initial diagnoses of brief, atypical or drug-induced 
psychoses were later revised, nearly half (46%) to schizophrenia. Index diagnoses of 
schizophrenia were more stable, but 18% were revised to other conditions over five years.  
The rate of diagnostic change in our sample was consistent with other studies that have 
found between 29% and 50% of people with brief or drug-induced psychoses later receive 
a diagnosis of schizophrenia (Arendt et al., 2005; Castagnini et al., 2008; Crebbin et al., 
2009; Naz et al., 2003). Initial diagnoses of schizophrenia have been revised to other 
conditions in 8% of people at two years (Schwartz et al., 2000) and up to 21% of people at 
five years (Baca-Garcia et al., 2007) .    
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Our first aim was to examine whether comorbid substance disorders were associated with 
diagnostic instability.  Nearly half of people with ongoing service contact had at least one 
comorbid illicit substance disorder. Considered together, ongoing substance disorders did 
not increase the likelihood of diagnostic progression from affective or other psychoses to 
schizophrenia.  These findings are consistent with reports (Bromet et al., 2005; Schwartz 
et al., 2000) that substance use after a first psychosis admission predicts unchanged or 
reduced risk of a later schizophrenia diagnosis.  However, we found that substance 
disorders were associated with diagnostic instability. In people with comorbid substance 
disorders, initial and final psychosis diagnoses agreed less than half of the time, because 
there was greater likelihood of revision of diagnosis away from index diagnoses of 
schizophrenia in people with substance disorders.  
Our second aim was to examine whether cannabis and stimulant disorders differed in their 
associations with diagnostic change.  We found that cannabis disorders had a modest 
association with diagnostic progression to schizophrenia; one additional person received 
this diagnosis for every 39 persons with an ongoing cannabis disorder diagnosis. In 
contrast, stimulant disorders were associated with diagnoses of briefer psychoses and with 
diagnostic change away from schizophrenia.  These findings add to those of Niemi-
Pynttari and colleagues (Niemi-Pynttari et al., 2013), who examined substance-induced 
psychoses. Together these studies underline the importance of examining cannabis and 
stimulants separately rather than grouping them together.  
In people with comorbid diagnoses of both cannabis and stimulant disorders, an additive 
risk and an increase in the likelihood of developing a more chronic psychosis may be 
expected. However we found that people with both diagnoses had an intermediate risk of 
diagnostic transition to schizophrenia when compared to those with stimulant or cannabis 
diagnoses alone.  There are a number of possible explanations for this finding, which 
warrant further research. If stimulants have greater potential than cannabis to trigger 
psychotic states then they may precipitate psychosis in individuals with a lower personal 
vulnerability to the development of schizophrenia. Persons with a first admission psychosis 
who also use stimulants may also have other factors associated with more positive 
outcomes, such as later age of drug use or psychosis onset, and a higher socio-economic 
status (Sara et al., 2013). It is also possible that stimulants and cannabis are associated 
with different responses to treatment. Stimulants act on the same dopamine pathways 
through which antipsychotic medications are thought to act (Hermens et al., 2009) , and so 
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antipsychotic medications may be more effective in stimulant-related psychoses. 
Psychoses associated with cannabis use may be less responsive to treatment because 
they involve abnormalities in other chemical pathways.   
Limitations 
The hospital data used do not have unique person identifiers prior to the start of the study 
period. Therefore we were unable to identify whether individuals had admissions prior to 
their index admission, and if so how many admissions they had. Older participants in our 
study are more likely to have had prior admissions, while for younger participants their 
index admission in the study period is more likely to have been their first ever hospital 
admission. Therefore age and stage of illness are likely to be confounded in our study.  
We included only persons with at least two years of service contact. People with stimulant 
disorders and affective, brief, drug-induced and atypical psychoses were more likely to 
have brief contact and therefore be excluded from the study. People with no ongoing 
service contact are less likely to have had severe or enduring psychoses such as 
schizophrenia. Therefore, we may have underestimated any association between 
stimulant disorders and positive outcomes.  
To obtain a population-wide sample, we used clinical diagnoses from administrative 
datasets. Routine diagnoses are less reliable than research diagnoses, and substance 
comorbidities may be particularly under-recorded (Large et al., 2012). In this study, the 
types of diagnoses, rates of substance comorbidity and patterns of diagnostic change 
were similar to those reported in clinical studies. However caution is needed in interpreting 
this study’s conclusions and further evidence is required from clinical studies using more 
rigorous diagnoses.  
We considered substance disorder diagnoses as a measure of ongoing substance 
problems. This measure is imprecise and cannot distinguish between different levels of 
duration or severity of substance disorder. Apparent differences between cannabis and 
stimulant groups in our study may have been due to the effects of different comorbidity 
with other drugs such as hallucinogens or opiates. However the rate of comorbid 
diagnoses with these substances was low.  
We derived a single study diagnosis from the most recent diagnosis in the study period. 
This is one of several ways in which multiple diagnoses may be combined (Morgan and 
Jablensky, 2010).  Our choice of method was based on testing of competing algorithms 
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against NSW administrative data and research diagnoses, as described in Appendix A 
(Sara et al., 2014d) .  
 
Conclusions  
Substance comorbidity is common in people with psychosis, and may contribute to 
diagnostic change by causing diagnostic uncertainty and by influencing the course of 
illness. Cannabis and stimulants differed in their impact on diagnostic change. Stimulant 
disorders were associated with diagnostic instability, a lower likelihood of change to 
schizophrenia, and greater likelihood of diagnostic revision away from schizophrenia. 
While many people with initial diagnoses of brief and affective psychoses may progress to 
a diagnosis of schizophrenia, it is important to avoid premature closure on a diagnosis of 















Stimulants may worsen psychotic symptoms but there is limited evidence about the impact 
of stimulant abuse in people with schizophrenia. This study examined the prevalence and 
correlates of stimulant and other drug disorders in a population-based sample of people 
with schizophrenia, examining associations with frequent service use, physical health 
comorbidities and accommodation instability.   
Methods 
New South Wales (NSW) hospital, community mental health and emergency department 
data were used to examine health service contact over five years in 13,624 people with a 
diagnosis of schizophrenia. Associations of stimulant disorders were examined with 
multinomial logistic regression, comparing people with no substance disorders to those 
with cannabis disorders, stimulant disorders or both.   
Results  
51% of people with schizophrenia had substance disorders, including 14% with stimulant 
disorders. Stimulant disorders were more common in young adults and in urban areas, 
less common in migrants, and unrelated to initial social disadvantage.  More than 80% of 
those with stimulant disorders also had cannabis disorders. Service use and harms were 
most common in this group, including frequent mental health admissions (59%), frequent 
Emergency Department presentations (52%), admissions with injury or self-harm (44%), 
This chapter is based on the publication: Sara, G., P. Burgess, G. Malhi, H. Whiteford 
and W. Hall (2014). Stimulant and other substance use disorders in schizophrenia: 
prevalence, associations and impacts in a population sample Australian and New 
Zealand Journal of Psychiatry. 48: 1036-1047. 
 Reproduction of the submitted original within a book or thesis is permitted by the Sage 
Publications Author rights policy. www.sagepub.com/journalgateway/authorGateway.htm 
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infectious disease diagnoses (22%), multiple changes of residence (61%), movement to 
more disadvantaged locations (42%) and periods of homelessness (18%). People with 
stimulant disorders alone had higher rates of self-harm, infectious disease and non-
mental-health admissions than people with cannabis disorders alone.  
Conclusions 
Stimulant disorders occur in people with schizophrenia and in first episode psychosis at 
rates more than ten times that of the broader population. Stimulant disorders are likely to 
worsen the burden of psychosis, and strategies are needed to engage and support the 
highly disadvantaged group of people with schizophrenia who have cannabis and 
stimulant disorders.  
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INTRODUCTION 
Stimulants such as amphetamines, cocaine and ecstasy are the most widely used illicit 
drugs after cannabis (United Nations Office on Drugs and Crime, 2011a). There is 
increasing evidence that cannabis contributes to the onset and course of psychosis (Hall 
and Degenhardt, 2011; Santos et al., 2013), however there is less evidence about the 
impact of stimulant abuse on people with psychosis.  
The pharmacology of stimulant drugs suggests a particular association with psychosis. 
Stimulants are powerful dopamine agonists, acting through a range of mechanisms to 
increase synaptic dopamine levels (Barr et al., 2006). These effects increase with 
repeated exposure due to a process of sensitization (Hermens et al., 2009; Curran et al., 
2004).  Dopamine over-activity may play a role in schizophrenia and other psychoses 
(Keshavan et al., 2008; Laruelle and Abi-Dargham, 1999), particularly in the development 
of positive psychotic symptoms (Paparelli et al., 2011).  
Clinical and experimental studies demonstrate the potential for stimulants to worsen acute 
psychotic symptoms. High dose amphetamines can produce psychotic symptoms in 
healthy volunteers (Angrist et al., 1987; Griffith et al., 1972). Recreational stimulant users 
report high rates of transient psychotic symptoms which are related to the dose and 
frequency of stimulant use (McKetin et al., 2010; Hall et al., 1996). Amphetamines are 
associated with hospital admissions for brief, transient and drug-induced psychoses 
(Degenhardt et al., 2008c; Degenhardt et al., 2007d; Sara et al., 2013).  Lieberman 
(Lieberman et al., 1984) found  that transient increases in symptoms after stimulant 
challenge predicted later relapse of psychosis, and argued that ongoing stimulant use 
worsens the course of schizophrenia (Lieberman et al., 1990). Curran et al reviewed 26 
studies of brief experimental methamphetamine challenge in people with schizophrenia 
(Curran et al., 2004) and found increased psychotic symptoms in more than half of those 
with current positive symptoms and nearly one third of those whose psychosis was in 
remission.  
The current study builds on our earlier work examining stimulant use disorders in the 
Australian population (Sara et al., 2012) and in people with a first admission for psychosis 
(Sara et al., 2013). Those studies found that people with a first admission psychosis have 
a rate of stimulant disorders around ten times greater than other young Australians, and 
that the correlates of stimulant disorders differed from those of cannabis disorders, both in 
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the Australian population and in first episode psychosis. This study focuses specifically on 
people with diagnoses of schizophrenia, and has three aims.  
Our first aim is to examine the rate of stimulant use disorders in people with schizophrenia. 
Many of the studies summarized above focus on brief or transient exposure to stimulants. 
Psychotic symptoms and other drug-related harms are especially associated with severe 
and dependent use (Degenhardt et al., 2014).  Few studies have reported the rate of 
stimulant disorders in people with established diagnoses of schizophrenia. The Australian 
Survey of High Impact Psychosis (SHIP) found that 73% of people with schizophrenia or 
schizoaffective psychoses reported lifetime stimulant use, and 40% reported past year use 
(Moore et al., 2012b). The SHIP study, however, did not report rates of stimulant abuse or 
dependence. In three US studies, between 11% and 37% of people with schizophrenia 
had cocaine use disorders (Chouljian et al., 1995; Gearon and Bellack, 2000; Miller and 
Tanenbaum, 1989).  Lower rates, ranging from 3% to 7%, have been reported in studies 
from Canada (Margolese et al., 2004) , Western Europe (Modestin et al., 2001) and 
Scandinavia (Ringen et al., 2013). However, all but one of these studies (Ringen et al., 
2013) examined cocaine disorders. Rates of methamphetamine abuse and dependence 
are higher in Australia than in many other countries because methamphetamine is much 
more widely used in Australia than cocaine  (Degenhardt et al., 2014) . Therefore current 
studies provide limited evidence about the scale of this problem in Australia.   
The second aim of this study is to examine the correlates of stimulant disorders in people 
with schizophrenia. Knowing which people with schizophrenia have higher rates of 
stimulant disorders is important in understanding where any impact of stimulants may be 
felt most strongly. This knowledge may inform service planning, appropriate assessment 
and treatment.  Most studies describing rates of stimulant use disorder in people with 
schizophrenia report this as a coincidental finding. To our knowledge no study has 
examined how people with schizophrenia who abuse stimulants differ from those who do 
not.  
The third aim of this study is to examine the impact of stimulant use disorders in people 
with schizophrenia. If stimulants increase psychotic symptoms or precipitate relapse, then 
severe or ongoing use is likely to be associated with more chronic illness course, more 
frequent hospitalisation and greater service use. Long term stimulant use may also be 
associated with specific physical health consequences, in particular with cardiovascular 
disease and with infectious disease due to progression to intravenous methods of 
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administration (Darke et al., 2008; Degenhardt et al., 2008c; Darke et al., 1994). 
Dependent drug use may also be associated with disrupted social supports and 
marginalisation. In the Australian population, one in five people with a lifetime history of 
stimulant disorders have been homeless (Sara et al., 2012). Physical health comorbidities 
and unstable housing are both significant contributors to the overall burden of 
schizophrenia. Therefore people with schizophrenia who also abuse stimulants are likely 
to be especially vulnerable to these harms.   
A major methodological challenge in studying stimulant use in psychosis is that most 
people with psychosis who use stimulants have also used cannabis.  For example, 
amongst participants in SHIP, 98.4% of amphetamine users reported prior cannabis use 
(Power et al., 2014). Therefore even very large clinical studies have not had sufficient 
statistical power to separate the associations of stimulant use from those of cannabis. One 
strategy is to use a large, population-based dataset with sufficient scale to examine 
stimulant disorders while controlling for comorbid cannabis disorders.  
Our study examines people admitted to hospital with psychosis in New South Wales 
(NSW) over an 11 year period. We examined people with at least two years of ongoing 
service contact, to ensure a sufficient period of observation to detect adverse outcomes 
that may be associated with stimulant disorders. We focused on ongoing substance 
problems rather than those recorded only at first contact, because many people cease 
substance use after a first psychosis episode, and it is ongoing use which appears to most 
adversely influence course and outcome in psychosis (González-Pinto et al., 2011; 
Sorbara et al., 2003; Wade et al., 2006a). 
METHODS 
The study was approved by the NSW Population and Health Services Research Ethics 
Committee. 
Sample 
Admissions of NSW residents to state operated (“public”) hospitals from 1 July 2000 to 30 
June 2011 were screened. Potential participants were aged 18-50, had an index 
admission to a designated mental health unit that lasted more than one day, and had a 
primary or secondary diagnosis of psychosis. People whose index admissions were longer 
than two years (n=109) were excluded. For each potential participant we used a unique 
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statewide person identifier and examined the five year follow-up period from the end of 
their index hospitalization to identify (i) further admissions to NSW public hospitals for 
mental health or physical health care, (ii) contacts with specialised community mental 
health services and (iii) Emergency Department (ED) contacts. Study participants were 
selected who had a final diagnosis of schizophrenia and a minimum of two years of 
ongoing contact with inpatient or community mental health services.  
Schizophrenia diagnosis 
NSW health services record diagnosis using the International Classification of Diseases 
(ICD-10-AM) (National Centre for Classification in Health, 2010).  Schizophrenia was 
defined by the presence of a primary or additional ICD-10 diagnosis code of schizophrenia 
(F20) or schizoaffective disorder (F25).  Final diagnosis was the last recorded mental 
health diagnosis in the five year follow-up period, including both inpatient and community 
care episodes. Where multiple diagnoses were recorded on the last date, priority was 
given to the diagnosis identified by the treating team as responsible for the episode of 
care.  
Substance diagnoses 
Only substance diagnoses in the study period were examined (excluding the index 
admission). Substance disorders were identified by primary or additional diagnosis codes 
for abuse, dependence, drug-induced psychosis, intoxication or poisoning by specific illicit 
drugs. Amphetamine and cocaine disorders were grouped together as stimulant disorders. 
Polydrug disorder was recorded only where specifically diagnosed (ICD code F19). A 
binary variable was constructed indicating the presence of any illicit drug diagnosis during 
the study period. A composite “Illicit Drug Disorder Group” variable was created with five 
mutually exclusive categories: (i) No illicit drug disorder; (ii) Other/unspecified only; (iii) 
Cannabis; (iv) Stimulants; and (v) Cannabis plus Stimulants. Some people in cannabis and 
stimulant disorder groups had additional substance diagnoses. People in the 
“Other/unspecified” category had no cannabis or stimulant disorders but one of: a polydrug 
diagnosis without indication of the substances involved; a diagnosis of unspecified or 
mixed substance disorder or; a specific diagnosis of opiate or hallucinogen disorders.   
Demographic variables 
Age, sex, country of birth and location of residence were recorded from the index 
admission. Migration status was derived from country of birth. The statistical local area 
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(SLA) of residence was linked to Australian Bureau of Statistics reference data to obtain (i) 
a measure of rurality, the Accessibility Remoteness Index of Australia (ARIA, 
www.abs.gov.au/websitedbs/d3310114.nsf/home/remoteness+structure) and (ii) a 
measure of disadvantage, the Index of Relative Socio-Economic Disadvantage (IRSD, 
www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001).  
Service use variables 
Four measures of contact with NSW health services over the 5 year follow-up period were 
derived: (i) mental health admissions (hospital admissions with at least one day of 
specialist mental health care); (ii) other admissions (hospital admissions with no specialist 
mental health care); (iii) ED presentations, and; (iv) community mental health contacts. A 
community mental health contact is a single visit with any NSW specialist ambulatory or 
community mental health service. Where a person sees more than one clinician during 
that visit, this is recorded as a single contact. A person may have more than one contact 
per day if they have repeated visits or are seen by more than one team or service. No data 
were obtained from private hospital admissions, private psychiatrists or primary care 
services. Community mental health contacts were converted to a rate (community contacts 
per 100 days) and the denominator for this rate adjusted to remove days spent in hospital 
during the study period.  
Service use variables were anticipated to be highly skewed. For each of the four service 
use types a binary “frequent service use” variable was created by splitting at the 75th 
percentile. 
Physical comorbidities 
We created binary variables for the presence of three physical health conditions which 
may have particular associations with stimulant abuse or dependence: (i) self-harm and 
injury (ICD-10 codes S00- T88); (ii) infectious diseases (A00-B99); and (iii) cardiovascular 
diseases (I00-I99). These were coded as present if the person had at least one primary or 
additional diagnosis code for these conditions during the study period, in either inpatient or 
community mental health data.  
Accommodation instability 
Three proxy measures of accommodation instability were derived. First, we examined 
accommodation type at each hospital admission, and set a “Homeless period” flag if a 
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person had at least one admission with an accommodation type indicating homelessness 
(i.e., homeless, public place, homeless person’s shelter, refuge, boarding house or hostel). 
Second, we recorded the number of different residential locations (SLAs) per person in the 
study period and set a “Multiple locations” flag for people in the top quartile of this 
distribution. Third, we calculated the average index of socio-economic disadvantage 
(IRSD) for each person’s residential locations during the study period and set a “Move 
towards disadvantage” flag if this was higher than the IRSD of their residential location at 
index admission. IRSD cannot be calculated where a person has no address recorded.  
Statistical analysis 
All analyses were conducted using Stata v13 (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX, StataCorp LP.). Means and standard deviations were 
calculated for continuous variables. Frequencies were described for categorical variables. 
For service use variables and residential locations, cut points were calculated at the 75th 
percentile to create binary variables.  
The predictors of the presence and type of substance comorbidity were examined using 
multinomial logistic regression, with the composite five-level “Illicit Drug Disorder Group” 
as the categorical dependent variable and people with no illicit drug disorder as the 
reference category. All candidate variables were entered in a multivariate analysis. Multi-
collinearity was assessed to exclude collinear variables if required (Belsley, 1991). Odds 
Ratios and 95% CIs were calculated.  
The associations of drug type with service use, physical comorbidity and accommodation 
instability were described, reporting means and standard deviations for continuous 
variables, and frequencies with associated 95% confidence intervals for categorical 
variables. The association of these factors with drug type was examined using multinomial 
logistic regression. Regressions were conducted separately for each of the ten binary 
outcome variables as a dependent variable, entering age, sex and illicit drug disorder 
group as independent variables.  
Sensitivity analyses were conducted on three issues by repeating all regressions after 
exclusion of three groups of participants. First, to examine for the effect of diagnostic 
imprecision, people who did not have a diagnosis of schizophrenia at both index admission 
and final contact were excluded. Second, to assess the effects of right-censoring of 
participants, the subset of people with more than two but less than five years of follow-up 
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were excluded. Third, to examine the effect of overlap between participants in this study 
and those in our earlier studies of first admission psychosis, members of the latter group 
were excluded.  
RESULTS 
We identified 13,624 people with a diagnosis of schizophrenia who met the study criteria 
(Table 9.1). Their average age was 32.6, three quarters were aged 40 or below and two-
thirds were male. Migrant status and urban/rural distribution mirrored that of the overall 
NSW population. Only 13.5% had addresses in the least disadvantaged quintile of NSW 
local areas, while 22.3% resided in the most disadvantaged quintile. However a further 
4.2% of people had no recorded address at their index admission and some of these 
people were likely to have been homeless and resident in more disadvantaged areas.   
Substance use disorders were common; more than half (51.5%) of people had at least one 
primary or comorbid substance disorder diagnosis during the study period. The most 
common specific substance diagnoses were of cannabis (29.0%), alcohol (25.7%) and 
stimulant (13.9%) disorders. Many people had multiple substance diagnoses in the study 
period; 38.6% of people with cannabis disorders also had stimulant disorders and 80.2% 
of people with stimulant disorders also had cannabis disorders. A further 12.0% of persons 
had illicit substance disorder diagnoses involving neither cannabis nor stimulants; most of 
these people had polydrug or unspecified substance disorder diagnoses where an 
individual substance was not identified. Mixed or unspecified substance diagnoses were 
more common in community mental health records than inpatient records. Examining 
participants aged 18-29 only, 20.8% had at least one stimulant disorder diagnosis.   
Predictors of the presence and type of substance disorder were examined with multinomial 
logistic regression (Table 9.2). Tests for multi-collinearity did not require the exclusion of 
any variables. The odds of having any substance disorder were highest in younger people. 
In the “Cannabis” or “Cannabis and Stimulant” groups there was a steady decline in odds 
of disorder with increasing age, while for those in the “Stimulant” group the odds of 
disorder were highest in those aged between 21 and 30. Membership of the “Cannabis 





Table 9.1. Characteristics of study sample, people with a schizophrenia diagnosis. 13,624 people 
aged 18-50 who were admitted to NSW hospitals and had subsequent contact with hospital or 
community mental health services over five years.  
  N % 
Age a     
    Mean (SD) 32.6 (8.8) - 
    Median (Interquartile range)  32 (25 - 40) - 
Person characteristics a    
    Male 9,121 66.9 
    Migrant b 3,268 25.0 
Rurality a     
    Major cities 7,671 58.8 
    Inner regional 3,894 29.8 
    Outer regional and remote 1,487 11.4 
Disadvantage a    
    Quintile 1 (least disadvantaged) 1,844 13.5 
    Quintile 2 2,732 20.1 
    Quintile 3 2,680 19.7 
    Quintile 4 2,764 20.3 
    Quintile 5 (most disadvantaged) 3,032 22.3 
    Unknown or no fixed address 572 4.2 
Comorbid substance disorder c d     
    Any substance diagnosis 7,022 51.5 
    Alcohol 3,495 25.7 
    Any illicit drug 5,952 43.7 
    Cannabis 3,946 29.0 
    Stimulant 1,897 13.9 
    Hallucinogen 143 1.0 
Illicit drug disorder group e     
    Cannabis 2,424 17.8 
    Stimulant 375 2.8 
    Cannabis and  Stimulant 1,522 11.2 
    Other/Mixed/Unspecified f 1,631 12.0 
Notes: (a) Person details as recorded at index (first) hospital admission. (b) Country of birth data 
missing for 541 persons (4.1%). (c) Substance diagnoses during study period, excluding index 
admission. (d) Total exceeds 100% as individuals may have more than one substance diagnosis 
recorded. (e) Excludes alcohol disorders; total with any illicit drug disorder = 5,952. (f) Unspecified 






Table 9.2. Predictors of the presence and type of substance disorder over five years in people with schizophrenia (n=13,624). Multinomial logistic 
regression, separating those with any comorbid illicit substance diagnosis into four mutually exclusive substance disorder groups and comparing them 
to a reference group of people with schizophrenia but no substance disorder.  
 
SUBSTANCE DISORDER GROUP a 
 Other or unspecified Cannabis Stimulant Cannabis & stimulant 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Age group         
   18-20 1.8 (1.4 - 2.4)*** 5.9 (4.6 - 7.7)*** 4.6 (2.2 - 9.9)*** 16.8 (10.6 - 26.3)*** 
   21-25 1.7 (1.4 - 2.2)*** 4.8 (3.8 - 6.0)*** 7.3 (3.8 - 14.2)*** 16.6 (10.8 - 25.6)*** 
   26-30 1.6 (1.3 - 2.0)*** 3.3 (2.6 - 4.2)*** 6.7 (3.5 - 13.0)*** 10.1 (6.5 - 15.6)*** 
   31-35 1.5 (1.2 - 1.9)*** 2.4 (1.9 - 3.0)*** 4.7 (2.4 - 9.1)*** 6.5 (4.2 - 10.1)*** 
   36-40 1.0 (0.8 - 1.3) 2.0 (1.6 - 2.6)*** 3.4 (1.7 - 6.7)*** 3.7 (2.4 - 5.8)*** 
   41-45 1.2 (0.9 - 1.5) 1.5 (1.1 - 1.9)** 1.6 (0.8 - 3.5) 2.0 (1.2 - 3.2)* 
   46-50 1.0 1.0 1.0 1.0 
Male gender 1.8 (1.6 - 2.0)*** 2.2 (2.0 - 2.5)*** 1.6 (1.2 - 2.0)*** 2.1 (1.9 - 2.5)*** 
Migrant  0.6 (0.5 - 0.7)*** 0.6 (0.6 - 0.7)*** 0.6 (0.4 - 0.8)*** 0.6 (0.5 - 0.7)*** 
Regional and rural location b 1.1 (1.0 - 1.3)* 1.5 (1.4 - 1.7)*** 0.7 (0.5 - 0.9)** 1.4 (1.2 - 1.6)*** 
Most disadvantaged c 0.9 (0.8 - 1.0) 1.1 (1.0 - 1.2) 1.1 (0.8 - 1.3) 0.9 (0.8 - 1.0) 
Notes: * p<0.05. ** p<0.005. *** p<0.0005.  (a) Substance disorder diagnoses during study period, excluding index admission. (b) ARIA codes for inner regional, 
outer regional, rural and remote. (c) Address in most disadvantaged two quintiles of NSW local areas.  
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Compared to the reference group (people with schizophrenia but no drug disorder in the 
study period), all substance diagnoses were more likely in males, but slightly less skewed 
towards males in the “Stimulant” group (OR 1.6, 95% CI 1.2 – 2.0) than in the “Cannabis” 
(OR 2.2, 95% CI 2.0 – 2.5) or other drug groups. Cannabis and stimulant disorders 
differed in their distribution within the state: cannabis disorders were more likely in regional 
and rural areas; stimulant disorders were more likely in metropolitan areas. All substance 
disorders were significantly less common in people with schizophrenia born outside 
Australia, and substance disorders were not associated with residence in more 
disadvantaged local areas.  
Selected indicators of service use, physical health diagnoses and housing instability (Table 
9.3, Figure 9.1) showed a similar pattern: rates were lowest for those with no substance 
disorders, slightly higher in people with only mixed or unspecified substance disorders, 
then progressively higher in “Cannabis”, “Stimulant” and “Cannabis and Stimulant” groups.  
The only exceptions to this pattern were (i) the odds of having a cardiovascular disease 
diagnosis were elevated only in the “Stimulant” and “Cannabis and Stimulant” disorder 
groups, and (ii) the percent of persons with any period of homelessness was higher in 
people with mixed or unspecified substance disorders than in the “Cannabis” group.    
We used multinomial logistic regressions to examine the relationship between drug 
disorder group and indicators of frequent service use, physical health diagnoses and 
housing instability, after controlling for age and gender. Analyses were conducted 
separately for each binary indicator of service use or harm (Table 9.4). Substance 
disorders predicted greater service contact for all measures. The odds of being a frequent 
service user were highest in the “Cannabis and Stimulant” group, especially for mental 
health admissions (OR 8.9, 95% CI 7.9 – 10.1).  The odds of self-harm, injury or infectious 
disease diagnoses increased more than three-fold in the “Stimulant” group and more than 
fourfold in the “Cannabis and Stimulant” group. Measures of housing instability showed a 
similar pattern, with substantially increased risk of any homeless episode (OR 3.5, 95% CI 
2.9 – 4.2) and multiple changes of address (OR 5.0, 95% CI 4.5 – 5.7) in the “Cannabis 




Table 9.3. Service use, physical health diagnoses and housing stability by substance disorder group, showing average rate for continuous variables 
and frequency and 95% confidence intervals for categorical variables 
  SUBSTANCE DISORDER GROUP 
 
  
No illicit  
drug 
Other or  
unspecified 
Cannabis Stimulant Cannabis 
and  
i l  
Total 
Characteristics       
  Number 7,672 1,631 2,424 375 1,522 13,624 
  Average age (SD) 35 (9) 32 (9) 30 (8) 30 (7) 28 (7) 33 (9) 
  Percent male (95% CI) 59 (58 - 60) 74 (71 - 76) 79 (77 - 80) 73 (69 - 78) 79 (77 - 81) 67 (66 - 68) 
Rate of service use (Mean, SD)       
  Mental health admissions 2.2 (3.0) 2.7 (3.7) 4.4 (4.0) 4.3 (3.7) 6.9 (5.8) 3.2 (4.0) 
  Other admissions 0.6 (1.9) 1.2 (3.3) 1.2 (2.6) 1.5 (2.3) 1.9 (3.8) 1.0 (2.5) 
  Community contacts per 100 days a 9.9 (13.0) 15.8 (21.3) 12.6 (14.6) 11.2 (13.0) 13.5 (14.3) 11.5 (14.8) 
  ED presentations 3.4 (13.5) 6.0 (16.3) 6.3 (12.2) 8.3 (12.7) 11.1 (19.9) 5.2 (14.7) 
Service use in top quartile (%, 95% CI)       
  Frequent mental health admissions b 14 (13 - 15) 19 (17 - 21) 35 (33 - 36) 37 (33 - 42) 59 (56 - 61) 24 (23 - 24) 
  Frequent community mental health contacts c 21 (20 - 22) 32 (30 - 34) 29 (28 - 31) 26 (22 - 31) 34 (32 - 37) 25 (25 - 26) 
  Frequent Emergency Department 
presentations d 16 (15 - 17) 26 (24 - 28) 33 (31 - 34) 38 (33 - 43) 52 (49 - 54) 25 (24 - 26) 
Physical health diagnoses (%, 95% CI)       
  Self-harm and injury e 16 (15 - 17) 26 (24 - 28) 30 (28 - 31) 38 (33 - 43) 44 (41 - 46) 23 (23 - 24) 
  Cardiac disease f 9 (8 - 10) 8 (7 - 10) 8 (7 - 9) 12 (9 - 16) 10 (9 - 12) 9 (8 - 9) 
  Infectious disease g 7 (6 - 8) 11 (9 - 12) 12 (11 - 13) 18 (15 - 23) 22 (20 - 24) 10 (10 - 11) 
Housing instability (%, 95% CI)       
  Any homeless period h 5 (5 - 6) 16 (14 - 18) 10 (9 - 12) 16 (13 - 20) 18 (16 - 20) 10 (9 - 10) 
  Address in 3 or more areas 22 (21 - 22) 36 (33 - 38) 45 (43 - 47) 50 (45 - 55) 61 (59 - 64) 33 (32 - 33) 
  Move to more disadvantaged area i 24 (23 - 25) 32 (30 - 34) 37 (35 - 38) 37 (32 - 42) 42 (39 - 44) 30 (29 - 30) 
Notes. (a) Rate corrected for days spent in hospital. (b) 5 or more mental health admissions. (c) 14 or more contacts per 100 days. (d) 6 or more Emergency 
Department presentations. (e) ICD-10 codes S00- T88. (f) ICD-10 codes A00-B99. (g) ICD-10 codes I00-I99. (h) Based on coding of accommodation type at hospital 



























Figure 9.1. Service use, physical health diagnoses and housing stability in 13 624 people with 
schizophrenia over five years, grouped by type of illicit substance disorder in period: no illicit 
substance disorder (n=7,672), cannabis (2,424), cannabis and stimulant (1,522), stimulant (375) or 





Table 9.4.  Relationship between substance diagnosis group and selected harms over five years in people with schizophrenia (n=13,624). Multinomial 
logistic regressions conducted separately for each indicator of harm as an independent variable; reference group is people with no substance 
disorder. Age and sex are included as covariates in all regressions.   
  SUBSTANCE DISORDER GROUP 
  Other or 
unspecified 
Cannabis Stimulant Cannabis and 
stimulant 
Frequent service use         
  Frequent mental health admissions 1.5 (1.3 - 1.7)*** 3.4 (3.0 - 3.8)*** 3.8 (3.0 - 4.7)*** 8.9 (7.9 - 10.1)*** 
  Any non-mental health admission a 1.9 (1.7 - 2.1)*** 2.4 (2.1 - 2.6)*** 3.8 (3.1 - 4.7)*** 4.0 (3.5 - 4.5)*** 
  Frequent community mental health contacts 1.8 (1.6 - 2.0)*** 1.5 (1.4 - 1.7)*** 1.3 (1.0 - 1.6)* 1.9 (1.7 - 2.1)*** 
  Frequent Emergency Department contacts 1.9 (1.7 - 2.1)*** 2.6 (2.4 - 2.9)*** 3.3 (2.7 - 4.1)*** 5.9 (5.2 - 6.7)*** 
Physical diagnoses         
  Self-harm and injury 1.9 (1.7 - 2.1)*** 2.3 (2.1 - 2.6)*** 3.3 (2.7 - 4.1)*** 4.3 (3.8 - 4.9)*** 
  Infectious disease 1.8 (1.5 - 2.1)*** 2.2 (1.9 - 2.6)*** 3.6 (2.7 - 4.8)*** 4.9 (4.1 - 5.7)*** 
  Cardiac disease 1.0 (0.8 - 1.3) 1.2 (1.0 - 1.4) 1.8 (1.3 - 2.5)*** 1.7 (1.4 - 2.1)*** 
Housing instability      
  Any homeless period 3.1 (2.6 - 3.8)*** 1.8 (1.5 - 2.2)*** 3.2 (2.4 - 4.4)*** 3.5 (2.9 - 4.2)*** 
  Address in 3 or more areas 1.9 (1.7 - 2.2)*** 2.7 (2.4 - 3.0)*** 3.4 (2.7 - 4.2)*** 5.0 (4.5 - 5.7)*** 
  Move to more disadvantaged area 1.4 (1.3 - 1.6)*** 1.7 (1.5 - 1.9)*** 1.7 (1.4 - 2.1)*** 2.1 (1.9 - 2.4)*** 
Notes: * p<0.05. *** p<0.0005.  (a) One or more hospital admissions with no mental health care.  
 
151 
The risk of frequent mental health admission, community mental health contact, change of 
local area and increase in IRSD all reduced with age, while cardiac disease, infectious 
disease and non-mental health admission increased with age. Self-harm or injury, 
infectious disease and frequent service use were more common in women, while housing 
instability was more common in men on all measures. 
While the most substantial impacts were seen in the “Cannabis and Stimulant” group there 
were four indicators for which the “Stimulant” group had significantly higher rates than the 
“Cannabis” group, using the conservative test of non-overlapping confidence intervals 
(Schenker and Gentleman, 2001). These were non-mental health admissions, self-harm 
and injury, infectious disease and any period of homelessness. Three sensitivity analyses 
were conducted. First, all regressions were repeated including only the 9,172 participants 
(67% of total) who met the more specific diagnostic test of having a schizophrenia 
diagnosis at both index admission and final contact. The strength of most associations with 
cannabis and stimulant disorders was increased non-significantly in this subgroup but all 
regression models remained unchanged. Second, there were 1,709 right-censored 
participants (12.5%). They did not differ from non-censored participants on age or sex, but 
had lower rates of illicit drug diagnoses. Exclusion of this group resulted in a non-
significant increase in the rates of service use and in the odds ratios reported in all 
regressions, but the findings of all regression models remained unchanged.  Third, 1,618 
participants (11.9%) in the current study had also been included in our previous studies of 
early psychosis during the first two years of their care. After excluding early psychosis 
participants, the remaining subjects were significantly older, more likely to be male and 
more likely to reside in metropolitan areas. However they did not differ in their rate of 
cannabis or stimulant use or the proportions using multiple substances. They had a slightly 
lower rate of ED presentations but they did not differ significantly on any other measure of 
service use, physical diagnosis or housing instability. All regression models remained 
unchanged after exclusion of this group 
DISCUSSION  
We followed people with a diagnosis of schizophrenia for five years after an index hospital 
admission. More than half had at least one comorbid substance use disorder. Because the 
group was defined by ongoing service contact it is unsurprising that many had further 
hospital admissions or emergency presentations, despite having a community mental 
health contact, on average, every ten days. We found substantial physical comorbidity and 
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housing instability; nearly one third lived in a more disadvantaged area at the end of the 
study period than at first contact; one quarter had further hospital admissions with self-
harm or injury; and nearly one in ten had indicators of infectious disease, cardiovascular 
disease or homelessness. Our measures are drawn from routine administrative data, and 
are likely to under-estimate the prevalence of many of these outcomes. However even with 
limited sensitivity, these findings underline the challenges of substance misuse, physical 
ill-health and social dislocation which face many people with schizophrenia.  
Our first aim was to estimate the rate of stimulant use disorders in people with 
schizophrenia. We estimated that 13.9% of this group (and 20.8% of those aged 18-29) 
had at least one stimulant disorder diagnosis. This is consistent with estimated rates of 
cocaine dependence in some US studies (Chouljian et al., 1995; Miller and Tanenbaum, 
1989), and with the prevalence of stimulant disorders (15.5%) in people aged 15-29 with a 
first psychosis admission in NSW (Sara et al., 2013). The 12-month prevalence of 
stimulant abuse or dependence in Australians aged 16-49 is 0.97% (Sara et al., 2011a). 
While these population and clinical studies use different methodologies and are therefore 
not directly comparable, they suggest that stimulant disorders may be at least ten times 
more prevalent in people with early psychosis or schizophrenia than in the general 
population.  
Our second aim was to describe the correlates of stimulant disorders. Like all substance 
disorders, stimulant disorders were more common in younger adults and males. By 
comparison with cannabis disorders, stimulant disorders were slightly more common in 
people in their mid and late 20s and were slightly less skewed towards males. Stimulant 
disorders were unrelated to social disadvantage (as measured by area of residence), were 
more common in urban areas and less common in people born outside Australia. These 
associations are consistent with those we have previously reported in the Australian 
population and in first admission psychosis in NSW. This suggests that the choice of illicit 
substance in people with psychosis is influenced by the same social and environmental 
factors that influence others. The much higher rate of use in psychosis may suggest that 
people with psychosis are more sensitive to these factors.  
Our third aim was to describe the impacts of stimulant disorders on people with a 
diagnosis of schizophrenia. We found that all comorbid illicit substance disorders were 
associated with greater service use, more frequent physical comorbidities and greater 
housing instability. More than 80% of people with stimulant disorders also had cannabis 
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disorder diagnoses in the study period, and the risk of all harms was highest in this group. 
It is not surprising that physical health problems and unstable residence are more frequent 
in this group, but the strength of these associations was striking. After controlling for age 
and sex differences between groups, people with both cannabis and stimulant disorders 
were nearly nine times more likely to have frequent inpatient admissions, more than four 
times as likely to have admissions with self-harm/injury or infectious disease diagnoses, 
and more than three times as likely to have at least one period of homelessness, when 
compared to people with schizophrenia who did not have an illicit drug disorder.   
An observational study of this type cannot demonstrate causation, or discriminate between 
several alternative explanations for these findings. First, it is possible that the association 
is partly an artifact of our method. We have extracted diagnoses from service data, 
therefore people with more service contacts have more opportunity to have multiple 
diagnoses recorded. More frequent service contact may have resulted in multiple 
substance diagnoses rather than vice versa. Similarly, people with comorbid physical 
health conditions may have been more likely to be admitted and therefore more likely to be 
included in our dataset.  Second it is possible that multiple comorbid substance diagnoses 
are markers of complexity and disadvantage; younger people who are marginalized or 
socially dislocated are more likely to use multiple drugs, including stimulants (Degenhardt 
et al., 2007b). It is also possible that people with more severe psychotic illness use more 
substances in response to their illness, although support for the “self-medication” 
hypothesis in psychosis is increasingly limited (Kolliakou et al., 2013; Martins and Gorelick, 
2011; Hall and Degenhardt, 2000). Third, cannabis and stimulants may have specific 
additive impacts in people with schizophrenia. Both have the potential to worsen psychotic 
symptoms and precipitate relapse, and together they may increase the likelihood of a more 
chronic course of illness. Recent speculations (Paparelli et al., 2011) suggest a role for 
endocannabinoid systems as well as dopaminergic pathways in the development of 
psychosis. Finally, it is likely that these social, personal and neurochemical factors interact 
in an iterative way; substance use may be both a contributor to and an effect of the 
psychological and social disruption associated with schizophrenia.  
Regardless of the nature of the association, these findings identify a challenge for mental 
health services. The overlap between stimulants and cannabis in people with psychosis 
should be seen as a marker of significant risk, and a need for more focused clinical effort. 
Comorbid substance use is associated with worse outcome in early psychosis (Sorbara et 
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al., 2003; Wade et al., 2006a; Wade et al., 2007), however people who discontinue 
substance abuse may have more positive outcomes than non-substance-users (Baeza et 
al., 2009; Lambert et al., 2005; Sara et al., 2014b; Strakowski et al., 2007). Evidence for 
the effect of discontinuation of substance use in established psychosis is more limited 
(Gupta et al., 2013). Attempts to engage and offer effective treatment are critical, but our 
findings also point to one difficulty in this task; more than 60% of people with both 
cannabis and stimulant disorders lived in three or more locations over a five year period. 
This degree of mobility is likely to disrupt treatment networks as well as broader family and 
social supports for abstinence and adherence to care.  
We also identified a small group of people with schizophrenia who had stimulant disorders 
but no cannabis disorders. This group had lower service use and fewer markers of 
physical or social harm than those with both cannabis and stimulant disorders. However 
when compared to people with cannabis disorders alone, they had higher rates of general 
hospital admission, self-harm or injury diagnoses, infectious disease diagnoses and 
homelessness. These findings are consistent with the physical health risks of stimulant 
use, particularly when used intravenously (Darke et al., 2008; Degenhardt et al., 2008c).  
This group was also more likely to live in urban areas. We have previously found the same 
regional association (an urban excess in stimulant disorders and a rural excess in 
cannabis disorders) in people with first admissions for psychosis (Sara and Burgess, 
2012), and a trend towards greater urban prevalence of stimulant disorders in the 
Australian population (Sara et al., 2012).  
Advantages and Limitations 
This study uses data from public hospitals and specialist mental health services for a 
population of more than 7 million people over more than a decade. This provides a large, 
naturalistic, population-based sample with sufficient power to examine stimulant disorders 
while controlling for comorbid cannabis disorders and other potential confounders. 
However the use of administrative datasets involves a tradeoff between precision and 
statistical power, and our study has a number of limitations. 
This study uses routine clinical diagnoses. Substance disorders may be particularly under-
recorded in routine clinical records. Compounding this underestimation, around 12% of 
participants had diagnoses of polydrug or unspecified substance abuse; many will have 
had cannabis and stimulant disorders. However, this study uses diagnostic information 
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extracted from inpatient records by trained coders, and adopts a low threshold for 
recording a diagnosis (at least one substance diagnosis in the follow-up period). Therefore 
underestimation in this study may be modest. We found that 51% of participants had a 
substance use disorder, including 29% with a cannabis disorder and 13.9% with a 
stimulant use disorder. By comparison, the Australian Survey of High Impact Psychosis 
(Moore et al., 2012b) found that 35% of people with schizophrenia spectrum disorders 
reported cannabis use at least monthly in the previous 12 months, and 13.8% reported  
stimulant use at least monthly.  A more significant limitation in our study may be that the 
quality of diagnostic information in this study is systematically poorer in community data, 
where diagnoses are recorded by clinicians rather than extracted by coders. Therefore 
apparent associations between substance use and hospital admission or physical health 
problems may merely reflect greater likelihood of accurate diagnosis in people admitted to 
hospital.  
People included in this study are likely to have differed systematically from people with 
schizophrenia who were not included. We have included people with schizophrenia who 
had at least one hospital admission during an 11 year study period, and who had at least 
two years of contact with public inpatient or community mental health services following 
that admission. People with schizophrenia who had no hospital admissions, or admissions 
but no ongoing follow-up, are likely to have had a more stable course of illness and lower 
rates of substance use, physical health problems and housing instability. Therefore our 
findings should not be generalised to people with schizophrenia who do not have contact 
with specialist mental health services.  
There is overlap between the dataset for the current study and that used in our previous 
studies, which examined the first two years of care in people aged 15-29 years with a first 
psychosis admission between 2005 and 2012. Some of that group had ongoing service 
contact over five years and a final diagnosis of schizophrenia. Sensitivity analysis 
demonstrated that removing those participants did not change the conclusions of this 
study. However the consistency of findings between the current study and our earlier 
studies may be partly due to overlapping participants.  
Accommodation status codes and changes in address are imprecise measures of housing 
instability. Addresses and accommodation status codes are often inaccurate in routine 
clinical records. We used statistical local area codes to estimate social disadvantage, 
however people with psychoses may be living in disadvantaged individual circumstances 
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even within more affluent areas. Due to incomplete application of a unique person 
identifier to ED data, we are likely to have under-recorded ED presentations, especially 
where people attended multiple hospitals. Together these limitations add imprecision to 
our results, and are likely to lead to underestimation of associations between substance 
use disorders and poor outcomes in persons with psychoses. 
Conclusions  
Stimulant use disorders are as common in people with persistent forms of schizophrenia 
as in first episode psychosis. Both groups have rates of stimulant use disorders more than 
ten times that of the broader population. Most people with schizophrenia and stimulant 
disorders also have cannabis disorders, and they experience very high rates of service 
use, physical comorbidity and social dislocation. Stimulant use disorders are likely to 
contribute to the burden of chronic psychosis. Better strategies are needed to identify and 
treat comorbid substance use disorders in people with schizophrenia, especially cannabis 















The research in this thesis has described the prevalence, correlates and impacts of 
stimulant use disorders in people with psychosis. These are important issues because 
psychotic disorders cause significant personal and social cost, and substance disorders 
are among the few modifiable factors affecting the outcome of psychosis. Stimulants such 
as amphetamines and cocaine have particular potential to affect psychotic symptoms, 
because of their specific dopaminergic actions.    
Most stimulant users have also used cannabis, so it is difficult to separate the associations 
of stimulants from those of cannabis.  Other personal and social factors such as age, 
gender, disadvantage, urban location and migrant status also confound the relationship 
between drug use and psychosis. Even very large clinical studies have not had usually 
had sufficient power to disentangle these effects. Exceptions have been studies conducted 
in South East Asian countries where stimulant use is common but cannabis use is rare, 
and in studies in developed countries of highly selected clinical samples receiving 
treatment for stimulant dependence in the absence of other drug comorbidity. It is difficult 
to generalise from these studies to the situations usually encountered by Australian mental 
health services where the use of multiple drugs is common.  
The studies presented in this thesis have used an epidemiological approach. They used 
data from an Australian national household survey of mental health and substance 
disorders, and routinely collected health service data on persons treated for psychoses in 
a population of more than seven million people in the state of New South Wales. Together 
these provided representative data with sufficient statistical power to examine the impacts 
of stimulants in people with different diagnostic subtypes and at different stages of 
psychosis, while controlling for cannabis disorders and other confounders. The studies 
focused on the types of acute and severe clinical problems encountered by mental health 
services. They examined psychotic syndromes rather than brief or transient psychotic 
symptoms. They focused on stimulant abuse and dependence rather than stimulant use, 
because severe harms such as psychosis are more common in persons who have a 
history of more severe and longstanding drug use disorders.  
This chapter summarises and integrates the findings of the studies presented in this 
thesis. First, it summarises the main findings of each study as they relate to the specific 
research questions outlined in Chapter 1. Second, it draws several broader conclusions 
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based on those findings. Third, it discusses the limitations of the studies, along with their 
strengths and their contribution to knowledge of this issue. Fourth, it discusses possible 
implications of these findings and how they fit with current models of psychosis and of the 
role of substance use in psychosis. Finally it considers possible implications for prevention, 
health service planning and clinical care.  
FINDINGS FOR SPECIFIC RESEARCH QUESTIONS   
Chapter 1 identified 14 specific research questions regarding the association of stimulant 
disorders with psychosis. The studies presented in chapters 2 to 9 of this thesis have been 
designed to address these questions.  Several of these studies have examined more than 
one question, and some questions draw on findings from several studies or chapters.  
Internationally, what is the prevalence of stimulant use disorder in people with 
psychosis? 
Chapter 2 presented a meta-analysis of 61 studies examining 22,500 people with 
psychosis. It calculated a pooled estimate of any stimulant use disorder of 8.9% (95% 
confidence interval 7.4% - 10.5%).This is substantially higher than the estimated rate of 
stimulant dependence in the general population. The Global Burden of Disease study 
estimated the 12-month prevalence of amphetamine or cocaine use in the general 
population to be 0.3%-1.3% (Degenhardt and Hall, 2012b), and the point prevalence of 
stimulant dependence to be 0.10%-0.25% (Degenhardt et al., 2014). These population 
estimates have used different methods and cannot be compared directly to the estimates 
obtained from clinical studies. However they suggest that people with psychosis use and 
abuse stimulants at a much higher rate than the general population.  
Are there regional or national differences in the prevalence of stimulant use 
disorders in people with psychosis? 
The meta-analysis presented in Chapter 2 identified significant regional differences in the 
prevalence of stimulant use disorders in people with psychosis. The highest rates were 
reported in studies from the USA (11.9%, 95% CI 9.1% - 15.3%) and Australia (10.8%, 
95% CI 6.8% - 16.9%). These were higher than rates in studies from the UK, Ireland, 
Europe and Scandinavia. The studies described in Chapters 6 and 9 provide additional 
estimates of the prevalence of stimulant disorders in Australians with first admission 
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psychosis or established diagnoses of schizophrenia. These are summarised further 
below. 
The type of stimulant drug used in people with psychosis (cocaine, amphetamine) also 
varied by region. Studies from the USA and Western Europe reported higher rates of 
cocaine use disorder, while studies from the UK and Australia reported only 
methamphetamine or unspecified stimulant disorders. In people with psychotic disorders, 
regional differences in the rates of stimulant disorder and type of stimulant drug used 
mirrored regional differences in the broader population.  
What person or service factors are associated with variations in prevalence? 
The meta-analysis reported in Chapter 2 also examined the predictors of stimulant use 
disorder in studies of people with psychosis. There was substantial between-study 
variation in reported rates of stimulant use disorder, however 68% of this variation could 
be explained using multiple meta-regression. Higher rates of stimulant use disorder were 
predicted by higher rates of cannabis use or disorder, diagnoses of affective psychosis, 
and studies from inpatient settings as well as by the regional differences discussed above. 
Cannabis use disorder was the strongest single predictor of stimulant use disorder, 
explaining 43% of between-study variance.  
Study methodology factors such as the period examined (lifetime or recent), the inclusion 
or exclusion of drug-induced psychosis or the type of diagnostic methods used had little 
impact on reported rates of stimulant use disorder. 
The meta-analysis in Chapter 2 found no significant increase in the rate of stimulant use 
disorder in people with psychosis between 1971 and 2009. These findings are not 
consistent with clinical concerns that stimulant abuse has increased among new 
presentations for psychosis in Australia, or with the overall increase in stimulant-related 
mental health admissions reported in Chapter 5. This null finding may reflect the very high 
heterogeneity in stimulant use disorder estimates.  Stimulant use disorders were unrelated 
to the stage of psychosis, being equally common in prodromal and early psychosis and in 
chronic schizophrenia. After controlling for other factors in multivariate analysis, there was 




What is the prevalence of stimulant use disorders in the Australian population? 
Chapter 3 used data from a national household survey, the 2007 Australian National 
Survey of Mental Health and Wellbeing (NSMHWB), to estimate the number of Australians 
with stimulant abuse or dependence diagnosed according to DSM-IV criteria.  Stimulant 
use was reported by 12.2% of the adult population, and 7.2% of persons had used 
stimulants on more than five occasions.  
For the Australian population aged 16-85, the lifetime prevalence of stimulant use disorder 
was estimated to be 3.3% (95% CI 2.8% - 3.9%). Just under half of these disorders (1.4%, 
95% CI 0.9% - 1.9%) were stimulant dependence. Serious drug-related harms such as 
psychosis are more likely to be related to recent use: the 12-month prevalence of any 
stimulant disorder was 0.6% (95% CI 0.4% - 0.8%) and the 12-month prevalence of 
stimulant dependence was 0.3% (0.1% - 0.4%). While stimulant disorders were 
uncommon, they affected a significant number of individuals; these prevalence estimates 
equate to more than 97,000 Australians having experienced features of stimulant abuse or 
dependence in the past year.  
Nearly half (46%) of people who reported having used stimulants on more than five 
occasions met criteria for a lifetime stimulant use disorder. This suggests that for stimulant 
drugs the window between use and harmful use is narrow.  
What are the characteristics of people with stimulant use disorders in Australia?  
Age and sex-specific prevalence rates for stimulant disorders were also reported in 
Chapter 3, using data from the Australian NSMHWB 2007. Stimulant use and psychosis 
were both more common in younger adults. For younger adults (aged 16-49) the 12-month 
prevalence of any stimulant disorder was 1.0% (95% CI 0.7% - 1.3%) and of stimulant 
dependence was 0.4% (95% CI 0.2% - 0.7%). 
Stimulant disorders were two to three times more common in males than females. They 
declined with age, with the highest rate among persons younger than 29 years. The 
highest prevalence rates were among males aged 16 to 29 years (lifetime 8.4%, 12-month 
2.0%). 
Chapter 4 used data from the NSMHWB 2007 to describe the more detailed correlates of 
lifetime stimulant disorders. The strongest predictor of stimulant disorders was the use or 
abuse of other substances: 86% of people with a stimulant disorder reported prior use of 
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cannabis and 73% met criteria for a lifetime cannabis disorder (OR 67, 95% CI 0.45 – 
1.00). People with stimulant disorders reported significantly earlier use of all drugs, and 
nearly 80% also had a history of lifetime alcohol or other drug use disorders. 
In multivariate analyses controlling for age, gender and other factors, cannabis disorders 
(OR 28, 95% CI 18-43) and alcohol disorders (OR 4.4, 95% CI 2.5 – 7.8) were the 
strongest predictors of stimulant disorders. Unlike cannabis disorders, stimulant disorders 
were not associated with social disadvantage, lower income, fewer years of education or 
rural location.  
People with lifetime stimulant disorders had rates of other lifetime mental health disorders 
which were 3 to 4 times greater than those of the general population: 42% had anxiety 
disorders and 29% affective disorders. One third (32%) reported suicidal ideation and 
nearly half of these (14%) reported a suicide attempt. Rates of imprisonment or 
homelessness were more than ten times those of the broader population.   
Together these findings indicate that while the population prevalence of stimulant abuse 
and dependence is low, the impact of stimulant disorders may be significant because of 
the characteristics of the persons who are affected. Stimulant disorders are rarely isolated 
conditions. They may be an important additive risk in people who also have a family 
history of mental health disorders, prior features of affective or anxiety disorders and 
earlier and more frequent use of cannabis, alcohol and other drugs.  These findings also 
underline the methodological challenge in separating the possible role of stimulants from 
those of cannabis and many other confounding factors. In addressing these challenges 
epidemiological approaches are needed to complement those of clinical studies.  
Are stimulant use disorders more common in people with other risk factors for 
psychosis? 
Chapter 1 briefly summarised arguments that vulnerability to psychosis occurs on a 
spectrum.  Up to 10-20% of the population may have a broad vulnerability to psychosis 
(van Os and Kapur, 2009), and this vulnerability is not specific to psychosis but is shared 
with other mental health conditions (Mitchell and Porteous, 2011; Jacka and Berk, 2014).  
The studies in Chapter 3 and Chapter 4 found that stimulant disorders were most common 
in people with other risk factors for psychosis. Younger males were the group most at risk 
for the onset of psychosis, and 8.4% of Australian males aged 16-29 had a lifetime 
stimulant use disorder. In addition, one in five (20%) people with a lifetime stimulant 
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disorder had a family history of psychosis or bipolar disorder, which was double the rate in 
the broader population. People with lifetime stimulant disorders were also twice as likely to 
have a family history of depression or anxiety.   
Brief or subclinical psychotic symptoms are one marker of vulnerability to psychosis. 
Thirteen percent of people with lifetime stimulant disorders reported one or more psychotic 
experiences, a rate almost five times that in the broader population.    
There is increasing evidence that cannabis use in early adolescence is a risk factor for the 
development of psychosis (Hall and Degenhardt, 2006; Murray et al., 2012). People with 
lifetime stimulant disorders have a much higher rate of adolescent cannabis use: 86% of 
people with lifetime stimulant disorders have used cannabis, and 50% of those first used 
cannabis by the age of 15.  
Is greater stimulant availability in the community associated with more frequent 
admission for psychosis? 
Variations in police arrests for drug possession can be used as an indirect measure of 
variations in drug availability in the community. Chapter 5 used police data on arrests for 
stimulant possession to assess whether variations in stimulant availability predicted 
variations in stimulant-related admissions to mental health units in NSW between 2000 
and 2009.  
Stimulant-related seizures and arrests increased steadily from 2000, peaked in 2007-2008 
and then declined. There were substantial quarterly variations against this long term trend. 
Admissions to mental health units for stimulant-related disorders appeared to mirror this 
trend, although analysis was complicated by an increase in the number of mental health 
beds between 2000 and 2006.  
After controlling for changes in mental health bed numbers, changes in stimulant 
availability predicted 34% of the variance in admissions to mental health units with a 
diagnosis of stimulant abuse or dependence, and 50% of the variance in stimulant-related 
(drug-induced) psychoses. There was no significant relationship between changes in 
stimulant availability and admissions for schizophrenia or other non-drug-induced 
psychoses.  
There are arguments about the validity of using police seizure or arrest data as a measure 
of drug availability. These are discussed further below. Within these limitations, these 
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findings suggest that stimulant use may have a significant impact on the burden of 
psychosis at a population level and on health services. They also suggest that this impact 
is particularly felt through the precipitation of brief and drug-induced psychosis rather than 
through an effect on long term psychoses such as schizophrenia.  
What is the prevalence of stimulant use disorders in people with first admission 
psychosis? 
Chapter 6 examined 9,919 New South Wales residents aged 15-29 with a first psychosis 
admission. Half of the group had a comorbid substance use disorder, most commonly a 
cannabis use disorder (30%). Sixteen percent (16%) of first psychosis admissions had a 
diagnosis of a stimulant use disorder, including stimulant abuse, stimulant dependence or 
a specific stimulant-induced psychosis. This rate was slightly higher than the rate of 
comorbid alcohol diagnoses (14%).  
The estimated prevalence of stimulant use disorders is likely to be an underestimate, for 
two reasons. First, 11% of the sample had a diagnosis of polydrug abuse or dependence, 
without further specification of the type of drug involved. In an unknown proportion of these 
cases stimulants will be one of the drugs involved. Second, the study used routine clinical 
diagnoses to identify substance comorbidity, and these are an insensitive measure. 
Therefore it is reasonable to conclude that at least one in six young people with a first 
psychosis admission in New South Wales had a stimulant use disorder.   
The meta-analysis reported in Chapter 2 included 25 studies reporting on rates of 
stimulant use disorders in people with a first episode of psychosis, calculating a pooled 
estimate of 7.8% (95% CI 5.7% - 10.6%). This is half of the rate of stimulant disorders 
identified in people with a first admission psychosis in New South Wales. This difference is 
consistent with epidemiological evidence of a high rate of stimulant use disorders in 
Australia: the pooled estimate for early psychosis included several large cohorts from 
Western Europe and Scandinavia where rates of stimulant use disorder appear to be lower 
than in the USA and Australia.   
People with a first admission psychosis in New South Wales were more than ten times as 
likely (OR 11.9, 95% CI 11.2 - 12.5) to have a stimulant use disorder than the age-
matched Australian population. Their risk of alcohol-related disorders was only slightly 
greater than the age-matched population (OR 1.5, 95% CI 1.4 - 1.6), suggesting that the 
higher rate of stimulant disorders is not due to a non-specific increase in the risk of any 
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substance disorder. However the rate of cannabis-related disorders was even more 
substantially increased (OR 16.8, 95% CI 16.0 - 17.5). This suggests that while stimulants 
are particularly associated with diagnoses of brief and drug-induced psychoses, cannabis 
may be a more significant risk factor than stimulants when considered across the spectrum 
of psychosis diagnoses.   
What are the correlates of stimulant use disorders in people with first admission 
psychosis? 
Chapter 6 also examined the correlates of stimulant and other substance use disorders. In 
multivariate analysis, comorbid diagnosis of any substance disorder was associated with 
being male (OR 2.0, 95% CI 1.8 - 2.2), being born in Australia (OR 1.9, 95% CI 1.7 - 2.2) 
and living in non-metropolitan locations (OR 1.3, 95% CI 1.1 - 1.4). However, the 
associations of stimulant disorders differed significantly from those of cannabis disorders. 
The odds of comorbid cannabis use disorders declined with age, while stimulant use 
disorders were more common through to the late 20s. The odds of cannabis use disorder 
were greatest in rural locations, while stimulant use disorders were more common in urban 
locations (OR 1.2, 95% CI 1.1 - 1.4) and in less disadvantaged areas (OR 1.2, 95% CI 1.1 
- 1.4).  Cannabis and stimulants showed a similar distribution across diagnostic subtypes 
of psychosis but stimulant use disorders were more common in those with diagnoses of 
Brief Psychosis and Drug Induced Psychosis. 
The findings of a particular association between stimulant diagnoses and brief and drug-
induced psychoses are consistent with the findings from Chapter 5 that variations in 
stimulant availability were only  associated with variations in admission for brief and drug-
induced psychoses. 
When compared to people with no comorbid substance diagnoses, cannabis use disorders 
were associated with a younger average age at first psychosis admission (22.7 years, 
compared to 23.5 years for people with no substance use disorder). By contrast, stimulant 
use disorders were associated with a significantly older average age at first psychosis 
admission (24.2 years).  Older age at psychosis onset is usually associated with a more 




Are stimulant use disorders associated with readmission in the first two years of 
psychosis? 
Chapter 7 examined 7,269 young people with a first psychosis admission and at least two 
years of follow-up with New South Wales mental health services. Readmission to hospital 
was used as an indirect measure of recurrence of psychosis, and predictors of time to 
readmission were examined using Cox proportional hazards regression. A diagnosis of 
stimulant or cannabis use disorder at first psychosis admission was not related to the risk 
of readmission over two years.  
The findings of this study suggest that the long term pattern of drug use is more important 
in influencing outcome in psychosis than the cross-sectional presence of a comorbid drug 
diagnosis. The study examined a subset of people (n=4,993) for whom it was possible to 
derive a measure of ongoing drug use after their index episode. People who had drug use 
disorders at baseline but who ceased problem drug use had the lowest readmission rate 
over two years (40%) and people whose problem drug use continued had the highest 
readmission rate (66%). The lack of any difference an association between baseline 
substance use and later readmission may therefore reflect the effects of averaging of risk 
in these two groups.  
The measure of ongoing drug use did not allow stimulants and cannabis to be examined 
separately. However the study found that a higher rate of readmission following a first 
psychosis episode occurred in people with longer or more severe stimulant use, as 
indicated by the presence of hospital admissions with a stimulant use disorder prior to the 
first psychosis admission (Hazard Ratio 1.4, 95% CI 1.1-1.7). The same was not true of 
cannabis use disorders. Previous chapters have suggested that stimulant use disorders 
are associated with brief and transient psychoses, which typically have a more positive 
outcome. The findings of this study suggest that more severe or prolonged stimulant 
misuse is a risk factor for recurrent psychosis.  
Are stimulant use disorders associated with increased risk of progression to 
schizophrenia over five years? 
Chapter 8 identified 24,306 individuals admitted to hospital with an ICD-10 psychosis 
diagnosis between 2000 and 2011. It examined the agreement between initial and final 
diagnosis over 5 years, and identified predictors of diagnostic change towards and away 
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from a final diagnosis of schizophrenia. The study examined persisting rather than 
baseline substance diagnoses.  
Ongoing comorbid substance use disorders contributed both “signal” and “noise” to the 
diagnoses of people with psychosis. Nearly half (46%) of people with initial diagnoses of 
brief, atypical or drug-induced psychosis were later diagnosed with schizophrenia. 
Comorbid substance use diagnoses were also associated with diagnostic instability, 
reduced agreement between initial and final diagnoses, and greater likelihood of an initial 
schizophrenia diagnosis being revised to other disorders.  
Stimulant use disorders differed significantly from cannabis use disorders in their 
associations with diagnostic instability and progression to schizophrenia. Stimulant use 
disorders were associated with greater diagnostic instability, less likelihood of diagnostic 
transition to schizophrenia (OR 0.81, 95% CI 0.67 – 0.97) and the highest likelihood that 
an initial schizophrenia diagnosis would be revised to other diagnoses (OR 2.21, 95% CI 
1.67-2.93). By contrast, ongoing cannabis use disorders were associated with increased 
risk of transition to schizophrenia (OR 1.12, 95% CI 1.01 – 1.24) and more modest 
likelihood of revision away from an initial schizophrenia diagnosis (OR 1.30, 95% CI 1.13-
1.49).  
These findings underline the importance of examining stimulants and cannabis separately 
because they suggest that these two drug classes have distinct and specific effects on the 
development of psychosis. If the effects of these drugs were simply additive, people who 
used both cannabis and stimulants would be expected to have the highest rates of 
diagnostic instability and transition to schizophrenia. Instead, people with both cannabis 
and stimulant use disorder diagnoses had effects that were intermediate between those 
with cannabis use disorders alone and those with stimulant use disorders alone.  
These findings also add to those of Chapters 5 and 6 in suggesting that while stimulant 
use disorders are common in psychosis they are associated with briefer psychoses and 
better outcomes. When compared to cannabis use disorders, stimulant use disorders – 
even if ongoing – may be associated with recurrent psychoses but appear to be 
associated with a lower risk of progression to a diagnosis of schizophrenia.   
What is the prevalence of stimulant use disorders in people with schizophrenia? 
Chapter 9 examined 13,624 people aged 18-50 with a diagnosis of schizophrenia who had 
ongoing contact with New South Wales mental health services.  More than half (52%) had 
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at least one primary or comorbid substance use disorder diagnosis during the five-year 
study period. The most common specific substance diagnoses were cannabis (29%), 
alcohol (26%) and stimulant use disorders (14%). A further 12% of persons had 
unspecified or mixed (e.g. polydrug) substance use disorder.  An unknown proportion of 
this group was likely to have had stimulant use disorders.  
In Chapter 6 the rate of stimulant use disorder in New South Wales residents with first 
episode psychosis was estimated to be 16%, which is higher than the estimate in New 
South Wales residents with a schizophrenia diagnosis. However, the first admission group 
included a younger age range (16-29 years), and stimulant use disorders were more 
common in younger adults. Of people with schizophrenia aged 18 to 29 years, 21% had at 
least one stimulant use disorder diagnosis. This suggests that the rate of stimulant 
disorder in people with established diagnoses of schizophrenia is at least as high as the 
rate in first episode psychosis.  
Consistent with findings in early psychosis, this rate of stimulant use disorder was higher 
than the meta-analytically derived pooled estimate for stimulant use disorders in people 
with established psychosis (Chapter 2). In that analysis the rate of stimulant use disorder 
in people with schizophrenia was 10.4% (95% CI 8.1%-13.4%).  The rate of stimulant use 
disorder appears to be higher in the USA and Australia than in some other developed 
countries, and this increase is seen across the spectrum from the broader population, 
through early psychosis to ongoing psychoses such as schizophrenia.  
What are the correlates of stimulant use disorders in people with schizophrenia? 
The correlates of stimulant use disorders in schizophrenia were examined in Chapter 9. As 
in people with earlier stages of psychosis, stimulant use disorders had very substantial 
overlap with cannabis use disorders in people with schizophrenia: 80% of people with 
stimulant use disorders also had cannabis use disorders. Both cannabis and stimulant use 
disorders were more common in males, but there was less gender imbalance for stimulant 
than for cannabis use disorders. Stimulant use disorders peaked in people aged between 
21 and 30 years, while cannabis use disorders were most common in teenagers and 
declined steadily with age. Stimulant use disorders were common in metropolitan locations 
(OR for rural locations 0.7, 95% CI 0.5 – 0.9) while cannabis use disorders were more 
common in rural locations (OR 1.5, 95% CI 1.4 – 1.7).  
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These differences in association between stimulant and cannabis use disorders in people 
with schizophrenia diagnoses were broadly consistent with the associations found in the 
Australian population (Chapters 3 and 4) and in people with a first psychosis admission 
(Chapter 6). In all groups, stimulant use disorders had a smaller gender imbalance than 
cannabis use disorders, occurred later, tended to be more common in urban rather than 
rural settings, were uncommon in migrants and were not associated with social 
disadvantage.  
In people with schizophrenia, are stimulant use disorders associated with frequent 
service use, physical health problems or housing instability? 
In people with early psychosis, stimulant use disorders were associated with more positive 
outcomes as reflected in shorter periods of specialist mental health service contact, 
diagnoses of brief, atypical or drug induced psychosis at first admission (Chapter 6 and 7) 
and a lower likelihood of making a diagnostic transition to schizophrenia (Chapter 8).  
These effects were largely in the opposite direction to those of cannabis. In people with 
both cannabis and stimulant use disorders most these associations were intermediate 
between those of cannabis use disorders alone and those of stimulant use disorders 
alone. 
Chapter 9 found a different pattern of associations in people with established diagnoses of 
schizophrenia. It found that stimulant use disorders were associated with much greater 
levels of harm and more negative outcomes. Their effects appeared additive with those of 
cannabis, so that people with both cannabis and stimulant use disorders had worse 
outcomes than those with either cannabis or stimulant diagnoses alone.  
People with schizophrenia who had both cannabis and stimulant diagnoses were nearly 
nine times more likely than peers with no substance use disorders (OR 8.9, 95% CI 7.9 – 
10.1) to have frequent mental health admissions: 59% had more than five admissions over 
a five year follow-up period. They were also much more likely to have frequent Emergency 
Department contacts (OR 5.9, 95% CI 5.2 – 6.7) and admissions for physical health 
problems (OR 4.0, 95% CI 3.5 – 4.5). Nearly half (44%) had a hospital admission for self-
harm or injury, 61% lived in more than three local areas during the follow-up period, 42% 
were living in a more disadvantaged area at the end of follow-up than at first admission 
and 18% had at least one period of homelessness.  
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The small group of people with schizophrenia who had stimulant use disorders but no 
cannabis use disorders had lower service use and fewer markers of physical or social 
harm than those with both cannabis and stimulant use disorders. However when 
compared to people with cannabis use disorders alone, they had higher rates of general 




Taken together, the findings of these studies support several broad conclusions.  
First, stimulant abuse and dependence have a significant impact on overall burden of 
psychosis and on the Australian health system. Stimulant use disorders are less common 
than cannabis or alcohol disorders in the population but they affect more than 97,000 
Australians annually, or more than 30,000 people each year in New South Wales. They 
occur most often in younger people who also have other risk factors for the development 
of psychotic disorders, including male gender, a history of early cannabis use, a family 
history of psychosis, sub-clinical psychotic experiences and prior symptoms of depression 
and anxiety. At least one in six people with psychotic disorders (16% in first admission 
psychosis, 21% in people aged under 29 with established psychosis) had a diagnosis of 
stimulant abuse or dependence, a rate at least ten times greater than other young 
Australians.  
In New South Wales mental health units, there were more than 400 admissions per year 
with diagnoses of stimulant-induced psychosis, and more than 1,100 admissions per year 
with a diagnosis of stimulant abuse or dependence. These comprised around 5% of total 
mental health admissions in the study period, and included more than 220 young people 
per year experiencing their first hospital admission. The rate of admission appeared to be 
influenced by stimulant drug supply, since hospital admissions with stimulant-related 
psychoses were significantly more common when stimulants were more available in the 
New South Wales community.  
The meta-analysis presented in Chapter 2 suggests that the rate of stimulant use disorder 
in people with psychosis is higher in the USA and Australia than in other developed 
countries. This is consistent with findings that stimulant dependence is more prevalent in 
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the general population in the USA and Australasia (Degenhardt et al., 2014). Together 
these findings suggest that the impacts of stimulant misuse on people with psychosis may 
be greater in Australia and the USA than in other comparable countries.  These impacts 
are likely to be felt by the individuals, their families and the health system.  
Second, comorbid stimulant use disorders are more strongly associated with acute 
psychoses than with progression to schizophrenia. People with comorbid stimulant use 
disorders were more likely than those without substance use disorders to have initial 
diagnoses of brief, atypical, drug induced and affective psychosis and they were less likely 
to remain in contact with specialist mental health services after their first psychosis 
admission. Of those who remained in contact with services over 2-5 years, people with 
ongoing stimulant use disorders had a 20% lower likelihood of making a transition to a 
diagnosis of schizophrenia, and more than double the chance that an initial schizophrenia 
diagnosis would be revised to other conditions when compared to people with no drug use 
disorders. By contrast, cannabis use disorders were associated with an increased risk of 
transition to a diagnosis of schizophrenia.  
Three published studies have directly assessed whether people who abuse cannabis and 
stimulants differ in their risk of acute or persistent psychosis. The findings in this thesis are 
consistent with findings that in the general population, stimulant abuse is associated with a 
greater risk of precipitating drug induced psychosis than is cannabis abuse (Degenhardt et 
al., 2007d). They are also consistent with findings that people with stimulant-induced 
psychoses have lower rates of transition to schizophrenia than people with cannabis-
induced psychoses (Niemi-Pynttari et al., 2013).   
The results reported here are less consistent with a recent large study (Callaghan et al., 
2012) which found that people admitted to Californian hospitals for methamphetamine 
abuse and dependence had the same risk of progression to schizophrenia as people with 
cannabis-related admissions. Both groups had a higher rate of progression to 
schizophrenia than people with cocaine-related admissions, other substance admissions 
or a matched control group of people hospitalised for appendicitis. The differences 
between these studies may reflect differences in the populations examined: the studies 
presented in this thesis, like the study of Niemi-Pynttari and colleagues (Niemi-Pynttari et 
al., 2013) examined the risk of progression to schizophrenia in people who have already 
had a first psychosis admission and hence were at a higher risk of progression to 
schizophrenia than people hospitalised for drug-related but non-psychotic conditions. It is 
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also possible that different personal and social factors (such as age, gender or 
disadvantage) influence whether individuals use methamphetamine rather than cocaine in 
California and New South Wales, and that these factors may be associated with different 
risks of developing schizophrenia.   
Third, while stimulant use disorders were associated with a lower risk of transition to 
schizophrenia, among people with schizophrenia, the continued use of stimulants was 
associated with very significant harms. As has been summarised above, people with 
diagnoses of schizophrenia who had ongoing stimulant use disorders had the highest 
rates of mental health admission, general hospital admission, Emergency Department 
contact, self-harm, injury, homelessness, housing instability and social decline. Most of 
these harms occurred more often among people who also had cannabis disorders. 
However, people with stimulant use disorders alone had higher rates of general hospital 
admission, self-harm, injury, infectious disease diagnoses and homelessness than those 
with cannabis use disorders alone.  
These impacts are consistent with evidence from experimental challenges that small 
amounts of stimulants can worsen acute psychotic symptoms in people with schizophrenia 
(Curran et al., 2004). These effects may become stronger with continued stimulant 
exposure due to a process of sensitisation (O'Daly et al., 2011; Wang et al., 2010; Peleg-
Raibstein et al., 2009; Featherstone et al., 2007; Ujike and Sato, 2004; Curran et al., 2004; 
Ujike, 2002; Hermens et al., 2009). However a simple dopamine sensitisation model is 
inconsistent with the finding (Chapter 8) that ongoing stimulant use is associated with a 
reduced risk of transition to schizophrenia following an index psychosis admission. Also, 
the harms seen in people with schizophrenia and stimulant use disorders are broader than 
a worsening of positive psychotic symptoms. They include social harms and instability as 
well as harms associated with dependent or intravenous drug use such as increased rates 
of physical health admissions, infectious disease and cardiovascular disease. In this 
seriously affected subgroup of people with schizophrenia, it is likely that continued 
stimulant misuse interacts with many other factors such as continuing cannabis use, 
greater vulnerability to positive psychotic symptoms and vulnerability to other cognitive, 
affective or interpersonal dimensions of psychosis.   
The studies in this thesis suggest that rates of stimulant use disorder in people with 
psychosis have not increased over time, and that stimulants are associated with reduced 
likelihood of transition to a diagnosis of schizophrenia. These findings contrast with 
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concerns expressed over the last decade by Australian clinicians that stimulant abuse has 
increased demand for acute mental health services (Australian Senate Select Committee 
on Mental Health, 2006). The very poor outcomes for people with schizophrenia who 
continue stimulant misuse are likely to have influenced this concern.  Around 11% of all 
people with schizophrenia had ongoing stimulant use disorders, but of those with frequent 
hospital admissions, one-third had a stimulant use disorder. Nearly 60% of people with 
both schizophrenia and a stimulant use disorder were frequent users of inpatient mental 
health services. Clinician concerns about the impact of stimulants at a population level 
may therefore partly reflect a “clinician’s illusion”  (Cohen and Cohen, 1984). However, the 
very serious impacts on individuals with schizophrenia who continue stimulant use are 
certainly not illusory.   
Fourth, the associations and impacts of stimulant use disorders in people with psychosis 
are distinct from those of cannabis. The very substantial overlap between cannabis and 
stimulant use disorders was one reason for using epidemiological approaches in this 
research. This overlap was present in all groups examined; the proportion of people with a 
stimulant use disorder who also had a cannabis use disorder was 73% in the Australian 
population (lifetime disorders), 56% in first admission psychosis, 58% in people with mixed 
psychotic disorders and 80% in people with a diagnosis of schizophrenia.  
Despite these overlaps, there were consistent differences in the associations of stimulant 
use disorders and cannabis use disorders. In all groups, cannabis use disorders were 
most common in people in their late teens and early twenties and were strongly associated 
with male gender and rural location. By contrast, stimulant use disorders were more 
common in people aged 25 to 30 years, had a less unequal gender balance, and were 
associated with less disadvantaged location (in first admission psychosis) and urban 
location (no rural excess in the general population or first admission psychosis, urban 
excess in established psychosis). Cannabis use disorders were associated with younger 
age at first drug use, younger age at first psychosis admission, greater likelihood of 
remaining in contact with specialist mental health services and greater likelihood of 
transition to a diagnosis of schizophrenia. Stimulant use disorders were associated with 
older age at first drug use and first psychosis admission, diagnoses of brief and drug 
induced psychosis, less ongoing service contact and reduced likelihood of diagnostic 
transition to schizophrenia. These differences remained in multivariate analyses which 
controlled for age, sex, social disadvantage and other potential confounders.  
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In the general population and in people with first admission psychosis, people with both 
cannabis and stimulant use disorders showed patterns of associations and clinical impacts 
that were intermediate between those with cannabis or stimulant disorders alone. This 
suggests that these substances had diverse impacts and actions. Only in people with 
diagnoses of schizophrenia did the impacts of cannabis and stimulant use disorders 
appear additive: those with both diagnoses experienced greater harms than those with 
either diagnosis alone.  
 
LIMITATIONS  
Each chapter has included a section addressing limitations of the specific study which it 
presents. This section briefly discusses some additional limitations of individual studies, 
and brings together some limitations shared by several of the studies presented in this 
thesis.  
Before discussing the implications of these findings, this section briefly addresses some of 
the limitations of the studies presented in this thesis. Each chapter has described its 
individual limitations, but there are number of shared limitations which affect several of 
these studies.  
All studies presented here combined disorders of individual stimulant drug use 
(methamphetamine, amphetamine, ecstasy, cocaine) into a single “stimulant use disorder” 
category. The rationale for this has been described in Chapter 1. These drugs share some 
common mechanisms but also differ from each other in some important respects. 
Therefore the associations and impacts of stimulant use disorders are likely to involve a 
mix of shared and specific effects. Combining these drugs into a single category may help 
to highlight shared effects but obscure important differences between drugs which may be 
relevant to any association between stimulants and psychosis. 
 First, there may be differences in who uses which drugs: within the population studied 
there may be differences in age, gender or socio-cultural background between users of 
methamphetamine, ecstasy and cocaine.  Second, there may be differences in how 
individual stimulant drugs are used. In Australia, amphetamine users report more frequent 
use than users of other stimulants: 24% of amphetamine users report using monthly or 
more frequently, compared with 15% of ecstasy users and 13% of cocaine users  
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(Australian Institute of Health and Welfare, 2011). Amphetamine is much more likely to be 
injected than cocaine: 25% of injecting drug users in NSW report that methamphetamine 
was the most frequent drug injected, compared to 1% for cocaine (Stafford and Burns, 
2014). Third, there may be differences in the mechanisms by which stimulant drugs affect 
neurological function. Some of the mechanisms through which stimulants are 
hypothesised to contribute to psychosis, such as neurotoxity (Barr et al., 2006; Hanson et 
al., 2004)  and dopaminergic sensitisation (Hermens et al., 2009; Curran et al., 2004), 
appear to be more marked for methamphetamine than for cocaine, perhaps due to 
methamphetamine’s effects on intracellular dopamine function as well as intrasynaptic 
dopamine levels (Seger, 2010). Fourth, there may be differences in the impacts and 
associations of individual stimulant drugs within the population being studied. For example, 
Australian methamphetamine users report higher rates of self-reported mental health 
disorder (25%) and high or very high psychological distress (21%) when compared to 
users of ecstasy (mental disorder 16%, psychological distress 15%) or cocaine (mental 
disorder 17%, psychological distress 18%)   (Australian Institute of Health and Welfare, 
2011). 
In summary, it follows that in combining different stimulant drugs into a single category, 
there is a risk of reducing sensitivity and producing Type II error when examining for 
associations and impacts.  However, it is difficult to find a sample with sufficient diagnostic 
precision to examine individual drugs meaningfully as well as sufficient scale and power to 
examine associations and impacts while controlling for other confounders and cannabis 
use. As discussed in Chapter 1, the main reason for using a single stimulant disorder 
category has been that the data sources used in this research cannot reliably distinguish 
individual stimulant drug disorders.  
The studies use data from a cross-sectional household survey and from longitudinal health 
databases. Observational epidemiology is a powerful tool for identifying disease risk 
factors and generating hypotheses, but it is less effective in testing causal hypotheses 
(McGrath, 2007; McGrath, 2008). The results of several studies are consistent with 
stimulants playing a causal role in precipitating or worsening some episodes of psychosis 
but they fall short of demonstrating a causal link. The studies have attempted to measure 
and control for relevant confounders but it is possible that other unmeasured factors may 
explain the associations reported.   
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Chapters 3 and 4 used data from a national household survey, the Australian National 
Survey of Mental Health and Wellbeing (NSMHWB). Household surveys are likely to 
underestimate the prevalence of illicit drug use (McKetin et al., 2005). They sample 
conventional households, and so they may not include groups with high rates of drug use 
such as people in transient or temporary accommodation or people who are homeless. 
They are unlikely to detect small geographical “hotspots” of drug use. They require people 
to disclose drug use to an interviewer not known to them, and so may be sensitive to the 
effects of stigma.  These effects may differ for different subgroups and for different types of 
illicit drugs.  
The NSMHWB was designed to study high prevalence mental health and substance use 
disorders (Slade et al., 2009). There is uncertainty in the survey’s estimates of stimulant 
use disorder prevalence, especially when examining 12-month rates or subgroups by age 
or sex. The response rate for the 2007 survey was 60% (Slade et al., 2009) creating the 
potential for selection or sampling bias. 
Because drug markets are illegal and unregulated, there is no simple and reliable measure 
of drug supply within a population. Three indirect measures of drug supply have typically 
been used: drug price (Cunningham et al., 2013a; Hyatt and Rhodes, 1995; Cook et al., 
2002; Caulkins, 2007; Johnson and Golub, 2007), drug purity (Cunningham et al., 2009; 
Hyatt and Rhodes, 1995; Caulkins, 2007) and  drug-related arrests or seizures 
(Cunningham and Liu, 2005; Rosenfeld and Decker, 1999) . Chapter 5 used data on police 
arrests for drug possession as an indirect measure of variations in drug availability in the 
community. Some have argued that arrest data of this type is not a valid measure of drug 
supply because changes in political focus or policing activity may also lead to an increase 
in arrests independent of changes in drug availability (Caulkins, 2007; Rosenfeld and 
Decker, 1999).  However, there are also limitations to other potential indicators. In 
particular price data may be a less sensitive measure of availability, because in variations 
in supply drug suppliers will typically modify drug purity (e.g. “cutting” drugs with other 
substances) in order to maintain standardised sale amounts and prices (Caulkins, 2007). 
Drug purity data was not available for the current research. Rosenfeld (Rosenfeld and 
Decker, 1999) argued that, despite real limitations, police arrests data were a valid 
indicator of drug supply. The concurrent and construct validity of the measure has also 
been demonstrated in a series of studies examining the effectiveness of drug precursor 
controls in the USA, Canada and Mexico. Cunningham and colleagues have used arrests 
data from the US Drug Enforcement Agency’s “System to Retrieve Information from Drug 
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Evidence” (STRIDE) and other state data systems (Cunningham and Liu, 2005; 
Cunningham et al., 2012; Cunningham et al., 2013b; Cunningham et al., 2013a) and found 
that precursor controls were followed by specific reductions in arrests. These were 
consistent with changes in other indicators including reductions in purity (Cunningham et 
al., 2013a; Cunningham et al., 2009) reductions in admissions for drug-related problems 
(Cunningham et al., 2010; Cunningham and Liu, 2008 ; Cunningham and Liu, 2003) and  
increases in drug price Cunningham, 2013 #2157}.   
There are several other possible limitations of the use of arrest data. In NSW in the period 
studied there was a degree of public concern about amphetamine use, including concern 
that reductions in heroin availability in Australia in the early 2000s may have resulted in 
substitution of amphetamine use for heroin use (Snowball et al., 2008).  Amphetamines 
were a focus of police activity during this period (NSW Police Force, 2007). Therefore it is 
possible that some of the increase in arrests during this period reflected an increase in 
police focus or activity as well as, and related to, an increase in amphetamine availability. 
A program of accelerated commissioning of mental health beds was undertaken in NSW 
from 2002-03, although this occurred in response to broader concerns about bed access 
and occupancy and was not linked to specific concerns about or resources for any 
individual drug1 . However, chapter 5 did not examine for change in arrests or drug 
availability after a certain time point, as is typically done in studies examining the 
effectiveness of precursor controls. It examined quarterly fluctuations in arrests and 
hospital admissions, finding a significant correlation between these over a decade. The 
political or police focus on amphetamines is unlikely to have fluctuated on a quarterly basis 
over this extended period.  
An additional limitation to consider regarding the use of arrests data in Chapter 5 is that 
police arrests and hospital admissions are not entirely independent, because some 
individuals may be present in both datasets. Some people arrested for substance-related 
offences will be found to have features of psychosis and be referred by police for hospital 
admission. This may be one factor explaining a relationship between arrests and hospital 
admissions. However this is unlikely to account for the findings of Chapter 5: it is likely that 
only a small minority of police arrests for possession would be found to be unwell in this 





way, and only a minority of NSW hospital admissions for psychosis occur on referral from 
Police (unpublished NSW Health data). In addition, NSW Police encountering a person 
who is so unwell as to require immediate referral to hospital would usually divert that 
person out of the criminal justice system using the provisions of the NSW Mental Health 
Act, and many such individuals would not be charged or appear in crime statistics.   
 A final limitation to consider regarding Chapter 5 is that it used an Ordinary Least Squares 
Regression approach to examine time-based data. This approach was used because the 
study examined quarterly fluctuations over an extended period rather than seeking to 
examine for a sustained change following a specific time-based event such as a change in 
regulations. This approach was undertaken after testing indicated that there was no 
systematic seasonal variation in the data being examined. However, the use of time-series 
approaches may have been more robust and should be considered in extending this study 
to examine more recent time period.  
Chapters 5 to 9 used clinical data collected by New South Wales health services, including 
data from hospital admissions, community mental health service contacts and Emergency 
Department (ED) visits.  Using routine health service data is one strategy for obtaining a 
large, representative population sample. Registers or datasets based on routine health 
service data may be particularly valuable for studying psychotic disorders, because people 
with these disorders have very high rates of service contact (Morgan and Jablensky, 2010; 
Byrne et al., 2005). However using these datasets involves a trade-off between statistical 
power and precision. There are at least four key areas of limitation that affect these data, 
namely, the accuracy of psychosis diagnoses, the accuracy of substance use diagnoses, 
the bluntness of available measures and the completeness of data gathered from “public” 
(state-operated) mental health services.  
First, Chapters 5 to 9 used clinical diagnoses to define study inclusion, identify subgroups 
of psychosis, and examine diagnostic progression and change. These purposes all require 
reliable diagnostic data. An individual may have many diagnoses made by different 
clinicians at different times, without use of structured interviews or standardised diagnostic 
instruments. These diagnoses are accordingly less reliable than research diagnoses. To 
maximise diagnostic accuracy, most of the studies in this thesis have prioritised diagnostic 
data from inpatient settings. In New South Wales health services, inpatient diagnostic data 
is extracted and coded by professional medical records coders using all available 
information in the clinical record, and the rate of incomplete diagnosis is low when 
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compared to community mental health data. The studies have also used diagnostic 
algorithms which were tested against a reference dataset of people with psychosis who 
had been diagnosed using a research diagnostic interview: this testing process is 
described in Appendix A (Sara et al., 2014d). This testing found acceptable agreement 
between algorithm-based and research diagnoses.  
Second, the studies in Chapters 5 to 9 used clinical diagnoses of substance use disorders 
as indirect measures of problem drug use. Substance comorbidities are often under-
recorded in routine clinical practice because of lack of disclosure of substance use, lack of 
questioning about substance use or failure to record a substance diagnosis even when 
substance use is recognised by the clinician. Therefore diagnoses of substance use 
disorders are likely to be a specific but insensitive measure of problem substance use 
(Large et al., 2012). Compounding this problem, around 10% of people in the first 
admission psychosis and schizophrenia clinical samples had diagnoses of polydrug or 
unspecified substance disorder. It was not possible in these cases to identify the specific 
substances used.  It is reassuring that the prevalence estimates for cannabis and stimulant 
use disorders in these studies were comparable with estimates from studies which had 
used clinical or research methods to identify substance use disorders. The use of 
diagnoses extracted by clinical coders may have reduced some of the under-enumeration 
of substance comorbidity. In addition, in the five years preceding these studies, New South 
Wales mental health services also maintained an active process of clinical benchmarking. 
This provided service managers with regular feedback on the quantity and quality of 
diagnostic data entered by their services, and aimed to encourage improved data 
collection.   
Third, the use of routine data collections has also required the use of “blunt” and indirect 
measures. Direct measures of the severity of psychotic symptoms, level of function or 
degree of recovery were not available for this research. Substance use diagnoses have 
been used as measures of both initial (Chapter 6) and continuing drug use (Chapters 7, 8 
and 9); these do not measure the duration or severity of substance use disorders. Hospital 
readmission was used to measure relapse following a first psychosis episode (Chapter 7), 
and hospital readmission, service contacts and changes in address were used as 
measures of clinical and social outcomes in people with schizophrenia (Chapter 9). 
Hospital readmission is a widely used indicator of relapse in psychosis (Gleeson et al., 
2010), however lack of readmission does not equate with symptomatic or functional 
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recovery, and many significant relapses in persons with psychoses may be managed 
without hospital readmission.   
Fourth, these studies only included people with psychosis who had contact with NSW 
state-operated (“public”) mental health services. People with psychosis who were only in 
contact with “private” health services (primary care, specialist outpatient psychiatry, private 
hospitals) or who were not in contact with any health service were not included. However, 
in the Australian health system, the care of people with psychoses is primarily the 
responsibility of state-operated mental health services. In New South Wales, private 
hospitals do not provide involuntary psychiatric care, and less than 5% of admissions of 
young people with psychosis occur in private hospitals (see Chapter 6). Most Australians 
with schizophrenia and other enduring psychoses have contact with public specialist 
mental health services (Morgan et al., 2011). People with psychosis who only had contact 
with community services and no hospital admissions over the periods studied (varying 
from 5 to 11 years) would not have been included in the studies in Chapters 6 through 9. 
Their diagnoses, substance comorbidities and outcomes are likely to have differed 
systematically from people who had at least one admission in the period. They are likely to 
have had less severe psychotic disorders and a lower rate of comorbid drug use disorders.   
In examining diagnostic change or the course of illness over time (Chapters 7, 8 and 9), 
information was only available on people who had continued contact with specialist mental 
health services. Following a first psychosis admission, 31% of people had no further 
contact with New South Wales inpatient or community mental health services during the 
follow-up period (Chapter 7). In people with persisting psychosis 40% had service contact 
for less than two years after an index admission, and so were excluded from analysis of 
diagnostic stability and outcomes (Chapter 8). Having brief contact with services was 
associated with being younger and having diagnoses of brief, atypical or drug-induced 
psychosis. It was not consistently associated with substance comorbidity. For some 
people, loss of contact with specialised services may be a sign of symptom resolution and 
recovery (Warner, 2009; Emsley et al., 2011). By focusing on people remaining in contact 
with services, the results of these studies may therefore be biased towards people with 
more severe illnesses and more negative outcomes. However, some people losing contact 
with specialised services have equivalent rates of positive symptoms and substance use to 
those remaining in care (Stowkowy et al., 2012). The focus of the current research has 
been on people accessing public mental health services. The findings of these studies 
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may therefore not generalise to the smaller group of people with psychoses who are in 
contact only with private services or who have no service contact.   
 
STRENGTHS  
These limitations are partly balanced by some strengths of the current research. Evidence 
about the impacts of stimulants on psychotic disorders has been limited because of the 
methodological challenge of separating stimulants from other confounders, and particularly 
from cannabis disorders. The use of an epidemiological approach has allowed the 
development of large, representative, multi-diagnostic datasets which have had the 
statistical power to separate any effects of stimulant and cannabis abuse. These studies 
showed that stimulant and cannabis abuse appeared to have distinct and at times 
opposing effects on the course and outcome of psychosis. They join only a handful of 
other studies that have examined this question (Degenhardt et al., 2007d; Callaghan et al., 
2012; Niemi-Pynttari et al., 2013). All of these studies have used epidemiological 
approaches, demonstrating the potential for such approaches to complement clinical 
studies. Indeed, they may be one of the few ways of untangling a highly confounded issue 
such as stimulant comorbidity.  
A second strength was that the current research combined data from a national household 
survey of the Australian population with data collected over a comparable period in a large 
state health system serving around one third of the Australian population. Together these 
datasets allow comparison of the rate and correlates of stimulant use disorders on a 
spectrum from the general population, through early psychosis, to established psychoses 
such as schizophrenia. Few studies of psychosis have taken such an approach. This 
approach has shown that many of the correlates of stimulant use disorders in people with 
psychosis are shared by people with stimulant use disorders in the broader population. 
The consistency of associations within these different data sources allows greater 
confidence in the reliability of these findings. New South Wales has similar population 
characteristics, patterns of drug use and health system organisation to other Australian 
states and territories, meaning that findings from this research can be generalised within 
Australia. This strength is of course also a limitation, in that some findings from this 
research may not apply to other countries if their population characteristics, patterns of 
drug use, health systems or pathways to care differ substantially from those in Australia.  
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The component studies have individual strengths, and contribute to the limited evidence 
base on this issue in several additional ways. Chapter 2 provides the first meta-analysis of 
the rates of stimulant use disorder in people with psychosis. Chapter 3 provides the first 
study since the Epidemiological Catchment Area (ECA) Survey (Regier et al., 1990) to 
report rates of stimulant abuse or dependence diagnosed according to standardised 
criteria in a representative population sample. In Chapters 6 and 7, data are presented on 
9,919 people with a first admission for psychosis: this one of the largest cohorts of first 
episode psychosis described and one of the few to specifically examine stimulant use 
disorders. Chapters 8 and 9 examine diagnostic stability, course and outcome in 
established psychosis. They add to the few studies of this issue by examining a broad, 
multi-diagnostic clinical sample of the type usually encountered in “real world” mental 
health service delivery.  
IMPLICATIONS  
The final section of this discussion first considers the implications of these findings in the 
context of current models of psychotic disorder and current views of substance comorbidity 
in psychosis. It then considers possible implications of these studies for prevention, for 
health service planning and for individual clinical care.   
Models of psychosis 
Chapter 1 briefly summarised evidence that psychotic disorders are heterogeneous 
conditions which involve a broad spectrum of vulnerability within the population.  For a 
minority of vulnerable individuals, genetic, developmental, personal and environmental 
factors may interact in complex ways to cause progression from psychotic symptoms to 
enduring psychotic syndromes such as schizophrenia.  Dimensional and developmental 
models of psychosis provide the theoretical background to this thesis, and offer a way of 
interpreting the findings of the studies presented here.  
Dopamine abnormalities have been seen as central to the pathophysiology of 
schizophrenia (Laruelle and Abi-Dargham, 1999; Keshavan et al., 2011; Seeman, 2011). 
Because stimulants are potent dopamine agonists whose effects increase with repeated 
use through a process of sensitisation, stimulant-induced psychoses have often been used 
as model psychoses in studying schizophrenia (Hermens et al., 2009; Machiyama, 1992; 
Sato et al., 1992; Snyder, 1973). A dopamine sensitisation model of stimulant psychosis 
would predict that repeated stimulant use should increase the risk of developing 
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schizophrenia. Instead, the studies in this thesis have found that while stimulant use was 
associated with acute psychosis, ongoing stimulant use was associated with a reduced 
risk of receiving a later diagnosis of schizophrenia, when compared to people with no 
continuing drug use or with cannabis use disorders.   
There are a number of possible explanations for these findings. They may reflect limits in 
our diagnostic measures for substance use or psychosis, therefore reflecting the “noise” of 
substance-related diagnostic uncertainty rather than the “signal” of true reduction in risk. 
However, the findings are consistent with other research (Niemi-Pynttari et al., 2013) 
which has found that stimulant-induced psychoses are associated with a lower risk of 
progression to schizophrenia than cannabis-induced psychoses.  Alternatively, the findings 
may be due to confounding, since stimulant use disorders were associated with other 
positive prognostic factors, including older age at first psychosis admission, more acute 
onset of psychosis and a lesser gender imbalance. In first admission psychosis, stimulant 
disorders were associated with higher socio-economic status and urban location, which 
may predict better access to services and supports. However differences between 
cannabis and stimulants remained after controlling for these confounding factors in 
multivariate analyses.  
Dimensional models of psychosis offer another explanation for these findings. These 
models emphasise that positive psychotic symptoms such as hallucinations and delusions 
are only one dimension of psychosis, and that the full syndrome of schizophrenia typically 
involves abnormal function in other dimensions such as cognition, affect or interpersonal 
function (van Os and Kapur, 2009; Heckers et al., 2013; Barch et al., 2013). Abnormalities 
in dopamine function appear to be particularly associated with positive psychotic 
symptoms (Insel, 2010; Paparelli et al., 2011). Other dimensions of psychosis may instead 
be associated with abnormalities in other neurotransmitter systems and pathways; for 
example glutamate abnormalities have been implicated in negative symptoms (Paparelli et 
al., 2011)  and GABA abnormalities may play a role in motivational and affective 
processes (D'Souza et al., 2009; Thoma and Daum, 2013; Wong, 2013). Therefore 
stimulants may act on dopamine pathways to precipitate acute psychotic symptoms, but 
their effects may be insufficient to produce a syndrome of schizophrenia unless they occur 
in people with broader vulnerabilities and/or other stressors (such as continued cannabis 
use) which also act on cognition, motivation or other clinical dimensions. Consistent with 
this, a recent study found that people with acute amphetamine-related psychoses had the 
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same levels of hallucinations and delusions as people with schizophrenia, but much lower 
levels of negative, cognitive and affective symptoms (Panenka et al., 2013).    
Dimensional and staged models of psychosis may also explain why cannabis is associated 
with a greater risk of developing schizophrenia when it is less directly associated with 
increased positive psychotic symptoms. Amphetamines and cocaine are more potent 
dopamine agonists than cannabis (Paparelli et al., 2011; McKetin et al., 2013), and 
therefore it is possible that stimulants precipitate positive psychotic symptoms in people 
with lower personal vulnerability to psychosis. There is growing evidence that people with 
substance-related psychosis who cease substance use may have better outcomes than 
people with psychosis who have never used substances (Mullin et al., 2012; Lambert et 
al., 2005). These “former substance users” have fewer neurological soft signs and fewer 
negative symptoms than those without substance abuse (Yucel et al., 2012; Loberg and 
Hugdahl, 2009), probably reflecting lower developmental vulnerability to psychosis. 
However these studies have not examined whether former cannabis users and former 
stimulant users differ systematically in other ways that may affect vulnerability to 
psychoses.  
A further explanatory factor may be that people use cannabis at a younger age than they 
use stimulants. This means that people are exposed to cannabis at a time of greater 
developmental vulnerability. In addition, most people with stimulant disorders have had 
prior cannabis use or disorder. Therefore, most people with a first episode stimulant-
induced psychosis have already cleared a lower “first hurdle” of cannabis exposure without 
having had a psychotic episode. Therefore people with a first episode of stimulant-induced 
psychosis are most probably drawn from a lower risk sub-population from which 
individuals with the greatest vulnerability to schizophrenia have been selected out at an 
earlier age due to cannabis exposure.  
There are several ways in which these hypotheses could be tested in future research. To 
assess whether stimulants are more “psychotogenic” than cannabis, it would be possible 
to compare the nature and severity of transient psychotic symptoms in recreational users 
of cannabis, stimulants or other drugs. One recent study has found that the odds of 
psychotic symptoms were increased more than ten-fold during periods of regular 
amphetamine use, compared to a doubling of psychotic symptoms during periods of 
cannabis use (McKetin et al., 2013). To assess whether different drugs precipitate 
psychosis in people with different levels of vulnerability it would be possible to compare 
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people with cannabis or stimulant related psychoses for differences in neurological soft 
signs, neurocognitive function, prior academic achievement or family history of psychosis. 
Population-level case registers could be used to examine outcomes for the small group of 
people with psychoses precipitated by hallucinogens such as LSD, by assessing whether 
they also have positive outcomes and a lower rate of transition to schizophrenia than 
persons with cannabis use disorders.  
Substance comorbidity in psychosis 
Debate continues about the nature of the relationship between substance use and 
psychosis. Does the association reflect causation (drugs causing psychosis), self-
medication (psychosis leading to drug use) or confounding (shared vulnerabilities 
underlying both drug use and psychosis)? All three factors are likely to contribute, however 
there is growing consensus that causal explanations account for at least part of the 
relationship. 
There are several strands of evidence that substance misuse plays a causal role in 
psychosis. Cannabis, stimulants and other drugs have been shown to produce psychotic 
symptoms in experimental challenges in healthy volunteers and people with psychoses 
(Murray et al., 2012; D'Souza et al., 2004; Angrist et al., 1974), and psychosis-like 
behaviours in animal models (Gururajan et al., 2012). Meta-analytic evidence suggests 
that drug use is associated with earlier onset of psychosis (Large et al., 2011). 
Observational studies find a dose-relationship between greater drug use and more severe 
psychotic symptoms (McKetin et al., 2006b; Wade et al., 2007; Foti et al., 2010; McKetin et 
al., 2013). Longitudinal studies show that drug use typically precedes psychosis (Hall and 
Degenhardt, 2000; van Dijk et al., 2012) and that continued drug use affects course and 
outcome (Wade et al., 2007).  
There are also plausible theoretical mechanisms linking drug use and psychotic 
symptoms. Cannabis, stimulants and other substances are likely to contribute to the 
development of psychosis through complex and interacting neurochemical, genetic, 
epigenetic and structural mechanisms (Remington et al., 2014; Wobrock et al., 2013; 
Thoma and Daum, 2013; Maziade and Paccalet, 2013; Di Forti et al., 2013; Yucel et al., 
2012; Palaniyappan et al., 2012; Murray et al., 2012).  
The research in this thesis has not aimed to explore or test these mechanisms. However 
the findings of this research highlight ways in which social and environmental factors may 
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contribute to the relationship between substance use and psychosis. While people with 
psychosis misused stimulants at a higher rate than the general population, the rate and 
type of stimulant drug misused in people with psychosis mirrored regional variations in the 
broader population. Stimulant use disorders in Australia were associated with age, gender, 
rural location, migrant status and disadvantage in a way that was broadly consistent in the 
general population, in early psychosis and in established psychosis. Factors such as the 
type and quantity of drugs available, social attitudes to drug use, exposure to drug use in 
peers, mental health literacy, social and educational opportunities, stressors, support and 
resilience are all likely to influence whether a young person initiates or continues to use 
stimulants  or other substances. The shared associations of stimulant use disorders in 
people with psychosis and the broader population suggest that young people with 
psychosis who misuse stimulants may do so for the same reasons as other young people. 
The much higher rate of stimulant use disorders in young people with psychosis may 
suggest that they are more sensitive to these social and environmental factors.  
One implication of these findings for future research is that studies comparing stimulants 
and other substances in psychosis should, where possible, measure and control for 
potential social confounders such as age, rural/urban location, migration status and social 
disadvantage. It may be possible to test whether people with a vulnerability to psychosis 
are more sensitive to social and environmental pressures towards drug use. Two 
interesting research strategies for studying cannabis comorbidity have been the use of 
structural equation modelling in longitudinal clinical data (Foti et al., 2010)  and asking 
young people with psychosis about their reasons for drug use (Kolliakou et al., 2013; 
Kolliakou et al., 2011; Henquet et al., 2010). Both strategies could be applied specifically 
to examine the subjective experience and time-course of stimulant use in young people 
who are at risk of psychosis, such as people accessing primary care youth services.   
Prevention  
Effective prevention strategies for psychosis could have significant impacts on suffering, 
disability and cost (World Health Organisation, 2004).  It may be feasible to reduce the 
incidence of psychosis by targeting well understood and potentially preventable risk 
factors. Substance abuse is prominent amongst these, along with factors such as perinatal 
complications, head injury and trauma.   
Like many other countries, Australia has used criminal sanctions and seizures to limit drug 
supply and prevent drug-related harms. There is currently robust debate about the 
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effectiveness of this strategy (Magura and Magura, 2007; Hall and Lynskey, 2009; Roehr, 
2011; Strang et al., 2012). Two findings of the current research are relevant to this issue. 
First, stimulant disorders were common in people with psychosis and had a significant 
impact on the overall burden of psychosis in the population through their association with 
acute psychosis and their impact in people with chronic psychosis. Second, during periods 
of increased availability of stimulants in the community, there were increases in 
admissions for stimulant-related psychoses. These findings suggest that strategies which 
reduced stimulant availability could reduce the prevalence of stimulant-related psychoses 
and the impact on individuals and health services. Conversely, strategies which increased 
stimulant availability would be likely to increase the prevalence of stimulant-related 
psychoses.  
However, these findings do not provide a sufficient argument against decriminalisation of 
amphetamine or other substances. They do not demonstrate that criminal sanctions 
reduce drug availability, or that decriminalisation would lead to increased availability. One 
argument against current legal approaches is that they have failed to reduce drug supply: 
cannabis, stimulants and other substances are widely available despite their illegal status.  
Stimulant supply may be targeted by border controls, seizures and control of precursor 
chemicals required for domestically manufactured drugs such as methamphetamines. 
Evidence regarding the effectiveness of these strategies is mixed: some studies have 
shown that amphetamine precursor controls lead to a reduction in measures of 
amphetamine supply or use, however this may be offset by importation or the use of 
alternative manufacturing methods which may limit the effectiveness of these strategies in 
preventing drug-related harms (Callaghan et al., 2009; Nonnemaker et al., 2011; McKetin 
et al., 2011; Colfax et al., 2010). Measures restricting access to over the counter 
compound preparations may have a paradoxical effect of increasing amphetamine purity, 
because they target precursors used by smaller scale and lower quality producers (Colfax 
et al., 2010; Cunningham et al., 2009). A recent analysis of Australian national crime and 
health service data found that even large drug seizures had no measurable effect on 
stimulant or other drug-related presentations in Australia (Wan et al., 2014).   
The types of prevention strategies used for other chronic health conditions provide an 
alternative to legal approaches. Dimensional and clinical staging models of psychosis are 
particularly compatible with broader mental health prevention frameworks (Mrazek and 
Hagerty, 1994). Universal mental health prevention measures may focus on many issues 
including mental health literacy and “first aid”, stigma, resilience, health behaviours such 
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as substance use and the treatment of common mental symptoms. All may be relevant in 
preventing substance-related psychoses.  
The research in this thesis suggests several groups in the Australian population who may 
benefit from targeted prevention activities. First, rural youth, who have very high rates of 
cannabis use and dependence and in whom stimulant use may therefore be a significant 
additive risk factor for psychoses. Second, older, urban and less socially disadvantaged 
stimulant users, such as those accessing stimulants through music festivals and social 
events. This group may benefit from more specific messages about the risks of psychosis 
with stimulant use, the possible prognostic significance of brief and transient psychotic 
symptoms and the potential for stimulant-related harms to sensitise and increase with 
repeated use. Third, people with a history of psychosis or other serious mental health 
problem in a close relative such as a parent, grandparent or sibling. The evidence for 
genetic vulnerability in psychosis is very clear, and family history is one of the strongest 
predictors of individual risk (Tsuang et al., 2010). However, mental health prevention 
strategies rarely include messages about family history and the way in which this may 
interact with environmental stressors such as drugs. The inclusion of family history in 
preventative health messages has become more frequent in some areas of physical 
health, such as prevention strategies aimed at breast cancer or melanoma. However, 
there are also clear reasons for caution. A family history of mental illness substantially 
increases the relative risk of psychosis, but psychoses are still uncommon disorders and 
the absolute risk of developing psychosis remains low even in people with an affected first-
degree relative. We need to avoid creating unnecessary anxiety or avoidance of help-
seeking in either the person targeted or their affected relatives. However once a person 
has presented for the first time with a psychotic disorder, it should be a high priority to 
ensure that they understand their own genetic and developmental risk factors for 
recurrence or progression to a more severe disorder.  
Further research is needed to develop, implement and evaluate targeted prevention 
strategies for cannabis and stimulant-related psychoses. Such research could include the 
development and assessment of strategies specifically targeting rural youth. It could also 
include further research on community knowledge about the importance of family risk 
factors in developing mental health conditions, and the effectiveness and acceptability of 
prevention messages which target this issue.  
Health services planning 
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The findings from the current research have implications for health service planning in 
New South Wales and other Australian states and territories. They underline the 
importance of broadly focused and accessible mental health services for young people 
and adults, including those with stimulant-associated psychoses. This research found that 
many people with stimulant use disorders in the broader population had brief and transient 
psychotic symptoms, and often also had mood and anxiety disorders. At first contact with 
mental health services many had diagnoses of brief, atypical and drug-induced psychosis. 
These initial diagnoses were poor predictors of final diagnosis, and more than half went on 
to have a diagnosis of schizophrenia. Many had positive outcomes, but a subgroup 
experienced very significant problems, including physical health problems and social 
dislocation.  
A service system responsive to these needs should have several attributes. It would have 
low barriers to entry, assessing people as early as possible. It would be multi-diagnostic, 
accepting people with a spectrum of symptoms, as well as established psychotic 
disorders. It would see the diagnosis and treatment of comorbid substance use disorders 
as part of its core business, and not a reason to exclude people from care. It would also be 
able to offer continuity of care as people’s needs, clinical situation or living conditions 
change. These are not novel messages in Australian healthcare: many state and territory 
specialist mental health services have implemented reforms of this type (New South Wales 
Health Department, 2001; Petrakis et al., 2012; Preston et al., 2003), and model youth and 
early intervention services developed in the state of Victoria, Australia, have played an 
important leadership role (McGorry et al., 2009; McGorry et al., 2008; Yung and McGorry, 
2007; Alvarez-Jimenez et al., 2011; Henry et al., 2010). More recently Australia has made 
a significant national investment in a youth-focused mental health service model 
(‘headspace’) providing easier entry to primary care mental health services (McGorry et 
al., 2007; Rickwood et al., 2014) . Debate continues about the cost-effectiveness of these 
service models and the opportunity costs of these investments (Nielssen et al., 2012; 
McGorry, 2012; Yung, 2012; Castle, 2012). The studies in this thesis do not address 
whether one service model is more effective than another, but underline some of the 
properties that any effective service model should have.  
Services can only be effective if they deliver effective interventions. However, there is 
limited evidence for effective interventions in stimulant use disorders. A systematic review 
of psychosocial interventions in stimulant dependence (Knapp et al., 2007) found that 
overall response to treatment was modest and that no single psychosocial treatment was 
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more effective than any other. CBT, relapse prevention approaches and contingency 
management have all been found to have some effectiveness, especially when delivered 
more intensively (Colfax et al., 2010).  The Methamphetamine Treatment Project (MTP) 
tested an integrated “Matrix model” of treatment, which combined CBT with 12-step 
program approaches, family therapy and psychoeducation in an intensive program 
requiring between 1 and 13 hours per week of attendance (Rawson et al., 2004): the 
program reported modest positive outcomes, with better retention in care and fewer 
positive urine drug screens in the active treatment group.   A recent review suggests that 
contingency management may be more effective than CBT in cocaine dependence 
(Farronato et al., 2013).   
Medication strategies have been described as a “frustrating therapeutic landscape” 
(Panenka et al., 2013) (p174). It has been proposed that prescribed stimulants, including 
dexamphetamine, methylphenidate or modafanil, could be used as a replacement 
treatment in amphetamine or cocaine dependence (Elkashef et al., 2008; Castells et al., 
2010; Mariani and Levin, 2012).  However a recent Cochrane review of 11 trials found no 
benefit of stimulant replacement therapy in amphetamine dependence (PerezMana et al., 
2012). In addition, prescribed stimulants are typically contraindicated in people with 
psychosis due to the risk that they may worsen psychotic symptoms. Many other 
medications have also been trialled, including naltrexone, buproprion, antipsychotics and 
antidepressants. Some evidence supports the use of mirtazapine (an antidepressant which 
blocks both serotonin and noradrenaline reuptake) (Panenka et al., 2013), however most 
reviewers have concluded that “clinical trials have yielded no broadly effective 
pharmacotherapy” (Brensilver et al., 2013)(p.449).  
For people who have stimulant use disorders and psychosis, intervention is even more 
complex and the evidence even more limited. A recent Cochrane review (Hunt et al., 2013) 
of psychosocial treatments in people with a dual diagnosis of psychosis and substance 
use disorder examined broad outcomes including retention in care and reductions in 
substance use. The interventions studied included long term integrated care, contingency 
management, motivational interviewing, cognitive behavioural therapy and skills training. 
The review found few differences between any specific intervention and treatment as 
usual, and no evidence favouring any one intervention over others.  
A recent review of medication strategies for people with dual diagnoses (Murthy and 
Chand, 2012) focused on antipsychotic choice, arguing that more sedating antipsychotics 
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such as clozapine or quetiapine may offer some advantages. However, the clinical 
challenge for young people with psychosis and stimulant use is rarely one of medication 
choice: the greater challenges involve engagement, motivation, supporting changes in 
substance use and encouraging adherence to any form of psychosocial or medical 
treatment.  
The research findings outlined in this thesis underline the scale of stimulant comorbidity 
and its potential impact in people with psychosis. The lack of specific and effective 
interventions for this problem has several implications for health service research and 
planning. First, services should prioritise clinical research to develop and test interventions 
for this group. Because evidence is so limited, there is an important role for clinical 
innovation and properly conducted pilot studies.  Second, the mental health workforce 
needs support in delivering “treatment as usual” as effectively as possible. Rather than 
focusing on highly specialised interventions, mental health staff need a broad base of skills 
in engagement, education, and motivational interventions. The studies in this thesis found 
that people with early psychoses and stimulant use disorder had lower rates of 
progression to schizophrenia, but that once people had an established diagnosis of 
schizophrenia they had worse outcomes and much greater service use. This suggests that 
services have a window of opportunity in which to act assertively to prevent poor long term 
outcomes. This requires clinicians to see comorbid psychosis and stimulant use disorder 
as a marker of both high risk and high opportunity, and not as a reason for therapeutic 
pessimism. It also requires service structures and resources which support clinicians in 
responding assertively.   
Care for the individual 
This thesis began by describing “Tim”, a young man who had presented to hospital with an 
acute psychosis in the context of stimulant abuse. This discussion concludes by 
considering implications for an individual such as Tim. Considering the evidence regarding 
stimulant use disorders and psychosis, including the findings of the current research, what 
might good care look like for Tim and his family?  
Ideally, Tim and his family would have been exposed to a range of prevention messages 
long before he first used any substances. School-based programs might have detected 
and responded to his shyness and social anxiety, perhaps equipping him with strategies 
for managing stress and anxiety, and building his resilience. They would have provided 
him with age-appropriate information about the potential health and mental health risks of 
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drug use, including the risks of psychosis. This should have included broad information 
about detecting and responding to common mental health symptoms and ways of 
accessing advice and health care. It might also have included messages about the 
importance of family history and genetic vulnerability as risk factors.   
During Tim’s education at technical college, there would have been opportunity for some 
of these messages to be reinforced more strongly. In his attendance at live music events, 
he might have been exposed to targeted campaigns about the importance of seeking help 
for transient psychotic symptoms and the risks of developing enduring psychoses. These 
messages could again emphasise the importance for Tim of understanding his own family 
history and other risk factors. Ideally, Tim and his family would have had awareness of and 
access to a range of health or counselling services. 
At the time of Tim’s first presentation with psychosis, services would have responded 
assertively. They would have conducted a detailed assessment that included urine drug 
screening to ensure accurate identification of any substances he was using, as well as a 
detailed developmental, family and drug-use history. While managing Tim’s acute 
psychosis according to current treatment guidelines, they would also have ensured that 
Tim’s substance use was a specific target of treatment. Clinical staff would have had a 
range of assessment and basic treatment skills that allowed them to focus on these 
conditions without requiring referral to an external service, and to be supported by 
appropriate supervision, consultation and professional development.  
Tim and his family would have received good education and information, including 
information about drug and alcohol treatment and support services. Critically, clinicians 
would ensure that Tim and his family were aware that his choices about whether he 
continued substance use would have a major impact on his outcome, and that people who 
cease substance use after a first episode of psychosis have good outcomes, low rates of 
readmission and low rates of progression to schizophrenia.  Mental health services would 
ensure that Tim was offered assertive follow-up and support even if his symptoms 
resolved quickly, and these efforts would include helping him to return to his studies.   
If Tim did continue to use stimulants and other substances, or have ongoing psychotic 
symptoms, services would continue to work assertively with him, aiming to minimise any 
harms, ensuring that he had relevant information about safe drug use (such as injecting if 
he was using drugs intravenously) or safe sex. They would ensure detailed cognitive 
assessment, and tailor their messages and care to Tim’s particular strengths and needs. 
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They would ensure ongoing support and education for Tim’s family. If Tim did change 
address, they would work assertively to encourage him to remain in contact with services, 
continuing to see him or ensuring good communication and handover to a new treatment 
service.     
The paragraphs above describe how an ideal health care system might respond to a 
person with a stimulant-related psychosis. A strong clinical and economic case has been 
made for the importance of early intervention in people with risk factors for psychosis 
(Fusar-Poli et al., 2013).  For a young person like Tim, an episode of psychosis may have 
many possible trajectories and may end in positive outcomes. Good clinical care has the 
potential to influence Tim’s trajectory, however even with ideal care Tim may develop an 
enduring psychosis. Once a person has developed an enduring psychosis such as 
schizophrenia, the personal and social costs are substantial: current treatments, even 
optimally delivered, can avert less than one quarter of the burden of schizophrenia 
(Andrews et al., 2004). The studies reported in this thesis suggest that addressing 
stimulant use should be one component of good care. Some strategies for providing this 
care would require service changes or investments, but many could be delivered by 
current services within existing resources. Further research is needed to identify the most 
effective and efficient interventions for stimulant use in psychosis.  
Conclusion 
Epidemiological approaches can help to distinguish the effects of stimulants from those of 
cannabis. The studies in this thesis have shown that stimulants make a significant 
contribution to the burden of psychosis in Australia. Stimulant use disorders are also most 
common in people with other vulnerabilities to psychosis. It follows that strategies aimed at 
preventing stimulant use or responding to the earliest symptoms of psychosis are 
essential. Once a psychotic episode has been precipitated, there is an important 
opportunity for effective intervention, because stimulant disorders are associated with brief 
psychoses and with a lower risk of transition to schizophrenia. Comorbid stimulant use is a 
positive prognostic sign in early psychosis, but only if stimulant use stops. People with 
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Appendix A: Testing of diagnostic algorithms 
 
This appendix describes the development and testing of the method used for extraction of 








Registers derived from administrative datasets are valuable tools in psychosis research, 
but diagnostic accuracy can be problematic. We sought to compare the relative 
performance of four methods for assigning a single diagnosis from longitudinal 
administrative clinical records when compared to reference diagnoses.  
Methods 
Diagnoses recorded in inpatient and community mental health records were compared to 
research diagnoses of psychotic disorders obtained from semi-structured clinical 
interviews for 289 persons. Diagnoses were derived from administrative datasets using 
four algorithms; ‘At least one’ diagnosis, ‘Last’ or most recent diagnosis, ‘Modal’ or most 
frequently occurring diagnosis, and ‘Hierarchy’ in which a diagnostic hierarchy was 
applied. Agreements between algorithm-based and reference diagnoses for overall 
presence/absence of psychosis and for specific diagnoses of schizophrenia, 
schizoaffective disorder, and affective psychosis were examined using estimated 
prevalence rates, overall agreement, ROC analysis and kappa statistics.  
Results 
For the presence/absence of psychosis, the most sensitive and least specific algorithm (‘At 
least one’ diagnosis) performed best. For schizophrenia, ‘Modal’ and ‘Last’ diagnoses had 
This chapter is based on the publication: Sara, G., L. M. Luo, V. J. Carr, A. Raudino, M. 
J. Green, K. R. Laurens, K. Dean, M. Cohen, P. Burgess and V. Morgan (2014). 
Comparing algorithms for deriving psychosis diagnoses from longitudinal 
administrative clinical records. Social Psychiatry and Psychiatric Epidemiology.  
49: 1729-1737. 
Reproduced with kind permission from Springer Science and Business Media 
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greatest agreement with reference diagnosis. For affective psychosis, ‘Hierarchy’ 
diagnosis performed best. Agreement between clinical and reference diagnoses was no 
better than chance for diagnoses of schizoaffective disorder. Overall agreement between 
administrative and reference diagnoses was modest, but may have been limited by the 
use of participants who had been screened for likely psychosis prior to assessment.  
Conclusions 
The choice of algorithm for extracting a psychosis diagnosis from administrative datasets 
may have a substantial impact on the accuracy of the diagnoses derived. An ‘Any 
diagnosis’ algorithm provides a sensitive measure for the presence of any psychosis, while 
‘Last diagnosis’ is more accurate for specific diagnosis of schizophrenia and a hierarchical 
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There is increasing scope to derive case register information from electronic health 
records and administrative databases (Perera et al., 2009). As most people living with 
psychotic illnesses have contact with health services (Jablensky et al., 2000; Morgan et 
al., 2011) such registers may be particularly helpful for research into psychotic disorders 
(Morgan and Jablensky, 2010; Byrne et al., 2005).  
Diagnostic accuracy is essential for an effective case register. It forms the first of four 
dimensions proposed by Mortensen (Mortensen, 1995), who argued that an effective case 
register should (i) maximise the precision of the disease estimate, (ii) minimise selection 
bias, (iii) minimise information bias, and (iv) allow for control of relevant confounders. 
Byrne and colleagues (Byrne et al., 2005) reviewed studies of diagnostic accuracy in case 
registers, finding that there was no ‘gold standard’ on this issue. Morgan and Jablensky 
(Morgan and Jablensky, 2010) have recently called for further studies examining and 
benchmarking the quality of register data.  
Diagnostic accuracy may be considered both cross-sectionally and longitudinally. Cross-
sectional studies validate register diagnoses against research or clinical diagnoses for a 
single episode of illness, such as an individual hospital admission, or over a limited follow-
up period (Crabbe et al., 1999; Fennig et al., 1994; Goodman et al., 1984; Kristjansson et 
al., 1987; Löffler et al., 1994; Øiesvold et al., 2012; Sytema et al., 1989; Taiminen et al., 
2001; Keskimani, 1991; Robinson and Tataryn, 1997; Kessing, 1998). However, a 
longitudinal perspective is also important for enduring or recurring conditions such as 
schizophrenia and other psychotic disorders. An individual may have contact with services 
over many years, and their records may include several diagnoses made by different 
clinicians at different stages of care. For most research purposes it is necessary to allocate 
a single diagnosis for an individual. Therefore, an algorithm is required to derive a single 
diagnosis for an individual from diagnoses made during multiple episodes of care.  
Four main methods have been used, each with possible advantages and disadvantages. 
First, the occurrence of at least one diagnosis of psychosis in a person’s record may be 
seen as sufficient for defining the condition of interest (Jin et al., 2004; Kirkby et al., 1998; 
West et al., 2000). This approach (‘At least one’ psychosis diagnosis) is likely to be 
sensitive, but risks a high false positive rate. Second, diagnoses may be weighted by 
frequency of occurrence, focusing on the modal (‘dominant’) diagnosis for an individual 
(Kirkby et al., 1998; McConville and Walker, 2000), or defining a threshold such as two or 
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more occurrences of a diagnosis (Lichtenstein et al., 2006). This approach may be more 
specific, but its results may vary depending on the level of detail at which diagnoses are 
grouped, or the frequency threshold set. Third, the timing of diagnosis may be considered, 
using the first (‘incident’) diagnosis for an individual (Jin et al., 2004; McConville and 
Walker, 2000; Sigurdsson et al., 1999) or the most recent diagnosis (Valuri et al., 2001). 
Psychosis diagnoses can change over time, and may vary more for some subtypes of 
psychosis, so timing-based approaches may produce different results for different 
conditions. Finally, a diagnostic hierarchy may be applied so that when multiple diagnoses 
are present, one is seen as representing a ‘higher order’ diagnostic concept which can 
account for the others (McConville and Walker, 2000; Isohanni et al., 1997; Makikyro et al., 
1998; Ruschena et al., 1998; Wallace et al., 1998). This approach is familiar to clinicians, 
however currently proposed hierarchies have a limited evidence base, and different 
diagnostic systems may apply different hierarchies.  
To our knowledge, no study has compared the relative performance of these methods in a 
single clinical sample. These methods may produce estimates of psychosis prevalence 
that differ in sensitivity, specificity and accuracy. Understanding the properties of these 
methods may assist in method selection when designing studies using linked register data.   
The aim of this study is to compare the relative performance of four different algorithms (at 
least one diagnosis, last diagnosis, modal diagnosis, and hierarchical diagnosis) for 
deriving a single person diagnosis from a large longitudinal administrative database. 
Diagnoses were extracted from hospital admissions and community mental health 
contacts over a ten-year period in the state of New South Wales (NSW), Australia. These 
were compared with a reference diagnosis obtained from a semi-structured clinical 
interview. Agreement between administrative and reference diagnoses was examined for 
broad categorisation (psychosis/no psychosis) and for individual psychosis diagnoses of 





Participants were drawn from the second Australian national survey of psychosis (Morgan 
et al., 2011), which sampled people aged 18 – 64 with severe mental disorders who were 
in contact with public specialised mental health services or non-government organisations 
from April 2009 to March 2010.  
Participants in the national survey were recruited from seven regions, covering 
approximately 10% of the age-matched Australian population (Morgan et al., 2012) and 
were identified by a two phase screening process. First a psychosis screener  (Jablensky 
et al., 2000) assessed for a lifetime history of hallucinations, delusions, antipsychotic 
medication or receiving a diagnosis of psychotic disorder from a doctor. The screener was 
designed to favour sensitivity, and testing showed acceptable screening properties: 
sensitivity 0.98 (95% CI 0.97−0.98), specificity 0.41 (95% CI 0.35−0.46), positive predictive 
value 0.90 (95% CI 0.89−0.91) and negative predictive value 0.76 (95% CI 0.69−0.83) 
(Morgan et al., 2012) . Second, a random sample (stratified by catchment site and age) of 
those who screened positive underwent a semi-structured clinical interview. 
 Enumeration and clinical characteristics of national survey participants have been detailed 
elsewhere (Morgan et al., 2012). Of 7,995 people screened and randomised, 1,825 (23%) 
were interviewed. Reasons for non-interview included refusal (30%), being uncontactable 
(15%), being too unwell for interview (12%), having other exclusion criteria (6%), or not 
being required at the completion of planned interviews (14%).  Sixty percent of participants 
were male, 58% were aged over 35, and most had diagnoses of schizophrenia (47%), 
bipolar disorder (18%) or schizoaffective disorder (16%). Average duration of illness was 
15 years (median 12 years), 51% had multiple episodes with good or partial recovery 
between episodes and 31% had a continuous chronic illness.   
Participants in the current study were all 319 individuals from the two NSW sites of the 
national survey.   
Reference diagnoses 
Diagnoses made by the national survey were used as reference diagnoses. These were 
obtained using the Diagnostic Interview for Psychosis (DIP), which is designed for use by 
clinical interviewers in large epidemiological surveys (Castle et al., 2006). The DIP has 
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good inter-rater (kappa 0.74) and test-retest (kappa 0.65) reliability for broad ICD-10 
diagnostic categories, and good diagnostic validity compared with the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) (Castle et al., 2006). Interviews were 
conducted by mental health professionals who worked in public mental health services and 
were trained in administration of the DIP. Inter-rater reliability between interviewers was 
good (averaged pairwise agreement = 0.94) (Morgan et al., 2012) . The OPCRIT algorithm 
(McGuffin et al., 1991) within the DIP software provided lifetime diagnoses according  to 
ICD-10 and DSM-IV criteria, reducing subjective bias in the interpretation of symptoms and 
signs.  
Administrative diagnoses 
Data on hospital admissions and community mental health contacts were obtained from 
the NSW Health Information Exchange (HIE) from the beginning of available register data 
(July 2000) to the time of national survey assessment (March 2010). Only admissions 
staying at least one night in a designated mental health unit were included. Inpatient 
diagnoses were recorded at discharge from hospital by trained medical record coders, 
based on the diagnoses recorded by the treating psychiatrist or other medical officer. 
Community diagnoses were recorded by treating mental health clinicians at each 
community contact. Data for both settings included principal (primary reason for 
hospitalisation or contact) and secondary diagnoses, coded using the Australian 
Modification of ICD-10 (National Centre for Classification in Health, 2010).  
Diagnostic algorithms  
Three-month statistical episodes of care were constructed for community contacts. This 
was required because NSW community mental health data records diagnoses at each 
individual contact. Inpatient and community episodes of care for an individual were then 
combined to derive a single person diagnosis.  
Four diagnostic algorithms were applied. ‘At least one’ diagnosis was present if the 
individual had at least one primary diagnosis of a particular psychosis diagnosis. ‘Last’ 
diagnosis was coded using the most recent mental health diagnosis; if multiple diagnoses 
were made at the last episode, the primary diagnosis was used. ‘Modal’ diagnosis was the 
most frequent primary mental health diagnosis, summarised to the three-digit level (e.g. 
‘F20’). ‘Hierarchy’ psychosis diagnosis applied the following sequence: organic psychoses, 
schizophrenia, schizoaffective disorder, affective psychosis, brief/drug induced/atypical 
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psychosis, and then all other diagnoses. Personality disorder and intellectual disability 
diagnoses were excluded from calculation in all algorithms, since the presence of these 
disorders does not exclude concurrent diagnosis of psychosis. For statistical episodes of 
community care, each diagnostic algorithm was first applied to derive a single diagnosis 
per community episode, and then applied to combine all inpatient and community episodes 
for that person.  
Diagnoses were grouped at two levels. First, a binary psychosis/no psychosis variable was 
examined. Psychoses included all diagnoses of schizophrenia, schizoaffective disorder, 
bipolar disorder, depression with psychosis specified, acute and transient psychoses, 
delusional disorders, induced delusional disorders, drug-induced psychosis, other 
psychoses and psychoses not otherwise specified. Schizotypal disorder and organic 
psychoses were excluded. Second, diagnostic agreement was examined for three 
mutually exclusive psychosis groups: Schizophrenia (F20), Schizoaffective Disorder (F25) 
and Affective Psychoses, which included bipolar disorder (F30, F31) and depressive 
episodes where psychosis was specified (F32.3, F32.30, F32.31, F33.3).  
Preliminary analyses tested different options for construction of ‘modal’ and ‘last’ 
diagnoses, giving different weightings to primary or additional diagnoses, and to Axis I or 
Axis II conditions. Preliminary analyses also found no systematic differences in diagnostic 
agreement between inpatient and community settings. Hence, inpatient and community 
diagnoses were combined for a final person diagnosis, with the same algorithm being 
applied across both settings. Details of these analyses are available from the 
corresponding author on request. 
Data Linkage 
All survey participants consented to linkage of their research data with state administrative 
databases. Ethics approval for linkage was obtained from the Human Research Ethics 
Committee of the Hunter New England Area Health Service. Participants’ survey records 
were linked to their NSW HIE records using name, date of birth, sex and local health 
service identifier where this was present.  
Statistical analysis 
DIP diagnoses were used as the ‘gold standard’ against which the derived clinical 
diagnoses were compared. Differences between included and excluded subjects were 
examined using Pearson’s Chi-square for categorical variables and independent sample t-
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tests for continuous variables. Agreement between administrative and reference 
diagnoses was evaluated using prevalence estimates, percentage agreement, positive 
predictive value, negative predictive value, sensitivity and specificity. ROC analysis was 
undertaken, calculating area under the curve (AUC). Cohen’s Kappa, and prevalence and 
bias adjusted kappa (PABAK) (Sim and Wright, 2005; Chen et al., 2009) were calculated.  
PABAK takes into account the prevalence of the disorder within the sample as well as the 
discrepancy between the proportion of diagnoses assigned by different raters. PABAK and 
95% confidence intervals for kappa were calculated using DAG_stat (Mackinnon, 2000). 
Other analyses were conducted in SPSS Version 21 (IBM Corp. 2012. IBM SPSS for 
Windows, Version 21. Armonk, NY. IBM Corp.).  
 
RESULTS 
Eighteen participants were excluded because their research and clinical records could not 
be linked. A further 12 participants had no recorded diagnosis in the HIE. Thus, the final 
sample for the present study consisted of 289 participants, 91% of the available sample. 
The 30 participants excluded did not differ significantly from study participants on age or 
gender but were more likely to have had a reference diagnosis of a non-psychotic 
condition (19% of excluded participants, 12% of included participants. Chi-square = 4.9, 
df=1, p < 0.05). All 12 subjects with no administrative diagnosis had only brief community 
mental health contact.  
 
The average age of participants was 40 (range 19 – 65) and 60% were male (Table A.1). 
Half had reference diagnoses of schizophrenia. Most (91%) had both inpatient and 
community mental health care prior to assessment; two had only received inpatient care. 
Participants had an average of 10.6 admissions to mental health units prior to their 
assessment (SD 16.9, range 0-188 admissions).  
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Table A.1. Characteristics of participants with administrative and reference diagnoses (n = 289). 
               
Male n (%) 174 (60%) 
Age  
 Mean (SD) 39.9 (10.6) 
 Range 19 - 65 
ICD-10 Reference diagnosis n (%)  
 Schizophrenia 144 (50%) 
 Schizoaffective Disorder 35 (12%) 
 Affective Psychosis 53 (18%) 
 Other psychosis 22 (8%) 
 Depression (without psychosis) 28 (10%) 
 Did not meet full criteria for psychosis  7 (2%) 
Type of contact n (%)  
 Inpatient and Community Care 263 (91%) 
 Community care only 24 (8%) 
 Inpatient care only 2 (0.6%) 
Hospital admissions  
 Mean (SD) 10.6 (16.9) 
 Range 1 - 188 
 
 
The ‘At least one’ psychosis algorithm produced higher rates for all diagnoses examined 
(Figure A.1) and a prevalence estimate closest to the reference diagnoses for the binary 
psychosis/no psychosis distinction. However, for all individual diagnoses, the ‘At least one’ 
algorithm produced higher prevalence estimates, including more than two-fold increases in 
estimated rates of schizoaffective disorder and affective psychoses. ‘Hierarchy’ diagnoses 
varied according to the priority given within the hierarchy, producing substantially higher 
estimates of schizophrenia prevalence than the reference diagnoses, but substantially 
lower estimates of affective psychosis. Using a ‘Hierarchy’ approach estimates of 
schizoaffective disorder were almost zero, because nearly all individuals with a 
schizoaffective disorder diagnosis also had other diagnoses of schizophrenia or affective 
psychosis. ‘Modal’ and ‘Last’ algorithms produced similar estimates for all diagnoses 
















Figure A.1. Comparison of diagnostic algorithms. Estimated prevalence of any psychosis and of 
specific psychosis diagnoses: reference diagnoses from research interview compared with four 
algorithms for deriving diagnoses from longitudinal administrative data.  
 
Absolute agreement between administrative and reference diagnoses was only in the ‘fair’ 
range (Landis and Koch, 1977), with kappa ranging from 0.23 to 0.36 (Table A.2). The 
exception was schizoaffective disorder, where kappa ranged from 0.01 to 0.09. For the 
broader ‘any psychosis’ group, the ‘At least one’ diagnosis algorithm had the highest 
overall agreement, but had lower specificity than ‘Modal’ and ‘Last’ algorithms. For 
schizophrenia, ‘Modal’ and ‘Last’ algorithms performed best on most measures and 
appeared indistinguishable from each other. For affective psychoses, the ‘Hierarchy’ 
algorithm achieved the best overall agreement with reference diagnoses. PABAK corrects 
for either high or low prevalence within the sample and therefore produced increased 
estimates of agreement in disorders whose prevalence in our sample was closer to 0% or 
100% (any psychosis kappa 0.27 – 0.36, PABAK 0.60 – 0.76. Schizoaffective disorder, 
kappa 0.01 – 0.09, PABAK 0.33 – 0.73), but no change in estimated agreement for 
schizophrenia, whose prevalence in our sample was close to 50%. The Area Under the 
Curve (AUC) obtained from ROC analysis was highest for ‘Modal’ and ‘Last’ diagnoses in 
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in affective psychosis. However the confidence intervals for most AUC estimates 
overlapped, suggesting modest differences in performance of these algorithms.   
Of 142 persons with a ‘Last’ administrative diagnosis of schizophrenia, 44 (31%) were 
reassigned to other reference diagnoses, particularly schizoaffective disorder (15 
participants), affective psychoses (14), and other psychoses (12). Conversely, of 28 
persons with a ‘Last’ administrative diagnosis of schizoaffective disorder, only six had a 
reference diagnosis of the same disorder and a third (10) were reassigned to a reference 




Table A.2.  Concordance between administrative and reference diagnoses, comparing four different algorithms for assignation of diagnosis from 
administrative data.  
Diagnosis and  


















Psychosis                 
  At least one 88 95 37 0.66 (0.55 - 0.77) 92 50 0.36 (0.19 - 0.53) 0.76 (0.68 - 0.83) 
  Hierarchy  81 85 49 0.67 (0.56 - 0.77) 92 31 0.27 (0.13 - 0.41) 0.61 (0.52 - 0.70) 
  Modal  80 82 66 0.74 (0.64 - 0.84) 95 33 0.34 (0.21 - 0.46) 0.60 (0.51 - 0.69) 
  Last  81 83 66 0.74 (0.65 - 0.84) 95 34 0.35 (0.22 - 0.48) 0.61 (0.52 - 0.70) 
Schizophrenia          
  At least one  64 86 41 0.64 (0.57 - 0.70) 59 75 0.27 (0.17 - 0.37) 0.27 (0.16 - 0.38) 
  Hierarchy  61 78 45 0.61 (0.55 - 0.68) 58 67 0.23 (0.12 - 0.33) 0.22 (0.11 - 0.34) 
  Modal  66 68 65 0.66 (0.60 - 0.73) 66 67 0.33 (0.22 - 0.44) 0.33 (0.22 - 0.44) 
  Last  68 67 68 0.67 (0.61 - 0.74) 68 67 0.35 (0.24 - 0.46) 0.35 (0.24 - 0.46) 
Schizoaffective         
  At least one 66 43 70 0.56 (0.46 - 0.67) 16 90 0.07 (-0.03 - 0.18) 0.33 (0.22 - 0.44) 
  Hierarchy  87 3 98 0.50 (0.40 - 0.61) 17 88 0.01 (-0.08 - 0.10) 0.73 (0.65 - 0.81) 
  Modal  85 9 95 0.52 (0.41 - 0.62) 20 88 0.05 (-0.08 - 0.18) 0.70 (0.61 - 0.78) 
  Last  82 17 91 0.54 (0.44 - 0.65) 21 89 0.09 (-0.05 - 0.23) 0.65 (0.56 - 0.73) 
Affective Psychosis         
  At least one  74 65 75 0.70 (0.60 - 0.79) 28 94 0.25 (0.14 - 0.37) 0.47 (0.37 - 0.58) 
  Hierarchy  87 38 94 0.66 (0.55 - 0.77) 48 91 0.35 (0.19 - 0.51) 0.74 (0.66 - 0.81) 
  Modal  82 41 88 0.64 (0.54 - 0.75) 33 91 0.26 (0.12 - 0.41) 0.64 (0.55 - 0.73) 
  Last  82 38 89 0.63 (0.53 - 0.74) 33 91 0.25 (0.10 - 0.40) 0.65 (0.56 - 0.73) 
 






























Note: (a) Reference diagnoses of ‘Affective disorder’ exclude Affective psychosis. (b) Did not meet full criteria for an ICD-10 diagnosis of a psychotic disorder.  
  













psychosis b TOTAL 
Schizophrenia 96 15 14 12 5  142 
Schizoaffective 10 6 6 2 3 1 28 
Affective psychosis 14 5 19 2 1 1 42 
Other Psychosis 7 0 1 1 1  10 
Affective disorder 8 5 8 2 7 3 33 
Non-psychotic disorder 9 4 5 3 11 2 34 
TOTAL 144 35 53 22 28 7 289 
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DISCUSSION 
We compared longitudinal diagnoses obtained from routinely-collected administrative 
health data with reference diagnoses obtained from the Diagnostic Interview for Psychosis 
in 289 people who screened positive for psychotic illness. We found significant differences 
in performance between the four algorithms. Our findings are consistent with the few 
studies that have compared the relative performance of different diagnostic methods.  
Kirkby (Kirkby et al., 1998) found that diagnostic reliability for schizophrenia was low in 
individuals for whom schizophrenia diagnosis constituted a minority of their total 
diagnoses, and that a ‘Modal’ diagnosis was therefore more accurate than an ‘At least one’ 
diagnosis. McConville and Walker (McConville and Walker, 2000) found that modal 
diagnosis performed better than first (incident) diagnosis for schizophrenia and related 
psychotic disorders. Valuri (Valuri et al., 2001) found that for psychotic disorders the 
diagnosis at most recent discharge had higher agreement with research (OPCRIT) 
(McGuffin et al., 1991) diagnoses than did modal diagnosis.  
Variation in diagnoses over time may reflect inter-rater and information variability, as well 
as true variation due to change in the individual’s condition. The mix of these factors may 
influence the performance of these algorithms differently for different disorders. Many 
people with later diagnoses of schizophrenia are initially diagnosed with brief, atypical, 
drug-induced or affective psychoses, However, a diagnosis of schizophrenia, once made,  
is relatively stable over time (Bromet et al., 2011; Schwartz et al., 2000).  Variation in 
specific diagnosis over time should have little impact on the binary psychosis/no psychosis 
distinction, since all are psychotic conditions. The most sensitive and least specific 
algorithm (‘At least one’) appeared to perform best for this broad distinction. By contrast, 
the finding that the ‘Last’ diagnosis was most accurate for schizophrenia is consistent with 
the progression to this diagnosis over time, as well as the greater diagnostic certainty that 
may follow a longer period of assessment. The similarity between ‘Modal’ and ‘Last’ 
diagnoses for schizophrenia is consistent with the stability of the diagnosis of 
schizophrenia once made. Although ‘Modal’ and ‘Last’ algorithms performed identically for 
schizophrenia, a ‘Last’ diagnosis approach may be preferable for identifying schizophrenia, 
as it may be less sensitive to variations in the period of time included in calculation, and is 
computationally simpler.  
For affective psychosis (including bipolar disorder) ‘Hierarchy’ diagnosis performed 
relatively well on measures of agreement. This implies that administrative diagnoses for 
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people with these conditions may not converge on a stable diagnosis over time as seen in 
schizophrenia. People with reference diagnoses of bipolar disorder continued to have 
episodes of care with other diagnoses, including non-psychotic depressive episodes, 
anxiety disorders, and substance disorders; this may reflect true clinical variation and 
comorbidity as well as diagnostic error. Using a diagnostic hierarchy may have filtered out 
these effects.  
Overall agreement between clinical and reference diagnoses was no better than chance 
for schizoaffective disorder. This may reflect the smaller size of this group; however it also 
highlights the imprecision of this diagnosis in routine clinical practice. Many people with 
clinical diagnoses of schizophrenia or bipolar disorder had at least one diagnosis of 
schizoaffective disorder, and therefore an ‘At least one’ diagnosis algorithm greatly over-
estimated its prevalence. Conversely, nearly all people with a clinical diagnosis of 
schizoaffective disorder also had clinical diagnoses of schizophrenia, and so a hierarchical 
approach produced a very low estimate for the rate of schizoaffective disorder.  
Limitations 
The absolute level of agreement between administrative diagnoses and reference 
diagnoses was in the lower part of the range for published studies. We found overall rates 
of diagnostic agreement from 61% to 88% depending on algorithm and diagnosis, with 
kappa up to 0.36. Studies validating clinical diagnoses of schizophrenia against research 
diagnoses have reported overall rates of diagnostic agreement from 71% (Arajärvi et al., 
2005) to 98% (Keskimani, 1991), and kappa from 0.31 (Erdman et al., 1987) to 0.69 
(McConville and Walker, 2000).  
Several limitations of this study may have contributed to the modest overall agreement 
between administrative and reference diagnoses.  First, administrative systems record 
diagnoses made by many clinicians over a long period, and are unlikely to align completely 
with a cross-sectional research diagnosis.  Second, the reference diagnoses in this study 
may itself also be imprecise, being based on a two stage assessment using a psychosis 
screener then a research interview (the DIP) conducted by a clinician without long prior 
contact with the participant. A recent study of long term diagnostic stability in psychosis 
suggests that clinician diagnoses may at times be more sensitive than research diagnoses 
in anticipating later diagnostic changes (Bromet et al., 2011). Third, the administrative 
register used in this study commenced approximately ten years prior to the study, limiting 
the timespan of diagnostic data available for each individual.  
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The method of selection of participants for this study is also likely to have had a significant 
impact on absolute levels of diagnostic agreement.  Participants were not a random 
sample of service users, and underwent diagnostic interview only after screening positive 
for probable psychosis. As a result, only 12% of the study group had a reference diagnosis 
of a non-psychotic disorder, compared with at least 50% of NSW public mental health 
service users whose primary diagnoses are of non-psychotic conditions. Administrative 
and reference diagnoses are likely to have agreed on the absence of psychosis for many 
of these people. The screening process therefore excluded many true negative diagnostic 
agreements from our study group, reducing agreement for measures dependent on the 
true negative rate (percent agreement, specificity, negative predictive value and kappa). 
The national survey from which our participants were drawn interviewed a random sample 
of 164 screen-negative participants, finding a false negative rate of 24%. We have 
modelled the potential impact of these missing cases on diagnostic agreement, assuming 
(i) the screener false negative rate for the two sites in our study was the same as the 
national rate, (ii) 50% of service users at our sites had a non-psychotic disorder and (iii) 
disagreement between administrative and reference diagnoses for non-psychotic disorders 
was equal to that for psychotic disorders. For agreement on the binary ‘psychosis/no 
psychosis’ distinction and using the ‘At least one’ algorithm, inclusion of these screened 
cases increased specificity from 37% to 90% and kappa from 0.36 to 0.65. Our study 
focuses on the relative performance of algorithms rather than on the absolute level of 
agreement: it is unlikely that the effect of screening would differentially affect the 
performance of any of the algorithms tested, since the threshold used in screening was 
substantially lower than that set by any of the algorithms, and the items included in 
screening (e.g. lifetime presence of psychotic symptoms) are independent of the items 
included in those algorithms.  
Conclusions 
The choice of algorithm for extracting a psychosis diagnosis from clinical datasets may 
have a substantial impact on the accuracy of the diagnoses constructed. There may be no 
single ideal algorithm for all diagnoses. The ‘At least one’ algorithm had highest agreement 
for identifying the presence of a psychotic disorder generally. ‘Modal’ and ‘Last’ diagnosis 
performed best for schizophrenia, while ‘Hierarchy’ diagnoses performed best for affective 
psychoses. Overall agreement between clinical and reference diagnosis was very poor for 
schizoaffective disorder. Larger samples including a balance of psychotic and non-
psychotic conditions would be of value for future studies.  
